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Scope of this thesis 
Lysosomal neuraminidase initiates the hydrolysis of oligosaccharldes, gangliosides, 
glycolipids and glycoprotelns by removing their terminal sialic acid residues. The 
enzyme functions exclusively In a multi-enzyme complex, together with fl-
galactosidase and protective protein/cathepsin A (PPCA) and Is dependent for Its 
activity and stability on the latter protein. Mutations In the neuraminidase gene are 
the basis for the lysosomal storage disorder sialidosls, while mutations In the PPCA 
gene Indirectly results In the Impairment of neuraminidase and p·galactosidase 
activity, causing the lysosomal storage disorder galactoslalldosls. The experimental 
work that is described in this thesis involves the Isolation and characterization of the 
cDNA's encoding human and mouse lysosomal neuraminidase. Structural and 
functional analysis of this enzyme has focused on the Interaction with PPCA in 
relation to Its transport to the Iysosomes and the mechanism of catalytic activation. 
These studies, In combination with the Identification and functional analysis of a 
large number of novel mutations In slalidosls patients, have given new Insights Into 
the biochemical functions and properties of neuraminidase and provided reliable 
phenotype-genotype correlations. The results presented In this thesis may form the 
basis for understanding the structural characteristics of this unusual lysosomal 
protein and for the future development of strategies for therapy of both slalldosis 
and galactoslalldosis patients. 
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Introduction and history 
Neuraminidases (neuraminidases EC 3.2.1.18) belong to a class of exoglycosyl hydrolases 
that release o:-glycosidically linked terminal N-acylneuraminate (sialic acid) from a variety of 
glycoproteins, glycolipids and polysaccharides. The initial work in this field started with the 
observation that influenza virus particles were able to agglutinate chicken erythrocytes and 
that it was not possible to reagglutinate the red blood cells after they had been agglutinated 
by the virus once (1). Later it. was shown that certain bacterial extracts could destroy 
receptor sites for influenza virus on the surface of human erythrocytes (2). The responsible 
enzyme was named receptor-destroying enzyme. The name 'sialldase' was proposed in 
1956 by Heimer (3), and the name 'neuraminidase' by Gollschalk (4) after they showed that 
upon incubation of salivary mucin with bacterial or viral extracts, sialic acid was released. 
Both names have been used interchangeably ever since. The enzyme was first purified 
from the bacterium Vibrio cholerae and shown to be catalytically identical to the receptor-
destroying enzyme (5). Since then, the worldwide public health burden of Influenza has 
accounted for a wealth of research on viral neuraminidases, which extended to 
neuraminidases from other species. It is now known that these enzymes are common in 
viruses, bacteria, protozoa, mycoplasma, fungi, as well as in higher organisms, including all 
mammalian species, but absent in plants (reviewed in: (6·9)). 
In contrast to the viral neuraminidases, the function of these enzymes in bacteria is 
less clear. Interestingly, in bacteria neuraminidases are found both in pathogenic and non-
pathogenic species. However, they are not expressed In all bacteria, and even different 
strains of a single species may differ In neuraminidase expression (6,10). Moreover, many 
neuraminidase-containing bacteria are unable to synthesize sialic acid, whereas others, 
that do synthesize sialic acid, lack sialidases. Homologies of neuraminidases at the 
molecular level support the hypothesis of a common origin and hence of a neuraminidase 
superfamily. 
Biological significance of sialic acid 
The sialic acids are a group of 9-carbon carboxylated sugars (Figure 1), usually positioned 
at the termini of complex carbohydrates (Figure 2). They are structurally very diverse, with 
over 25 identified forms (Figure 1; (11-15)), In addition, they are target molecules in a variety 
of important biological events, mainly as ligands In recognitive Interactions (14). The release 
of sialic acid from the oligosaccharide chain by neuraminidase is required for the hydrolysis 
of subsequent sugar residues by other glycosidases (Figure 2; (16). Sialic acid derivatives 
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have been found in higher organisms, from the echinoderms upwards and in some bacteria, 
viruses and protozoa (14). 
The biosynthesis of sialic acids is a complex multiple-step process (14) starting from 
D-glucose, which is first converted to N-acetylglucosamine (GlcNAc). The sialic acid 
pathway reaches its first key slep with the epimerisation of GlcNAc to N-
acetylmannosamine (ManNAc). The biosynthetic route proceeds with the 6-phosphorylation 
of Ihe amino sugar, using ATP as the phosphate donor. ManNAc-6-phosphate (ManNAc-6-
P) is condensed with pyruvate to N-acelylneuraminic acid-9-phosphate (Neu5Ac-9-P). 
Dephosphorylalion of Ihe latter compound yields Neu5Ac, which needs to be activated to 
CMP-Neu5Ac for incorporation into complex carbohydrates. Sialyltransferases, which are 
responsible for the formation of sialoglycoconjugates, can process various Neu5Ac CMP-
glycosides, but are highly specific for the carbohydrale acceptor structure and the type of 
glycosidic bond formed (17-19). Glycosidically bound Neu5Ac can undergo modifications of 
the OH groups, such as 8-0-methylation, 8-0-sulphation (20-22), 9-0-lactoylation, and 4, 7, 
8 and 9 O-acetylation (Figure 1; Schauer, 1987; Diaz et aI., 1989; Varki, 1992; (12, 23-26). 
Sometimes several of these substiluents are presenl in one sialic acid molecule and no 
other nalural sugar shows such a great variety. Moreover, this variation is often tissue 
andlor animal specific, some having only one form of sialic acid, while others have several 
kinds (14). For instance, significant differences in sialic acid types have been described 
between adult and fetal bovine tissues, suggesting their involvement in development (27). 
In general, oligosaccharide chains of glycoconjugates are no longer believed to be 
inert structures, but ralher structures that store biological information (28-30). The wide 
distribution of sialic acids in nalure, their multiplicity, adult and embryonal tissue specificity 
and terminal position on carbohydrate chains, reflect their importance in a variety of cellular 
functions. Sialic acids can serve as recognition markers for several mammalian proteins, 
such as members of the selectin family (31-33) and the I-type lectins or sialoadhesin 
subgroup (12, 34-36). The enzymatic addition or removal of sialic acids can lead to 
significant differences in the biological properties of carbohydrates, resulting In altered 
recognition by sialic acid binding proteins and ultimalely influencing the function or fate of 
cells. Numerous functions have been attributed to sialic acids (11, 14, 37-39). Because of 
their negative charge they are involved in cell adhesion, but also in cell repulsion, for 
Instance between circulating blood cells (40). Furthermore, their negative charge is 
important for the maintenance of the viscoelastic properties of sialic acid rich compounds, 
such as mucins (41). They Influence the properties of glycoproteins, Including their 
conformation, enzyme activity and resistance to proteolytic degradation (11). N- and 0-
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Figurel. Natural sialic acid compounds. The 9-carbon backbone common to all sialic acids is 
shown in chair formation. Substituents (R1.2.3) at different positions are Indicated. Additional 
diversity is generated by various types of glycosidic linkage at positions 2. by generation of 
lactones at position 1. and by dehydro and anhydro forms. Adapted from (12). 
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Figure 2. Composite complex type N-glycosidic oligosaccharide and the hydrolytic steps 
required for its degradation. Adapted from (16). 
acetylated sialic acids are antigenic determinants. For instance, B-cells have O-acetylated 
sialic acids, whereas T-cells do not (42). Interestingly, the T-cells of patients with various 
malignancies have acquired O-acetylation (43). Sialic acids function in the suppression of 
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antigenic recognition and their loss has been implicated as one of the causes of 
autoimmune disease. In contrast, tumor cells appear to be protected from the immune 
system by highly sialylated cell surfaces (11). Sialic acids are also often present on the 
carbohydrate chains of receptors such as peptide hormones, toxins, viruses and 
mycoplasma species, where they apparently serve as essential recognition markers, for 
instance in the virus-receptor interaction. However, they can also function as biological 
masks, preventing ligand recognition of receptors (11). 
In conclusion, sialic acids are involved in many Important cellular mechanisms and 
pathways. Thus, neuramlnidases, being responsible for the hydrolysis of sialic acid, are 
equally important participants for such processes. 
Mammalian neuraminidases 
Mammalian neuraminidases are expressed in all tissues and cell types (reviewed in: (8)) 
and they have been implicated In several critical and diverse metabolic processes, including 
the regulation of cell proliferation and cell differentiation (44·46), clearance of plasma 
proteins (47), membrane fusion and membrane fluidity (48-52), cell adhesion (53-55), 
catabolism of gangliosides and glycoproteins (56, 57), immunocyte function (58, 59), 
modification of receptors (60, 61) and the developmental modelling of myelin (57). The 
pivotal involvement of neuraminidases in these cellular mechanisms may account for the 
existence of four neuraminidases, differentially localized in (I) the cytosol, (II) the plasma 
membrane, (iii) the lysosome and (iv) the lysosomal membrane. These enzymes have been 
characterized by their subcellular distribution, pH optimum, stability, kinetics, effect of Ions, 
and substrate specificity (reviewed in: (8, 62, 63)). Recently cDNA's have been cloned that 
encode cytosollc, plasma membrane and lysosomal neuraminidases (64·69). 
Cytosolic neuraminidase 
The gene encoding cytosolic neuraminidase was the first mammalian enzyme to be 
cloned (64). The cDNA was isolated from a rat skeletal muscle cDNA library using 
degenerated oligonucleotide primers, derived from the partial amino acid sequence of the 
purified enzyme and encoded a protein of 379 amino acids. The amino acid sequence 
showed -20% homology to the bacterial neuraminidases. A secreted form of 
neuraminidase, with similar properties and molecular weight (43 kDa) as the rat skeletal 
muscle enzyme, was purified from the medium of cultured chinese hamster ovary cells 
(CHO) (70). Its corresponding cDNA was isolated from a CHO cDNA library (65), encoding a 
protein nearly identical to the rat skeletal muscle cytosolic neuraminidase, which most likely 
represented the Chinese hamster homologue. This enzyme was secreted by an unknown 
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mechanism, since it lacked an N-terminal signal peptide known to be associated with 
compartmentalization in the secretory pathway. 
The purified rat cytosolic neuraminidase was active in vitro towards sialo-
oligosaccharides, sialoglycoproteins and gangliosides (in the presence of bile salts), except 
for submaxillary mucins, and both GM, and GM, gangliosides. The enzyme hydrolyzed u2-
3 sialyl-linked substrates much faster than u2-6 and u2-8, with a pH optimum between 6 
and 6.5 (71). Interestingly, this enzyme seemed to playa role in myotube differentiation, 
since its mRNA and enzyme activity were not detectable in cultured myoblasts, but became 
induced upon in vitro myotube differentiation (72). Moreover, the myotube formation was 
completely blocked by the addition of an antisense oligonucleotide primer complementary 
to the first 8 codons of the cytosolic neuraminidase. However, expression of cytosolic 
neuraminidase was not restricted to skeletal muscle, but was present in many other tissues, 
including kidney, brain, heart, stomach, intestine, testis, liver epithelium of cornea, blood 
vessels, Schwann cells and axons (8, 73, 74). The corresponding human and mouse genes 
encoding cytosolic neuraminidase have been cloned recently and shown to be -80% 
identical to the other cytosollc neuraminidases (68, 69). 
The exact function(s) of cytosolic neuraminidase in tissues and cell types other then 
muscle is unknown and no genetic disorders have as yet been associated with a deficiency 
of cytosolic neuraminidase. 
Plasma membrane neuraminidase 
A neuraminidase localized in the plasma membrane, specific for the hydrolysis of 
hydrophobic sialyl compounds, including gangliosides, has been characterized in various 
tissues and cell types, Including liver, thyroid gland, skeletal muscle, myelin, lymphocytes, 
neuroblastoma cells, fibroblasts, erythrocytes, and the brain (8, 57, 75-77). The latter Is one 
of the main sites for this enzyme, where it has been found in synaptisomal plasma 
membranes and myelin (72, 78-81). Plasma membrane ganglioside-neuraminidase is 
responsible for the growth control and differentiation of cultured human neuroblastoma cells 
(81-83). Inhibitors of ganglioside-neuraminidase, added to the culture medium of these cells, 
led to a complete release of contact inhibition of growth, loss of neuron-specific enolase 
differentiation marker and neurofilaments, and a decrease of cyclic AMP. A ganglioside 
neuraminidase present in mouse synaptic plasma membranes displayed a decreased 
activity with age (80), which correlated with age-related changes in ganglioside composition 
in these membranes (48). Thus far the functions of these age related changes are unknown. 
Unlike catabolic reactions involving soluble enzymes and hydrophilic substrates, the 
Interaction of ganglioside-neuraminidase with membranes and lipid substrates shows 
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unique kinetic features. Gangllosides are mainly located on the outer surface of the plasma 
membrane and are assumed to be involved in diverse biological functions, including 
receptor activity for hormones, toxins, bacteria and viruses, as well as modulation of 
membrane-bound enzyme activities, cell-growth, differentiation and ceil-adhesion (84, 85). 
Ganglioside substrates within membranes gain access to the enzyme through lateral 
diffusion (86, 87). Hence, membrane-bound neuraminidase activity can be enhanced by 
membrane-fluidizing reagents such as Triton X-100, which enhances enzyme-substrate 
access, resulting in enzyme activity (78, 81,82,88.89). 
Differences in size, pH optimum, substrate specificity, inhibitors and activators 
between plasma membrane neuraminidases isolated from various tissues and cell types, 
suggested the existence of more than one species of this enzyme (78. 81,90,91). Whereas 
most plasma membrane neuraminidases were released by extraction with non-ionic 
detergents, a plasma membrane neuraminidase from pig brain was released by treatment 
with phosphatidylinositol phospholipase C (PIPL), indicating that this enzyme is anchored 
by means of a glycosyl phospatidylinositol anchor (GPI) (79). However, only 28% of the 
plasma membrane neuraminidase activity could be released by PIPL treatment, which also 
indicated the possible existence of a second plasma membrane neuraminidases in pig 
brain. 
Recently a neuraminidase was purified from bovine brain to near homogeneity (89). 
The cDNA encoding this enzyme was cloned from a bovine brain cDNA library, using 
oligonucleotide primers that were based on partial amino acid sequences derived from the 
purified protein (66). The corresponding human gene was cloned from a human brain 
cDNA library and 83% identical to the bovine gene (67). This neuraminidase was expressed 
mainly in the brain and muscle, as indicated by Northern blot hybridization, which revealed 
a mRNA transcript of - 7.5 kb. The bovine protein of 428 amino acids had sequence 
homology to the rat and Chinese hamster cytosolic neuraminidase (-38%), the human and 
mouse lysosomal neuraminidase (-19%) and the bacterial neuraminidases (-19%). 
Curiously, the protein had no N-terminal signal sequence, but a putative trans-membrane 
domain, which was oddly located in the central part of the protein, dividing the catalytic 
domain at two sites of the plasma membrane. Analysis of the membrane topology indicated 
that this protein was an atypical type I membrane protein, with an extracellular N-terminus 
and a cytoplasmic C-termlnus. Although the localization of the protein in the plasma 
membrane was confirmed by Percoll density gradient centrifugation, as well as 
immunofluorescence staining of transfected COS-7 cells, it appears to be unlikely that this 
enzyme is active in a membrane anchored state. The authors speculated that the enzyme 
binds gangllosldes at the cell surface with its extracellular domain. The enzyme-substrate 
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complex may then be internalized in endosomal vesicles where it assumes the correct 
conformation to become catalytically active. The authors showed that the overexpressed 
enzyme was active at acidic pH, in the presence of Triton X-100, towards gangliosides 
other then GM, and GM" but was inactive with sialoglycoproteins, oligosaccharides and the 
synthetic 4MU-Neu5Ac substrate. The restricted expression patterns of this neuraminidase 
in brain and muscle and the presence of ATTTA motifs in the 3' un translated region, which 
are thought to be involved in the regulation of gene expression during cell growth and 
differentiation, indicate that this neuraminidase has a specialized function (66). 
A deficiency of ganglioside neuraminidase was suggested to be the cause of the rare 
autosomal metabolic storage disease mucolipidosis IV (MLlV) (92, 93). This was supported 
by the accumulation of gangliosides and mucopolysaccharides within membranous 
cytoplasmic bodies in patient's skin fibroblasts, Schwann cells, vessel walls, smooth muscle 
fibers and sweat glands (94, 95). Despite an early onset of the disease and severe mental 
retardation, the progression of the clinical symptoms is very slow during the first three 
decades of life. The patients have a deficiency In neuraminidase activity towards GO" and 
GO'b gangliosides, which is caused by the accumulation of sulfated glycosaminoglycans, 
that have a strong inhibitory effect on the neuraminidase activity (95-97). Interestingly, cells 
of the patients also appeared to have a defect In the endocytosis process of membranous 
components, resulting in excessive transport of sulfated glycosaminoglycans into 
Iysosomes, rather then recycling them to the plasma membrane (98). In MLiV cells none of 
the lysosomal hydrolases were found to be abnormal (98), however, the transport of lipids 
from the Iysosomes was impaired (99). These data suggest that the primary genetic defect 
responsible for MLiV involves a receptor and/or transporter that In turn causes the 
secondary inhibition/inactivation of ganglioside-neuraminidase. 
Recently the gene responsible for MLiV gene has been mapped to chromosome 
19p13.2-13.3 by linkage analysis with fifteen markers in thirteen MLlV-families (100). The 
authors constructed haplotypes In twenty-six Ashkenazi Jewish families and demonstrated 
the existence of two founder alleles that probably carry MLlV-causing structural defects in 
this population. The localization of MLiV to chromosome 19 should result in the cloning of 
the disease causing gene in the near future. 
Lysosomal neuraminidase 
Lysosomal neuraminidase is present In virtually all vertebrate tissues and cell types 
and has been purified and characterized from many sources, including placenta, mammary 
gland, brain, kidney, liver, testis, thyroid, salivary gland, leukocytes, lymphocytes, 
macrophages and fibroblasts (reviewed in: (8)). The cloning of the lysosomal neuraminidase 
0<> 
gene has been hampered by substantial loss of the enzyme activity during 
procedures (8, 101-105). 
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purification 
As was the case for plasma membrane neuraminidase, also for Iysosomes the 
potential existence of two neuraminidases has been reported (106). A neuraminidase from 
purified rat liver Iysosomes was released Into the supernatant by hypotonic shock and was 
active towards slalyllactose and fetuin. The lysosomal enzyme that was purified from bovine 
testis and human placenta was released by similar methods, which Indicated that this 
neuraminidase had an intra-lysosomal origin (101, 103, 104, 107). On the other hand, a 
neuraminidase aclive towards submaxillary mucin and gangliosides was Insoluble. These 
results argued for the existence of a soluble intra-lysosomal neuraminidase mainly active 
towards oligosaccharides and glycoproteins and a lysosomal membrane-bound 
neuraminidase that is specific for gangliosldes (108). Using antibodies that were raised 
against neuraminidases that were purified from rat plasma membrane, Iysosomes, and 
cytosol, it was shown that Iysosomes from rat liver actually contained three 
neuraminidases. One enzyme was present in the lysosomal lumen (I) and two were found 
in the lysosomal membrane (II and III), one of which was Identical to the plasma membrane 
ganglioside-neuraminidase (78, 109). Both lysosomal membrane neuraminidases II and 11/ 
had a molecular weight of - 70 kDa (gel filtration) and a pH optimum near 5. However, 
neuraminidase 11/ hydrolysed almost exclusively gangllosides, whereas neuraminidase II 
hydrolyzed preferentially gangliosides but also oligosaccharides, glycoproteins and 4MU-
Neu5Ac. The existence of a lysosomal-membrane ganglioside-specific neuraminidase has 
been confirmed by others (8, 90, 110). 
Different molecular weights have been reported for purified lysosomal 
neuraminidase, which may be dependent on the animal species and/or tissue. A 48.5-kDa 
form was purified from human leukocytes (111), a 56-60-kDa form from rat liver (108), a 55-
kDa species from bovine testis (112), 61- and 66-kDa forms from human placenta (105, 113) 
and a 70-kDa neuraminidase from human liver and rat brain (78, 109). 
The lysosomal neuraminidase that is active towards glycoproteins and 
oligosaccharides Is only found in a high molecular weight multi-enzyme complex of >1000 
kDa. Lysosomal neuraminidase activity is known to be particularly unstable during enzyme 
purifications, which is probably caused by its dissociation from the mUlti-enzyme complex. 
The multi-enzyme complex can be purified from different mammalian/avian tissues and 
species, including human, bovine, mouse, porcine, chicken, and rat. There is variation in 
the reported sizes of the multi-enzyme complex, which may be due to either species or 
tissue specific differences of the complex, or because of diversity in the applied purification 
methods. The purification of lysosomal neuraminidase usually requires tissue 
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homogenization, the isolation of a lysosomal/mitochondrial fraction and a hypotonic shock. 
The purification procedure may include one or more of the following chromatography 
techniques: Concanavalin A-sepharose (glycoprotein affinity), p-
aminophenylthiogalactoside-CH-sepharose (B-galactosidase affinity), sucrose-density 
gradient, gel filtration, ion exchange and the use of antibodies (8). Neuraminidase that was 
isolated from the supernatant of homogenized human placenta could be 'rescued' by 
concentration and acidification of the preparation, resulting in a four fold increase In 
catalytic activity for every two fold of concentration (102). The stabilized neuraminidase was 
associated with B-galactosidase, but also with lysosomal protective protein/cathepsin A 
(PPCA). This neuraminidase was the intra-lysosomal form, mainly active towards 
ollgosaccharides and 4MU-Neu5Ac synthetic substrate. However, most of the lysosomal 
neuraminidase remained in the lysosomal membrane fraction and could only be released 
with detergents, which suggested that this was a membrane bound enzyme (114, 115). 
There are two main forms of the lysosomal multi-enzyme complex, a >1000-kDa form which 
consists of neuraminidase and relatively small amounts of PPCA and B-galactosidase and a 
second complex of 600-700 kDa containing the iatter two proteins (101, 102, 105, 107, 116-
120). Figure 3 illustrates a classic gel filtration profile Illustrating the different forms of the 
three enzymes when purified from cultured bovine kidney cells (121). PPCA and B-
galactosidase activities were recovered in a >1000-kDa neuraminidase-containing complex 
(figure 3, complex i), in a iower molecular weight complex of -740 kDa (figure 3, complex 
II), and as free dimeric forms of -100 kDa and 160 kDa respectively. Neuraminidase activity 
was completely dependent on the presence and association with PPCA in the complex, 
although the cathepsin A activity in the >1000 kDa complex was very low. This suggests 
that oniy a small amount of PPCA is required to maintain neuraminidase activity. The co-
precipitation of neuraminidase, B-galactosidase and Cathepsin A activities from complex I 
and the co-precipitation of B-galactosidase and PPCA from complex II, using PPCA specific 
antibodies, confirmed the association of the enzymes in the two complexes (E. Bonten, 
unpublished data). There may exist equilibrium between the two multi-enzyme forms and 
the free forms of B-galactosidase and PPCA. This hypothesis was SUbstantiated by /n vitro 
experiments in which 'free' PPCA was separated from the neuraminidase complex, which 
resulted in instability and substantial loss of neuraminidase activity (90%). However, the 
latter was restored when the fraction that contained the PPCA was added to the inactivated 
neuraminidase (E. Bonten, unpublished data). This indicated that the presence of 'free' 
PPCA and/or other soluble factors was required to keep neuraminidase active. 
20 
N-acetylgalactosamine-6-sulfatase (GALNS) was identified as an component of the 
multi-enzyme complex (122). GALNS activity was found to range between 6 and 40% of the 
normal value in the fibroblasts of galactosialidosis patients, whose excretion of keratan 
sulfate in their urine was comparable to that of patients with GALNS deficiency. It is 
possible that the multi-enzyme complex in vivo may contain several other hydrolases in 
addition to the already identified ones. The composition of the multi-enzyme complex may 
depend on the presence of specific substrates, thus creating a highly flexible and efficient 
hydrolytic system. 
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Figure 3. Elution profile of neuraminidase (Neur), p-galactosldase (p·gal), and Cathepsin A 
(PPCA) activities from MDBK cell lysate (50 mM Na-Acetate pH 5.0/150 mM NaCIfO.4% 
NP40), separated on a Sephacryl S300HR column (FPLC). The sizes of the complex forms 
I and II, and the free forms of the enzymes are indicated, and calculated using the elution 
profiles of standard molecular weight markers. 
Deficiencies of lysosomal neuramlmldase 
Sial/dos/s 
Sialidosis is an autosomal recessive disorder, caused by structural lesions in the 
lysosomal neuraminidase gene. The clinical manifestations of patients with this lysosomal 
storage disorder have given insight into some of the functions of this enzyme. Type I 
sialidosis Is a mild form of the disease, with variable age of onset, but usually in the second 
decade of life. It is characterized by the cherry-red spot-myoclonus phenotype and 
progressive impaired vision, but absence of dysmorphic features, {reviewed In: (16)). 
Nystagmus, ataxia and grand mal seizures were also reported In these patients. Type II 
sialldosis is a severe form of the disease, which can be subdivided into three subtypes: (I) 
congenital or hydropic (in utero), (II) infantile (0-12 months) and (III) juvenile (2-20 years) 
(16). All type II patients eventually develop a progressive mucopolysaccharidosis-Iike 
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phenotype, including coarse facies, visceromegaly, dysostosis multiplex, vertebral 
deformities and severe mental retardation (16, 124-126). Cherry-red spots and myoclonus 
have been reported for older children and survival to the second decade for infantile 
patients. Congenital patients demonstrate hydrops fetalis and/or neonatal ascites with 
stillbirth or death at an early age; features may include facial edema, inguinal hernias, 
hepatosplenomegaly, stippling of the epiphyses and periosteal cloaking (123). Sialidosis 
patients have residual lysosomal neuraminidase activity, ranging from 0 to 10% of control 
values, with type I patients having the highest activities. Obligate carriers have Intermediate 
enzyme values, but are phenotypically normal (16, 126). Vacuolated lymphocy1es and bone 
marrow foam cells are prominent in type II, but absent in type I sialidosis. Vacuolation was 
further observed in Kuppfer cells, nerves, tissue fibroblasts, mysenteric plexus neurons and 
brain biopsy material (16). Electron microscopy analysis described the presence of 
membrane bound vacuoles, electron-dense bodies, floccular material, lamellar inclusions 
and lipofuscin (16). The concentration of the oligosaccharides in the urine of patients 
correlated with the severity of the clinical phenotype (127). Most compounds excreted in the 
urine of sialidosls patients contained N-acetylglucosamine at the reducing ends and N-
acetylneuramlnlc acid at the non-reducing termini (127-130). The neuraminic acids are 
linked to galactose via either a2-6 (70%), or a2-3-linkage (30%) and likely originated from 
carbohydrate side chains that had been cleaved from glycoproteins by an endo-N-acetyl-
glucosamlnidase (16). In the organs of a slalidosis patient, obtained at autopsy, the water-
soluble bound sialic acid was increased between 10- and 17-fold In visceral organs, but 
surprisingly only about 2-fold in the brain when compared to normal controls. Lipid-bound 
sialic acid was also increased up to 8-fold in visceral organs due to elevated amounts of 
gangliosides GM3, GD3 and probably GM, and LM" whereas the brain showed no deviation 
from controls. An alteration of the neutral glycolipid pattern was also observed (131). The 
results indicated an impaired catabolism of gangliosides in sialidosls in addition to that of 
sialo-oligosaccharides and sialoglycoproteins. This Is in line with evidence that lysosomal 
neuraminidase, under specific conditions, can be also active towards gangliosides (90, 91, 
110). 
Galae/osialldosis 
Patients with the lysosomal storage disorder galactosialidosis were shown to have a 
combined f3-galactosidase and neuraminidase deficiency, secondary to the deficiency of the 
'protective protein' (102, 132-136). There is a broad overlap in the clinical phenotypes of 
sialldosis and galactosialidosis patients, indicating an Important role for neuraminidase also 
in the pathogenesis of galactosialidosis. 
22 
Galjart and co-workers cloned the cDNA encoding the 'protective protein' and found 
it to be homologous to two yeast carboxypeptidases, carboxypeptidase Y (CPY) and the 
KEX1 gene product (137,138), as well as to the wheat serine carboxypeptidase CPW (139). 
The 'protective protein' is identical to the previously identified lysosomal serine-
carboxypeptidase cathepsin A and is now named 'protective protein/cathepsin A' (PPCA) 
(140). It also functions as an aminocylamidase (140-142) and a deamidase in vitro active 
towards a selected number of bloactive peptldes Including substance P, oxy1ocin, 
angiotensin I and endothelin I (143, 144). Fibroblasts from galactosialidosis patients were 
shown to have less than 1 % activity towards a specific synthetic substrate for cathepsin A 
(Z-Phe-Ala) and they were also impaired in lysosomal neuraminidase and p-galactosldase 
activities, whereas obligate carriers had about 50% activity compared to controls (140, 145). 
The two functions of PPCA, (I) protecting p-galactosldase and neuraminidase against 
intralysosomal degradation and (II) as serine carboxypeptidase/deamidase, were proven to 
be distinct, since it was shown that the cataly1ic activity was not required for its protective 
function towards the two glycosidases (140). However, it is yet unknown whether the 
cathepsin A deficiency in galactosialidosis patients also contributes to the disease 
phenotype. 
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Lysosomal neuraminidase can be regarded as a unique member of the sialidase 
superfamily, since it is the only sialidase that is deficient in a human metabolic storage 
disorder, sialidosis. 
The identification of lysosomal neuraminidase has been hampered by its apparent 
lability during purifications. This is reflected by many contradictory reports describing the 
characterization of the purified enzyme (molecular weights between 40 and 70 kDa), 
eventhough the purification methods were appropriate (Chapter 1 for references). Another 
factor that has complicated the identification of lysosomal neuraminidase is the existence of 
at least three distinct mammalian forms, characterized by different pH optimum, substrate 
specificity and subcellular localization. Of these enzymes the cytosolic neuraminidase was 
the first one to be cloned in 1993 by Miyagi and co-workers, who in 1999 were also 
responsible for the cloning of the plasma membrane neuraminidase (Chapter 1, pages 15-
17). Until now, many questions about lysosomal neuraminidase and the gene-mutations 
underlying sialidosis had remained unanswered. We had no information about the primary 
structure of this enzyme and its potential homology to other slalidases. Furthermore, we 
could not explain its strict dependency on the protective protein/cathepsin A, since most 
microbial neuramlnldases are generally stable and active, without the need of auxilary 
proteins. Last, but not least, we did not have Information about the mode of interaction 
between these two enzymes. In conclusion, a thorough understanding of the characteristics 
of lysosomal neuraminidase and the identification and characterization of the responsible 
molecular defects in sialidosis patients could help us to address the potential therapeutic 
strategies for affected children. 
In recent years the availability of rapidly expanding DNA databases, including the 
'Expressed Sequence Tag' database (dBEST), has become a powerful tool to identify new 
cDNA's and genes that are expected to share homology at the DNA or protein level with 
other known genes or proteins. As discussed in Chapters 3 and 4 we were able to identify 
and clone the human lysosomal neuraminidase cDNA from the dBEST database through its 
sequence similarity to bacterial neuraminidases, and subsequently we also cloned the 
mouse neuraminidase cDNA. We identified and characterized mutations in the lysosomal 
neuraminidase gene that are responsible for sialldosls in humans and the neuraminidase 
deficiency in the SM/J mouse strain (Chapter 3 and 4). We Identified mutations in a large 
group of sialidosis patients that cover the near complete clinical spectrum of the disease 
and established genotype-phenotype correlations (chapter 8). We analyzed the functional 
and intracellular behavior of different mutant proteins by over-expression experiments In 
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sialidosis fibroblasts (Chapter 8). Overall, the data showed that the level of residual activity 
and lysosomal localization of the mutant enzyme directly correlated with the severity of the 
patients' symptoms. In turn, the mildest type I patients had a small amount of functional 
neuraminidase in the Iysosomes, while the severe type II patients completely lacked 
functional enzyme. We also demonstrated that the mere ability of a mutant enzyme to reach 
the Iysosomes was not always sufficient to give a mild phenotype. One of the siatidosis 
patients had a mutation that involved one of the five active site residues of neuraminidase 
(Y370C). Despite normal amounts of correctly localized neuraminidase, the enzyme was 
inactive, and, as a result, the patient had the severe type" phenotype (Chapter 8). 
Another important aspect presented in this thesis addresses the contribution of 
protective protein/cathepsin A to the transport, stability and catalytic activity of lysosomal 
neuraminidase (Chapters 5-7). We found that the turnover and posttranslational 
modifications of neuraminidase were unaffected by the presence of PPCA. However 
association with PPCA was required for the transport of neuraminidase to Iysosomes, since 
it lacked a functional mannose-6-phosphate recognition marker (Chapter 6). We utilized the 
baculovirus expression system to characterize the mechanisms of catalytic activation of 
both PPCA and neuraminidase. We showed that through the excision of a linker peptide 
PPCA became a two-chain protein that was held together by disulfide bridges and was 
catalytically active (Chapter 6). In contrast, lysosomal neuraminidase did not require 
proteolytic processing to become catalytically active. PPCA associated with neuraminidase 
and promoted oligomerization of the latter enzyme, which, in turn, became fully active. The 
association with PPCA was pH Independent, however, oligomerization and activation of 
neuraminidase could only occur at acidic pH (Chapter 7). These findings correlate with the 
ability of PPCA to associate with neuraminidase In an early biosynthetic compartment and 
promote transport of neuraminidase to Iysosomes (Chapter 5). The acidic environment 
triggers the PPCA-mediated oligomerization and activation of neuraminidase (Chapter 7). 
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Characterization of human lysosomal 
neuraminidase defines the molecular 
basis of the metabolic storage 
disorder sialidosis 
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Neuraminidases (sialidasesJ have an essential role in the removal of terminal sialic acid residues from 
sialoglycoconjugates and are distributed widely in nature. The human lysosomal enzyme occms in complex 
with p·galactosidase and protective protein/cathepsin A (PPCA), and is deficient in two genetic disorders: 
sialidosls, caused by a structural defect in the neuraminidase gene, and galactosialidosis, in which the loss of 
neuraminidase activity Is secondary to a deficiency of PPCA. We identHied a full·length eDNA clone In the 
dbEST data base, of which the predicted amino acid sequence has extensive homology to other mammalian 
and bacterial neuramlnldases, including the F{Y)RIP domain and "Asp· boxes." In situ hybridization localized 
the human neuraminidase gene to chromosome band 6p21, a region known to contain the HLA locus. 
Transient expression of the eDNA in deficient human fibroblasts showed that the enzyme is 
compartmentalized in lysosomes and restored neuraminidase activity in a PPCA·dependent manner. The 
authenticity of the cDNA was veriHed by the identification of three independent mutations in the open 
reading frame of the mRNA from clinically distinct sialidosis patients. Coexpression of the mutant cDNAs 
with PPCA (ailed to generate neuraminidase activity, confirming the inactivating eHect of the mntations. 
These results establish the molecular basis of sialidosis in these patients, and clearly identify the 
cDNA·encoded protein as lysosomal neuraminidase. 
IKey Words: Neuraminidase; lysosome} sialidosis; galactosialidosis; protective protein/cathepsin AJ 
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Neuraminidases {sialidasesJ constitute a large, diverse 
family of hydrolytic enzymes known to occur in a vari· 
ety of organisms, including viruses, bacteria, protozoa, 
and vertebrates /Miyagi et a1. 1993; Roggentin et al. 
1993} Warner et aL 1993; Colman 1994} Schenkman et 
a1. 1994; chou et al. 1996). The wide distribution of sial· 
idases reflects their indispensable role in the catabolism 
of sialic acids from various sialoglycoconiugates, which, 
in tum, are required for important cellular processes 
{Corfield et a1. 1992a} Saito and Yu 1995) Schauer et a!. 
1995; Reuter and Gabius 1996). Sialidases have been im· 
plica ted both directly and indirectly in a number of hu· 
man pathologic conditions, including infectious diseases 
and genetic disorders of metabolism. Accordingly, a 
wealth of information is available on bacterial, viral, and 
protozoan sialidases {Corfield 1992b; Roggentin et a1. 
1989, 1993}. For instance, in pathogenic bacteria such as 
Vibrio cholerae, the neuraminidase is thought to act as a 
virulence factor by uncovering toxin binding sites {Galen 
IThese aUlhOIS (onlrlbuled equally 10 this work. 
'COllespondlngauthor, 
et OIL 1992J. The neuraminidase of influenza virus, on the 
other hand, is needed apparently for both virion entry 
into lung and intestinal mucosa and for virus budding 
from the infected host cell {Colman 1989, 19941. Com· 
parison of the primary structures of microbial and viral 
sialidases has revealed that the nonviral enzymes have 
an overall sequence identity of -35%, and that they all 
contain the so·called F{Y)RIP domain located amino·ter· 
minally froUl a series of "Asp boxes" [consensus se· 
quence Ser/Thr-X-Asp-{X}-Gly-X-Thr-Trp/Phc!, that 
appear two to five times depending on the protein 
{Roggentin et OIL 1993} Warner et at. 1993). Crystal struc· 
ture analysis has shown that the active site of these en· 
zymes is located in a conserved six·bladed p·propeller 
domain of -40 kD. The arginine of the FRIP motif is part 
of the active site, being located in the center of the pro· 
peller, whereas the Asp boxes are found on the periphery 
and seem to have a structural role {Gaskell et OIl. 19951, 
In contrast to the microbial and viral enzymes, inIor· 
mation on the mammalian neuraminidases is more lim· 
ited. The apparent low abundance, labile nature, and in 
some instances membrane association of these enzymes 
are features that have made their biochemical and ge-
netic characterization difficult. Three mammalian 
neuraminidascs, which differ in substrate preference, pH 
optimum, and subcellular localization, are known to 
date, They arc the cytosolic, plasma membrane, and ly-
sosomal neuraminidases. One of the best characterized 
is the cytosolic enzyme, which has been purified to ho-
mogeneity from rat liver and skeletal muscle, and its 
eDNA and gene have been cloned (Miyagi et al. 19903, 
1993) Miyagi and Tsuiki 1985; Sa to and Miyagi 1995). In 
addition, the eDNA encoding a soluble sialidasc, origi· 
nally purified from the culture medium of Chinese ham-
ster ovary {CHOj cells, but probably of cytosolic origin, 
also has been isolated (Warner et aL 1993; Ferrari et al. 
1994). These two enzymes are 88% homologous at the 
amino acid level and both contain the FRIP domain and 
Asp boxes (Ferrari et al. 1994). Cytosolic sialidase is ac-
tive at pH 6.5 and is expressed highly in skeletal muscle 
where it may have a role in myoblast differentiation 
(Sato and Miyagi 1996). 
The plasma mcmbrane neuraminidase, which is spe-
cific for ganglioside substrates, has been partially puri-
fied from brain tissues (Tettamanti et al. 1972; Miyagi 
et al. 1990aJ, although low levels have been measured 
in other tissues (Lieser et al. 1989) Zeigler et a1. 1989}. 
In addition to its acidic pH optimum, which is also 
charactcristic of the lysosomal neuraminidase, the 
plasma membrane enzyme seems to bear biochemical 
and immunological properties distinct from those of its 
lysosomal counterpart /Miyagi et al. 1990b; Schneider-
Jakob and Cantz 1991}, and appears unaffected in disor-
ders assoeiated with the lysosomal neuraminidase 
(Lieser et al. 1989) Zeigler et al. 1989) Schneider-Jakob 
and Cantz 1991). It is still unclear, however, whether the 
cytosolic and plasma membrane enzymcs really repre-
sent discrete proteins or merely different forms of the 
same enzyme. 
Lysosomal N-acetyl-u-neuraminidase initiates the hy-
drolysis of oligosaccharides, gangliosides, glycolipids, 
and glycoproteins by removing their terminal sialic acid 
residues. The human enzyme has a preference for u-
2~3 and 0. 2~6 sialyl linkages and is thought to act 
primarily on oligosaccharide and glycopeptide substrates 
(Frisch and Neufeld' 1979) Cantz 1982), but can hydro-
lyze gangliosides with the aid of detergents or the sphin-
golipid activator Sap B (Schneider-Jakob and Cantz 1991; 
Fingerhut et al. 1992). Biochemical characterization of 
lysosomal neuraminidase has been difficult because it is 
extremely labile on extraction and may be membrane-
bound. Since the first report by Verheijen et al. (1982), 
several other studies have established that neuramini-
dase activity can be recovered in mammalian tissues as 
part of a large molecular mass complex that eontains the 
glycosidase, p·galactosidase, and the carboxypeptidase 
protective protein/cathepsin A (PPCAJ. It is thought that 
by associating with PPCA, neuraminidase and p-galac-
tosidase acquire their active and stable conformation in 
lysosomes (d'Azzo et al. 1995). Biochemical evidence for 
the existence of the three-enzyme complex comes pri-
marily from copurification studies. In particular, the 
36 
three enzymes can be isolated together using either p-ga-
lactosidase or PPCA affinity matrices {Verheiien et a1. 
1985, Yamamoto and Nishimura 1987, Potier et aI. 
1990; Scheibe et a1. 1990} Pshezhetsky and Potier 1994). 
Only a small percentage of p-galactosidase and PPCA 
activities are consistently found in the complex, which 
nevertheless contains all of the neuraminidase activity. 
These studies support the notion that lysosomal neur-
aminidase activity cannot be isolated separately from 
the complex, whereas the other two hydrolases can exist 
in alternative forms (Hoogeveen et al. 1983/ Hubbes et 
al. 1992, and references above). The small yield of neur-
aminidase activity recovered after different purification 
procedures has Icd to inconsistent assignment of a mo-
lecular weight to the enzyme (Verheijen et a1. 1987; van 
der Horst et al. 1989) Warner et al. 1990). 
Our interest in human lysosomal neuraminidase 
stems from its direct involvement in two genetically 
distinct inborn errors of metabolism: sialidosis, which 
is eaused by structural lesions in the lysosomal neur-
aminidase locus /Thomas and Beaudet 1995), and galac-
tosialidosis, a combined deficiency of neuraminidase and 
p-galactosidase {Wenger et a1. 1978} Andria et al. 1981; 
d'Azzo et al. 1995) caused by the absence of PPCA 
(d'Azzo et al. 1982). Sialidosis and galactosialidosis pa-
tients accumulate sialylated oligosaccharides and glyco-
peptides in tissues and excrete abnormal quantities of 
these compounds in urine and body fluids (van Pelt et al. 
1988a,b,c). Different clinical forms of sialidosis are dis-
tinguished according to the age of onSet and the severity 
of the symptoms (Thomas and Beaudet 1995). Type I is a 
mild form of the disease, corresponding to the cherry-
red-spot-myoclonus syndrome. Symptoms appear in the 
second decade of life and are restricted to myoclonus and 
progressive impaired vision. Type II sialidosis has onset 
at birth or early infancy and is associated with progres-
sive neurologic deterioration and mental retardation. Re-
sidual neuraminidase activity, measured in patients' fi-
broblasts and leukocytes, varies from 0% to 10% of con-
trol values (Thomas and Beaudet 1995). The gene defect 
in a type II sialidosis patient was mapped by Mueller et 
al. (I986) to chromosome 10. However, analysis of a fe-
male patient with infantile sialidosis type II and congen-
ital adrenal hyperplasia, caused by 21-hydroxylase defi-
ciency, suggested that the neuraminidase gene could be 
linked to the HLA locus, which is on chromosome 6 
{Oohira et al. 1985; Harada et al. 1987). 
Here we report the isolation and characterization of a 
human cDNA that was identified through its homology 
with other known sialidases. Expression of the eDNA in 
COS-l cells and in patient fibroblasts confirmed the ly-
sosomal nature of the encoded protein. Further, the in-
crease in neuraminidase activity was strictly dependent 
on the presence of PPCA, an absolute requirement for 
physiologic enzyme activity. Our eDNA mapped to 
chromosome band 6p21, known to contain the HLA lo-
cus. In addition, we identified independent mutations in 
the mRNA of a type I and a type II sialidosis patient, 
which were shown to inactivate the enzyme. Taken to· 
gether, these data provide compelling evidence that .this 
eDNA encodes human lysosomal neurilminidase, and 
they define the molecular basis of sialidosis, 
Results 
Expression of human neuraminidase mRNA and 
chromosomal localization 
Given the degree of similarity among sialidases from dif-
ferent species, we reasoned that if cDNAs representing 
the human lysosomal neurilminidase were present as ex-
pressed sequence tags IESTs) in the dbEST computer 
data base (Boguski 1995), the enzyme might be cloned by 
screcning the data base with the text string "neuramin-
idase or siaHdase" by using an input device located on 
the World Wide Web [see also Materials and Methods). 
Therefore, cDNA sequence documents would be re-
turned by virtue of attached protein mapping data con-
taining the word neuraminidase or sialidase. Following 
this strategy, we found a putative neuraminidase eDNA 
clone lneur eDNA) of 1894 nucleotides, that showed a 
favomble alignmcnt at the amino acid level to several 
bacterial sialidases and includcd a potential ATG trans-
lation initiation codon and a canonical polyadenylation 
signal. Hybridization of a Northern blot containing mul-
tiple human tissue poly(A) + RNAs with this cDNA re-
vealed a single transcript of -1.9 kh in all tissues, indi-
cating that the acquired cDNA was full·length [Fig.IAI. 
The neur transcript appeared to be most abundant in 
pancreas and was expressed at relatively low levels in 
brain. Reprobing the Northern blot with PPCA cDNA 
showed remarkably similar expression patterns for the 
two mRNAs, with thc exception of pancreaS, where neur 
expression waS clearly higher than that of PPCA, and 
vice versa for kidney, However, Northern blot analysis of 
five type I and type II sialidosis patients did not reveal 
any irregularities or abnormalities in the 1.9-kb tran-
script (Fig. IB, upper panel). The only differences in in· 
tensity of the hybridizing bands were attributable to 
variations in the amount of RNA applied to the gel/Fig. 
IB, lower panel). 
In situ hybridization of metaphase chromosome 
spreads with either the I,8·kb eDNA or a 3.5·kb genomic 
peR product localized the neuraminidase gene to chro· 
mosome band 6p21 [Fig. 2), a chromosomal region 
known to contain the HLA locus. This confirmed previ-
ous observations that suggested an association between 
sialidosis and the HLA locus [Oohira et a1. 1985), 
NeUI eDNA encodes a protein with sequence 
homology to bacterial and mammalian sialidases 
The sequence of the L9-kb eDNA showed an open read-
ing frame [ORF) of 1245 nucleotides encoding a protein 
of 415 amino acids (Fig. 3A), The first 45 residues of the 
amino terminus have typical characteristics of a signal 
sequence [von Hcijne 1986): a positively charged amino-
terminal region (residues 1-18), a central hydrophobic 
core [residues 19--38), and a more polar carboxy-terminal 
domain {residues 39-45}. Ser43, Ser45, and Trp44 con-
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Figure I. Neuraminidase mRNA expression. (AJ Sequential 
h~'bridization of a multitissue Northern blot with the full-
length neuraminidase eDNA (NEUR) and with the protective 
protein/cathepsin A (PPCA) cDNA. The size of the two tran· 
scripts was calculated on the basis of RNA markers. Exposure 
time for both hybridizations was 24 hr. (8) Northern blot (upper 
panel) containing RNA (-10 p.g( isolated from the cultured fi-
broblasts of a normal individual (wtl, three type I sialidosis pa-
tients, and two type II sialidosis patients, h~'bIidized with the 
full-length 1.9-kb neuraminidase eDNA. The exposure time 
was .3 days_ The 10wo panel shows the ethidium bromide 
stained RNA gel for comparison of RNA quantities. 
form to the rules for amino acids at positions -1, -3 
(small and uncharged), and -2 [large, bulky, or charged} 
with respect to signal sequence cleavage sites (von He· 
ijne 1986). The protein also contains a FRIP domain, as 
well as three conserved and two degenerated Asp boxes. 
There arc three potential Asn·linked glycosyiation sites, 
at positions 185, 343, and 352, the last of which lies in 
the middle of Asp box V. The predicted molecular mass 
of the neuraminidase protein is 45.467 kD, which reo 
duces to 40.435 kD after removal of the signal sequence. 
Assuming that glycosylation occurs at all three sites, 
with the consequent addition of -6 kD, the estimated 
size of the protein would be 4S kD, which assigns the 
human enzyme to the low molecular mass group of sial-
idases [Crennell et al. 1996). 
The human neuraminidase shares extensive homology 
figure 2. chrornosomallocalization of human neuraminidase. 
Normal metaphase chromosomes were hybridized with a 3.5·kb 
neuraminidase genomic fragment, labeled with digoxigenin 
dUTP, and st;lincd with antidigoxigenin antibodies. The white 
arrowheads indicate the hybridization signals on the chroma-
tids of both copies of chromosome 6. 
with other members of the sialidase superfamily, includ-
ing bacteria, rodents, protozoa, and influenza virus. The 
rodent cytosolic neuraminidase and six bacterial siali-
clascs appeared to be the most closely related to the hu-
man enzyme. Because of the variation in sizes among the 
different sialidases used in the alignment, the entire hu-
man sequence, excluding the signal peptide, was com-
pared with only the fully overlapping regions of the other 
enzymes (Fig. 3B). The F(Y)RIP domain occurs in all eight 
neuraminidases. Interestingly, the extent of homology 
among the five Asp boxes identified in the different pro-
teins gradually decreases from the first (most amino-ter-
minal) to the fifth (most carboxy-terminal). It is worth 
noting that the rodent cytosolic neuraminidase lacks the 
first and most conserved Asp box, which may indicate 
that this motif corners biochemical specificity to the en-
zyme. The number of residues between the F{Y)RIP do-
main and the first Asp box is highly conserved among all 
low molecular mass neuraminidases, and the human ly-
sosomal protein shares this feature. The extent of ho-
mology, including identical and conserved residues, lies 
between 32% and 38%, with the Micromonospora viri-
difaciens and the Clostridium perfringens sialidases be-
ing the most homologous, and the Salmonella typhiml1-
38 
Jium the le.1st (Roggentin et a1. 1993). It is surprising that 
the human neuraminidase is overall more homologous 
to most of the bacterial sialidases than it is to the eyto-
solic enzyme from Chinese hamster and rat. 
The similar expression patterns of the neur and PPCA 
mRNAs, together with the neuraminidase primary 
structure data, strongly suggest that the isolated eDNA 
encodes a mammalian neuraminidase that is clearly dis-
tinct from the eytosolic enzyme. 
Subcellular localization and enzymatic activatioll 
To assess the lysosomal nature of the protein encoded by 
the eDNA, we determined its intracellular distribution, 
catalytic properties, and, most important, dependence on 
PPCA andlor jl-galactosidase for enzymatic activation. 
In single transfected cells, overexpression of the neur 
eDNA gave rise to a protein with a clear lysosome-like 
distribution, as evidenced by the punetated staining pat-
tern {Fig. 4A} NJ- This pattern was analogous to that 
observed in cells overexpressing the PPCA eDNA and 
probed with the anti-PPCA antibody a-BV32 {Fig. 4A; Pl. 
Surprisingly, in a significant number of neuraminidase-
expressing cells, square crystal-like structures were rec-
ognized by the a-neur antibody in the perinuclear region_ 
These structures were present either alone (Fig. 4A; N, 
upper right) or in combination with lysosomal staining 
(Fig. 4A; N, upper left). The size and total number of 
crystals varied (Fig. 4, N, d. upper left with upper right) 
and appeared to be inversely proportional to the amount 
of lysosomal staining. 
Apparently, the protein aggregates when produced in 
large amounts at the site of synthesis in the endoplasmic 
reticulum. When the neur eDNA was coexpressed with 
the PPCA (Fig. 4A; NIP) or jl-gal cDNAs, the intracel-
lular distribution of neuraminidase, in both lysosome-
like structures and crystals, was comparable to that ob-
served in single-transfccted cells. However, the crystals 
were recognized only by the a-neur antibodies and not by 
anti-PPCA or anti-jl·gal antibodies (data not shown), in-
dicating that they were devoid of PPCA and fl·gal. From 
these results we infer that neuraminidase, when overex-
pressed in COS-l cells, is independent of PPCA for its 
lysosomal-like compartimentalizatioll, unless it is able 
to use the endogenous simian PPCA. 
On Western blots prepared with Iysates of COS-l cells 
transfccted with neur eDNA alone or together with the 
PPCA eDNA, the c.-nem antibodies recognized two ma-
jor bands of 46 and 44 kD and some smaller, minor forms 
(Fig. 4B, lanes 2 and 4). These molecular weights closely 
conform with the predicted size for the glycosylated pro-
tein. After deglycosylation with N-glycosidase F, a single 
band of 40 kD stained with the antibodies, indicating 
that the neuraminidase polypeptide Deems in at least 
two differentially glycosylated forms {Fig. 4B, lane 6)-
Cell homogenates from transfected COSO! cells were 
assayed for neuraminidase activity using the artificial 
substrate 2'-{4-methylumbelliferyl)-a-D-N-acetylneura-
minie acid at pH 4.3, which is optimal for detecting ly-
sosomal neuraminidase. As seen in Figure 4C, ~ells 
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Figure 3, Predicted amino acid scquence of 
human neuraminidase eDNA and align-
ment with other sialidases. (A) The pre-
dicted amino·acid sequence, with residues 
l---45 (underlined) representing the signal 
peptide, and amino acids 46-4l5 represent· 
ing the neuraminidase polypeptide. The 
FRTP domain and three Asp boxes arc boxed, 
two degenerated Asp boxes are underlined, 
and the conserved residues in these do-
mains are printed in boldface. Three pOlen· 
lial Asn-linked g\ycosylation sites are 
marked with an asterisk. (n) Alignment of 
human lysosomal neuraminidase with 
other mammalian and bacterial members of 
the sialidase superfamily. selected regions 
of the human neuraminidase (Hu) sequence 
are compared with siaHdases from Chinese 
hamster (Ch.h.), MicromonoSp01Q vitidi· 
[aciem (M.v.), Stteplococcu~ pneumoniae 
(S.p.), Clostridium per[ringens (C.p.), GIos· 
Iridium seplicum (C.s.), salmonella typh-
imllrillln (S.t.), and Bacteroides [ragilis (B.f.) 
(Roggentin el al. 1993). Gaps were intro-
duced to optimi:l:e the alignment (dashes). 
Identical amino acids afe shaded in black; 
similar rcsidues are shaded in gray. Num-
bers refer to the positions of the amino ac-
ids. The Asp boxes are underlined and num-
bered r to V. 
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expressing either neuraminidase IN) or PPCA (P) had 
1,5-2.0 times higher neuraminidase activity than mock 
1M) or fl-gal IB) transfected cells. However, in cells 
cotransfcctcd with neuraminidase and PPCA (NIP), the 
activity was 16-fold higher than in mock transfected 
cells {M). This increase was less pronounced, although 
still substantial (ninefold), in cells expressing all three 
enzymes together {N/P/B). No change in activity was 
observed in cells cotransfected with the ncur and p-ga-
lactosidasc cDNAs (NIB). These data strongly support 
the notion that the presence of PPCA, but not p-galac-
tosidasc, is essential lor neuraminidase activity. Al-
though the kinetics and mode of association of the three 
enzyme complex is unknown, the relatively low neur-
aminidase activity in cells transfected with the rl-gal 
eDNA (NIB and N/P/B) could reflect competition be-
tween neuraminidase and ~-galactosidase for binding 
sites on PPCA. Taken together, these results provide 
compelling evidence that the isolated eDNA encodes hu-
man lysosomal neuraminidase. 
PPCA-dependent correction of nel1lamiJ1idase activity 
in deficient fibroblasts 
Cultured skin fibroblasts from one of two siblings with 
type I juvenile sialidosis and from a type II neonatal case 
were selected to ascertain whether the neul eDNA could 
correct their enzyme deficiencies. In addition, cells from 
an mRNA-negative galactosialidosis patient were used 
to establish the PPCA-dependent activation of the en-
zyme on a PPCA null background. To optimize expres-
sion in human cells, we subcloned the neur and PPCA 
cDNAs into the expression vector pSC-TOP, which con-
tains the strong cytomegalovirus promoter (see Materi· 
als and Mcthods). Cells electroporated with either the 
neul cDNA construct, the PPCA cDNA construct, or 
both were tcsted for neuraminidase subcellular localiza-
tion and enzymatic activity. Immunofluorescent stain-
ing of transfected cells with a-neur antibodies is shown 
in Figure SA. The endogenous neuraminidase in mock-
transfected control fibroblasts /WT/M) displayed a typj· 
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Figure 4. Immunocytochemical iocJlization and neuramini-
dase activity in transiently transfected COS-l cells. (A)lmmu-
nocytochemicallocalization of neuraminidase in COS-l cells, 
transfected with the oem eDNA clone (NI, or with both the 
neur and PPCA cDNAs (NIP), using affinity-purified o.-neur an-
tiserum. In addition, cells were transfccted with the PPCA 
eDNA alone and processed for immunofluorescence with 0.-32 
antiserum (PI. MagniHcatioll, 400x. (B) Western blots prepared 
with equal amounts of protein (S J.lg) from COS-l celllysates, 
transfected with vector (MI, ncur cDNA(NJ, PPCA eDNA (P), or 
both nem and PPCA cDNAs (NIP). Aliquo\s of lysates from 
neurarninidase-overexpressing COS-l cells wcce incubated ei· 
ther without (N, -G] or with N·glrcosidase F (N, + GI. The 
blots were incubated with affinity purified (X·nem antiserum. 
(e) COS-l cells were transfected with vector alone (M), ncur 
eDNA (N), PPCA eDNA !P), l3-galactosidase eDNA (8), or a 
combination of these, as indicated. Seventy·two hours post· 
transfection, cells were harvested and assayed for acidic neur· 
aminidase activity. 
cal puncta ted lysosomal pattern, In contrast, the endog· 
enous neuraminidase in mock-transfeeted sialidosis lSI 
MJ and galaetosialidosis (GS/M) cells was below the 
level of detection, The puncta ted pattern was restored 
when sialidosis fibroblasts were transfected with neur 
eDNA (SIN) or cotransfccted with neur and PPCA 
40 
cDNAs Idata not shown). We also reestablished the ly· 
sosomal localization of neuraminidase in PPCA·deli-
cient cells by transfecting them with PPCA cDNA (GSI 
PI, Overexpression of the neur cDNA alone in galacto· 
sialidosis cells IGS/N) creatcd a lysosomal staining 
pattern, despite the absence of PPCA. These data prove 
that overexpressed neuraminidase does not require 
PPCA to reach a lysosome·like compartment. 
We next tested neuraminidase activity in these trans· 
fected fibroblasts (Fig. SB), Because electroporation effi· 
ciency varied among the different cell strains, the rela· 
tive enzyme activities were compared only within trans· 
fcctions of the same strain, Transfections with the neur 
eDNA alone IN) raised the endogenous neuraminidase 
activity slightly in wild·type cells (WT), but generated 
enzyme activity in fibroblasts from sialidosis patients (S 
type 1 and II), demonstrating that both types of sialidosis 
result from a primary defect in the lysosomal neuramin-
idase, Despite the apparent lysosomal distribution of 
neuraminidase in neur·transfected galactosialidosis cells 
(see above), no increase in activity was measured (GS, N), 
again demonstrating that neuraminidase is inactive 
without PPCA, Transfections with PPCA alone {PI did 
not alter neuraminidase activity in wild-type cells, failed 
to correct the two sialidosis strains, and only slightly 
induced activity in galactosialidosis cells, The largest in-
crease in neuraminidase activity was measured when the 
neur and PPCA cDNAs were coexpressed (NIP), 
Lysosomal neuraminidase is mutated in type I and 
type Il sialidosis patients 
Because we were unable to detect any cross·reactive mao 
terial in either the sialidosis or the galactosialidosis fi-
broblasts with immunofluorescence, we tried to immu-
noprecipitate the protein from radiolabeled deficient 
cells (Fig. 6). In nOIOlal fibroblasts, the Q·neur antibodies 
recognized a polypeptide of -45 kD, that resolved on 
SDS-polyacrylamide gels as a broad heterogeneous band 
that probably represented different glycosylated forms of 
the enzyme (Fig, 6, lane 1), Cells from both type I siali· 
dosis siblings, the type II sialidosis patient, and the gao 
lactosialidosis patient also contained the neuraminidase 
polypeptide but a much smaller amount {Fig. 6, lanes 
2-5), In addition, the type II sialidosis cells contained a 
s3-kD product in an cquimolar ratio with the 4S·kD spe-
cies (Fig. 6, lane 3), Because the sialidosis patients had 
apparently normal amounts of neuraminidase mRNA, 
the severely reduced quantities of protein recovered from 
these fibroblasts could be attributed to decreased stabil-
ity of the mutant enzyme, 
We then searched for mutations in the neur gene of 
these patients by direct sequencing of reverse tran· 
scriptase jRTI-PCR·synthesized cDNAs, As indicated in 
Figure 7 A {left panel), both siblings With type I sialidosis 
were heterozygous lor a G to T transversion at nucle· 
otide 1258 of their neur eDNA, which introduced ;1 pre-
mature TAG termination codon at amino acid 377. The 
mutant protein would then have a carboxy· terminal 
truncation of 38 amino acids, The type II sialidosis pa-
Figure 5, Correction of neuraminidase defi· 
ciency in sialidosis fibroblasts. (Aj lmmunocy-
tochemicallocalization of neuraminidase in fi· 
broblasts of a normal individual (WT), a siaH· 
dosis type r patient (S), and a galactosiaHdosis 
patient (GSj, transfected with vector (M), neur 
cDNA IN), and PPCA eDNA IP). Cells were 
stained with affinity·purified (l·neur antise· 
rum. Magnification, 400x. (B) Neuraminidase 
activities in fibroblast ceillysates from a nor-
mal individual (WT), a galactosialidosis pa· 
tient (GS), a sialidosis type I patient (S type I), 
and a sialidosis type II patient (S type II), trans· 
feeted as described in Fig. 4C. 
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tient had one allele carrying a T to G transversion at 
nucleotide 401 and the other allele bearing a single-base 
deletion at nucleotide 1337 (Fig. 7 A, right panel). The 
point mutation gave rise to the amino acid substitution 
Leu9lArg, whereas the base deletion caused a frameshHt 
1 2 3 4 5 
Figure 6, lmmunoprecipitation of neuraminidase from sialido-
sis fibroblasts. Cultured fibroblasts from a normal individual 
(WTI, an E.l galactosialidosis patient (GSj, a Iype n sialidosis 
patient (S type II), and two siblings with type I sialidosis IS type 
I, PI, and P2) were labeled metabolically. The radiolabeled pro· 
teins were immunoprecipitated with (l·neur antibodies, and re-
solved by SD5-PAGE through a 12.5% gel. Estimated molecular 
masses arc indicated left. 
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at amino acid 403 that extended the protein by 69 amino 
acids, which explained the presence of the 53-kD protein 
in the patient's fibroblasts (Fig. 6, lane 3). 
Site·directed mutagenized cDNAs with either the type 
I mutation (premature stop) or the type II mutation 
(longer protein) were expressed alone or together with 
the PPCA eDNA in deficient fibroblasts and COSo} cells. 
Western blot analysis of transfected cell lysates con-
firmed that the eDNA-encoded proteins had abnormal 
molecular masses: 53 ko for the type II mutation, and 41 
kD for the type r mutation jFig. 8}. Both mutant proteins 
aberrantly localized to the perinuclear region but no ly-
sosomal staining or neuraminidase activity was noted, 
regardless of whether PPCA was present (data not shown 
and Table 1). These data confirm that these clinically 
relevant mutations produce nonfunctional ncuramini-
dase. 
Discussion 
The comprehensive characterization of lysosomal ncur-
aminidase has eluded investigators for many years be-
cause of the protein's apparent lability during purifica' 
tion procedures and its presumed membrane· bound 
character. Although these features have hampered the 
molccular cloning of this enzyme by conventional meth-
ods, interest in this important component of thc lysoso· 
mal system has persisted for several reasons. The en-
zyme has a pivotal role in the intralysosomal degrada-
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Figure 7. Mutations in the l~'sosomal neu'raminidase gene of type land type II sialidosis patients. (AI Partial nucleotide sequence of 
the neuraminidase eDNA from sialidosis patients. Total RNA was isolated from the fibroblasts of a normal individual (WTI, the two 
siblings with type I sialidosis (PI and P2, le/tl and the patient with type II sialidosis Irighll. This RNA was connected to eDNA by 
RT-PCR and the eDNA was directly sequenced through asymmetric peR. In the left panel a G to T transversion at nucleotide 1258 
in the neuraminidase eDNA is indicated !pI and P2, left pJncll. This transversion creates a premature SlOP codon. In the type II 
sialidosis patient, a deletion of a G at position 1337 in the cDNA (right panel, allele I, antisense sequence is shown) causes a frame 
shift that results in a longer ORF. The 5ame patient has a T to G tramversion at position 401, which causes an amino acid substitution 
at pOSition 91 in the protein (right panel, allele 2). (B) Schematic representation of the type I and type II mutant neuraminidase 
polypeptides. Shown are the normal protein (wt), with amino·terminal signal peptide (gray shaded), and the conserved and degenerated 
Asp boxes (numbered I to V). The type 1 sialidosis mutation gives rise to a truncated polypeptide of 377 amino acids (type Ij. Allele I 
of the type II sialidosis patient (type H, allele I), yields a longer protein of 484 amino acids that has a unique stretch of amino acids 
at the carboxyl terminus (shaded in gray). The second allele of the type II sialidosis patient (type II, allele 2) has a leu to Arg amino-acid 
substitution at pOSition 9] (L/R). 
tion of sialoglycoconjugates catalyzing the release of 
terminal sialic acids, which, in tum, triggers further deg-
radation of the sugar moiety. If this pivotal role is dis-
rupted, the defective enzyme contributes to two lyso-
somal storage disorders: sialidosis and galactosialidosis. 
The former is caused by structural defects in neuramin-
idase itself, whereas the latter results from a primary 
deficiency of PPCA, a pleitropic serine carboxypeptidase 
that is essential for neuraminidase activity {d'Azzo et al. 
1995), In fact, neuraminidase activity is strictly depen-
dent on the enzyme being part of a three-enzyme com· 
plex that includes PPCA and l3-galactosidase. 
In our effort to isolate the neur cDNA, We took advan· 
tage of the growing number of random, uncharacterized 
human cDNA sequences that are deposited daily in the 
dbEST data base. This "computer cloning" approach al-
lowed us to identify >30 overlapping neuraminidase 
eDNA clones, many of which are royalty-free and avail-
able through the Integrated Molecular Analysis of Ge-
nomes and their Expression (IMAGE) Consortium. In 
principle, this system could be used to identify other 
human proteins of known function that have resisted 
conventional molecular cloning. Only two criteria must 
be met: The cDNA clones representing the protein must 
be present in the dbEST data base, and the protein must 
have some sequence homology to known proteins with a 
similar fUnction in other organisms. In addition, care 
must be taken to ensure that the cDNAs do encode hu-
man mRNAs and arc not derived from contaminating 
organisms. 
Our neur cDNA clone recognizes an mRNA of - 1.9 
kb, that is ubiquitously but differentially expressed in 
human tissues. By using this cDNA to localize the hu· 
man neuraminidase gene to chromosomal band 6p21, in 
a region known to contain the HLA locus, we were able 
to not only establish that we had the correct cDNA, but 
also verify two other reports that mapped the neur gene 
to the 6p21 region [Oohira et at 1985} Harada et al. 
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Figure 8. Western blot analysis of mutant neuraminidase from 
sialidosis patlents, Western blot prepared with equal amounts 
of COS-I cell lysates, tr,msfected with vector IMOCK~, neur 
cDNA INEUR~, PPCA cDNA IPPCAI, or cotransfcctcd with 
both the neur and Pl'CA cDNAs INEUR/PPCA). In addition, 
two neuraminidase mutants type I Asp-377-stop INEUR oJ, and 
type II Ser403·frame shift INEUR' 'I were either expressed 
alone Of co-expressed with PPCA_ The Western blot was incu-
bated with affinity·purified a-neUl antibodies. Estimated mo-
lecular masses of the wild-type proteins afe indicated at left and 
of the aberrant pol~'peptides at the riglll. 
1987). Interestingly, the murine Neu-l locus, which 
seems to be responsible for the partial deficiency of neur-
aminidase in inbred SM/J mice, maps to chromosome 
17,' near the major histocompatibility complex H2, 
which is syntenic to the human 6p region [Womack et al. 
1981), 
Lysosomal neuraminidase shares significant homol-
ogy, with many members of the sialidase superfamily 
[Roggentin et a1. 1993). Based on our observations, we 
can speculate that rodent sialidases are positioned evo-
lutionarily betwcen the bacterial/human neuramini-
dases, which contain the FRIP domain and Asp boxes, 
and the viral sialidases, which mostly lack Asp boxes. 
The exact function of the Asp box is unknown but they 
have been found in at least seven other unrclated pro-
teins from plants, viruses, bacteria, and yeast (Rothe ct 
a1. 1991). The only characteristic these proteins share is 
their ability to bind carbohydrates, Because sialidases 
and their sialyl substrates are absent in plants and meta-
zoans, the occurrence of Asp boxes in plant proteins sug-
gests that these boxes do not contribute to sialic acid 
metabolism. In spite of the differences observed at the 
amino-acid level, the crystal structure of bacterial and 
viral sialidases indicates that the fold topology of these 
enzymes is identical and consist of the same six-bladed 
p-propeller around an axis that passes through the active 
site (Crcnnell et al. 1993; Gaskell et al. 1995j, Several of 
the residues in the catalytic pocket of bacterial sialidases 
are conserved in the human enzyme, including the Arg 
in the FRIP domain, It is therefore very likely that hu-
man neuraminidase has a similar three-dimensional 
structure. The primary structure of neuraminidase docs 
not reveal any obvious membrane targeting domain, be-
sides the signal peptide, which suggests that this protein 
is unlikely to associate with the membrane. This finding 
is not in keeping with the insoluble nature of the en-
zyme. 
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By expressing the fuU-Iength neur eDNA in COSo} 
cells, we confirmed the lysosomal localization of the 
protein and the generation of PPCA-dependent neur-
aminidase activity at an acidic pH optimum. Surpris-
ingly, we found that a significant number of cells over-
expressing neuraminidase accumulate crystal-like struc-
tures in their perinuclear regions, that stained only with 
anti-neur antibodies. Although this "crystallization" ef-
fect was most likely attributable to overexpression, it 
must reflect an intrinsic, unique property of the enzyme 
because crystals of this size of other overexpressed pro-
teins have not been reported previously. Another lyso-
somal enzyme, a-galactosidase, was shown to form crys-
talline structures when overexpressed in CHO cells; 
however, in this case, the crystals were only visible at 
the electron microscopy level (Ioannou ct al. 1992). In 
vivo crystallization of proteins is a rare though naturally 
occuring event. It has been reported for crystallin pro-
teins in the eye lens (Russell ct al. 1987) and for insulin 
in pancreatic acinar cells [Kuliawat and Arvan 1992). In 
both of these reports, the crystals are relatively small. It 
rna}' be that the insoluble nature of lysosomal neuramin-
idase is a direct result of this ability to crystallize or 
aggregate. 
Our most compelling evidence that the eDNA-en-
coded protein is the lysosomal neuraminidase came from 
studies on patient fibroblasts. Overexpression of our 
neur eDNA in the sialidosis patients'fibroblasts restored 
neuraminidase localization and activity. We found that 
PPCA is not required for correct lysosomal localization 
of neuraminidase, but is indispensable for enzyme acti-
vation. Catalytically inactive PPCA mutants rescue 
neuraminidase activity in the galactosialidosis fibro-
blasts Idata not shown; Galjart et al. 1991), which sug-
gests that the carboxypeptidase activity of PPCA is not 
Table 1. Transfection of sialidosis fibroblasts with mutallt 
neuraminidase cDNA constructs 
eDNA construct 
mock 
PPCA 
neur 
neur' 
neur' ° 
neurlPPCA 
neur'/PPCA 
neur' '/PPCA 
Neuraminidase activity 
Inmollhr per mg protein) 
wild-type fibroblasts sialidosis fibroblasts 
58 ± 8 0 
75:!; 9 0 
40:!; 5 30:!; 12 
nod. 0 
n.d. 0 
300:!; 21 108 ± 18 
n.d, 0 
n.d. 0 
Sialidosis type II fibroblasts were eJectroporated with the siali· 
dosis mutant pSCTOP eDNA constructs alone, type 1 Asp377-
stop (neur'), and type II Ser4OJ-frameshift (neur' '), and with 
the mutant neuraminidase and wild·type PPCA constructs 
(neur'/ppeA and neur' '/PPCA). Wild·type and sialidosis fibro-
blasts wefe also eJectroporated with the wild-type neuramini-
dase and PPCA cDNAs (neur and PPCA), and coelectroporated 
with both constructs !neurIPPCAj. The mutant cDNAs were 
not expressed in the wild-type fibroblasts (n_d.). 
required to activate neuraminidase. It is clear from these 
studies that l3"galactosidasc is not directly involved in 
neuraminidase activation, a finding thllt supports carlier 
observations in PPCA-dcficicnt knockout mice (Zhau ct 
al. 1995), where l3-ga1actosidase activity is reduced only 
in certain tissues, whereas neuraminidase deficiency 
parallels that of PPCA. Why then do PPCA, l3-ga1actosi-
clasc, and neuraminidase form a multienzymc complex~ 
A possible explanation is that association between the 
different components could alter the active sites of the 
enzymes, influencing their substrate specificity and/or 
catalytic activity. By coupling catalytic activity to as-
sembly, protein components can be regulated through 
coordinated activation or stoichiometry in the complex. 
Although the exact mode of neuraminidase activation 
remains unclear, it is conceivable that the inactive neur-
aminidase polypeptide associates with PPCA, which pro-
motes a crucial conformational change that renders the 
enzyme substrate accessible. Alternatively, PPCA could 
present the inactive neuraminidase to a different pro-
cessing enzyme, which then activates it. 
The identification of mutations in the neur mRNA 
from type I and II sialidosis patients, that are directly 
linked to the inactivation of the enzyme, provided the 
ultimate proof that the disease is caused b}' genetic le-
sions in the neuraminidase gene. On the basis of the 
experimental data presented here, we cannot at this time 
correlate the genetic defect in sialidosis type I with their 
mild phenotype. It is likely that an as yet unknown mu-
tation in the second allele from these patients produces 
an enzyme with residual activity. A comprehensive anal-
ysis of the mutations in these and other sialidosis pa-
tients and thcir eHect on the protein will be the subject 
of future studies. 
The availability of the lysosomal neuraminidase 
eDNA enables us to investigate the neuraminidase pro-
tein in depth, particularly its association with other 
components of the complex, such as PPCA. In addition, 
we should gain better insights into the mechanisms that 
regulate neuraminidase activation and inactivation. Elu-
cidation of the three-dimensional structure of lysosomal 
neuraminidase, either alone or complexed with PPCA 
and p-galactosidase, would offer essential insights into 
the specific physiological properties of the individual en-
zymes. This information, coupled with mutation analy-
ses from other sialidosis patients, will help to explain the 
structure and function relationships of the wild-type pro-
tein and the defcctive mutant enzymes. Finally, it will 
be particularly interesting to assess the relative contri-
butions of the three neuraminidase enzymes to catabo-
lism of sialic acid-containing compounds, both under 
normal conditions and in the diseased state. 
Materials and methods 
Cell culture 
Human skin fibroblasts from a normal individual and patients 
with galactosialidosis or sialidosis are deposited in the European 
Cell Bank, Rotterdam, The Netherlands (Dr. \V.T. Kleijer). fi-
broblasts from two siblings with the type I form of sialidosis 
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were kindly provided by Dr. Beck (Klinikum der rohanncs 
Gutenbelg·Universitat, Mainz, Germany), who diagnosed the 
disorder in these patients. Fibroblasts from the type 11 sialidosis 
patients were kindly sent to the Rotterdam cell bank by Drs. G. 
Parenti and P. Strisciuglio (Dipartimento di Pediatria, Univer' 
sita di Napoli, Italy). Primary fibroblasts and COS-I cells (Gluz-
man 1981) were maintained in Dulbecco's modified Eagle's me-
dium (D1\1E1\1), supplemented with antibiotics and 10% or 5% 
fetal bovine serum, respectively. 
Screening of the EST data base 
The dbEST data base (Boguski 1995) was searched with the text 
string: "neurJminidase or sialidasc" using an input device 10-
catcd on the World Wide Web (http://www,lncbLnlm.nih.gov/ 
dbest_query.htlml. Putative neuraminidase eDNA clones ho-
mologous to known sialidases were retrieved. Their nucleotide 
and amino acid sequences (translated in all six reading framesl 
were anJlyzed for actual homologies using the NCBI Blast 
e-mail server (blast ncbLnlm.nih.gov), and were compared with 
nonredundant peptide and nucleotide sequence data bases (PDB, 
S'r\'lSS-PROT, PIR, SPUpdate, GenPept, GPUpdate, GBUpdate, 
GenBank, EMBL, EMBLUpdate). A dbEST cDNA clone with 
favorable alignment to bacterial neuraminidases, accession no. 
RIJ552 (IMAGE clone 265251 was acquircd, royalty frce, from 
the IMAGE Consortium, Huntsville, Alabama. This clone is 
henceforth referred to as neur cDNA. 
Northern blot analYSis 
A Northern blot (Clolltech) containing equal amounts (2 fig) of 
human multitissue pol>'(A)+ RNA was hybIidized with the 1.9-
kb neurcDNA labeled accmding to Sam brook et al. (1989). The 
membrane was stripped according to the manufacturer's in-
structions and rehybridized with the 1.8-kb human PPCA 
eDNA (Hu54) (Galjan et al. 1988). Total RNA was isolated from 
control and sialidosis patients' fibroblasts using TRIzol reagent 
according to manuf.:!Cturer's instructions (Ufe Technologies). 
RNA (-10 fig) was separated on a 1% agarose gel containing 
0.66 M formaldehyde. After electrophoresis, the RNA was blot-
ted onto a Zeta·probe membrane (Bio·Rad) and hybridized with 
thc neur eDNA probe. Standard hybridization and washing con· 
ditions were applied (Sambrook et al. 1989). 
cDNA sequellcing 
The 1.9-kb neuraminidase cDNA clone was subcloned into 
pBlucscript II KS (Stratagenc) using standard procedures ISam· 
brook el al. 1989) and sequenced using the fmol kit /Promega) on 
double·stranded DNA (Murphy and Kavanagh 19881. Nucle-
otide sequence data were analyzed using the Wisconsin package 
(version 8, Genetics computer group). Homology searches were 
carried out using the NCBI Blast e-mail server, as stated above. 
Alignment of protein primary structures was performed using 
the computer programs ClustalW and Boxshade (Hofmann and 
Baron, Bioinformatics group, Swiss Institute for Experimental 
Cancer Research, Lausanne, Switzerlandl, with a gap penalty of 
10.0 and a gap extension of 0.05. 
Chromosomallocallzation 
A a.s-kb peR fragment WaS ;lmplified from human genomic 
DNA, using IS'mer oligonucleotide primers, synthesized ac-
cording to 5' (sense) and 3' [antisense) sequences In the neur-
aminidase cDNA. The 1.9-kb eDNA and the 3.5-kb genomiC 
fragment were labeled separately by nick translation with 
digoxigenin dUTP. The labeled probes wele then combined 
with sheared human DNA and hybridized independently to nor-
mal metaphase chromosomes derived from FHA-stimulated pe-
ripheral blood lymphocytes as described !Morris el ,11. 1990. 
Specific hybridization signals were detected by incubating the 
hybridized slides in fluorescein-conjugated antidigoxigenin an-
tibodies. The chromosomes were then stained with DAPl and 
analyzed. Fluorescence signals observed with these probes were 
specific to the middle of the short arm of a C group chromosome 
with DAPI-banded morphology consistent with chromosome 6. 
Based on the distance from the centromere of the h~'bridization 
signal relative to the entire length of the short aIm of chromo-
some 6, we aSSigned the neur locus to band pll. 
nansfcctions and enzyme IISSa}'S 
cDNAs encoding neuraminidase, PPCA lGaljart etaL 1988), and 
jl-galactosidase (Moneau et aL 1989), subcloncd into the expres-
sion vector pCD-X (Galjart et al. 1988; Okayama and Berg 1982), 
were transfected into COS-l cells using calcium phosphate pre-
cipitation as described !Chen and Okapma 1987). 
The cDNAs mentioned above were also subdoned into 
pSCTOP !Fornerod et al. 1995; Rusconi et at 1990) and electro-
poratcd into primary fibroblasts according to the manufactur-
cr's instructions IBio-Rad), with the following modifications. 
Primary fibroblasts were trypsinized, resuspended in DMEM 
supplemented with 10% fetal calf serum, and washed once in 
ISCOVE's medium. Plasmid DNA 130 Ilgl was then electropo-
rated into -I x 1O~ cells, suspended in 500 1-'-1 of ISCOVE's me-
dium, using a OA-cm electroporation cuvette in a BioRad Gene 
Pulser set at 0.320 kV, and 500 IlF (time constant 11-1.1). The 
dectroporated celts were then seeded into 50-mm Petri dishes 
and cultured for 16hr, at which point the medium was changed. 
Transfected COS-1 cells and primary fibroblasts were har-
vested by trypSinization 72 hr post-transfection and assayed for 
neuraminidase activity with the artificial4·mcthylumbelliferyl 
substrate, according to Galjaard 11980). Total protein concentra-
tions were quantitated with bicinchoninic add (Smith et ,11. 
1985) following the manufacturer's guidelines IPierce, Chemi-
cal Co.). 
Immunofluorescence, Western blolling. and 
immurl0pJcdpitation 
Antiserum was raised in rabbits against a bacterially produced 
CST-neuraminidase fusion protein that lacks ncuraminidase 
amino-acid residues I-50. This antiserum la-ncur) was affinity-
purified as described previously !Smith and Fisher 1984). The 
denatured 32-kD chain of PPCA, generated through its overex-
pression in insect cells lBonten et al. 1995), was used to raise 
anti-PPCA antiserum !a-32) in rabbits. 
For indirect immunofluorescence, COS-l cells and primary 
fibroblasts were seeded 48-72 hr posHransfcction on Super-
frost/plus glass slides (Fisher). The next day, the cells were pro· 
cessed according to van Dongen et al. (19851, using the antisera 
mentioned above and FITC-coniugated antirabbit IgG antibod-
ies (Sigma). 
For Western blotting, COS-l cells were harvested by trypsin-
ization 72 hr ppst-uansfection and lysed in milli.Q water (Mil-
lipore). Aliquots of celllysates containing 5 llg of protein were 
resolved on SDS-polyacrylamide gels and transferred to Immo-
bilon poiyvinylidene difluoride membranes !Millipore), West-
ern blots were incubated with affinity-purified a-neur antibod-
ies as described Bonten et al./1995), using either alkaline phos-
phatase- or horseradish peroxidase-conjugated antirabbit igG 
secondary antibodies, with a colorimetric lSigma) or chemilu-
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minescent (Renaissance, DuPont NENJ substrate, respectively. 
Deglyco5ylation reactions were performed with recombinant 
N-glycosidase F lBoehringer Mannheim) according to the sup· 
plier's instructions. 
For immunoprecipitation, fibroblasts were grown to con-
fluence in 85-mm Petri dishes and labeled with 350 /LCi 
L-[4,5-3H)-Leucine per dish for 20 hr. Proteins ..... ere precipitated 
with a-neur as reported prevIously !Proia et al. 1984) and re-
solved by SDS-PAGE under denaturing and reducing condi-
tions. Radioactive bands were visualized by fiuorography of gels 
impregnated in Amplify !Amersham). Apparent molecular 
masses were calculated by comparison with marker proteins 
!Life Technologies). 
Mutation anal},si5 
For amplification of mutant cDNAs, four sets of IS-mer oligo-
nucleutide primers were synthesized based on the wild-type 
cDNA sequence. Total RNA was isolated from controllibro-
blasts and the fibroblasts of sialidosis patients' by using TRlzol 
reagent according to the manufacturer'S instructions !Ufe Tech-
nologies). fuur OVerlapping cDNA fragments of -500 bp each 
encompassing the entire coding region of the neuraminidase 
cDNA, were syntheSized by RT-PCR (Hermans et a\. 1988). For 
direct cDNA sequence analysis, a portion of PCR-amplified 
cDNA was subsequently subjected to asymmetric PCR (Kad-
owaki et ,11. 1990), using a 1:100 ratio of sense:antisense or 
antisense:sense primer concentrations, for an additional 30 cy-
cles. The PCR products were phenul/chloroform extracted, de-
salted on Centricon-IOO units (Amicon), and precipitated with 
isopropanol. The single-stranded products were sequenced by 
the dideoxy-chain termination method (Sanger et al. 1977) using 
the Sel\uenase kit accordinji to the manufacturer's instructions 
IUSB(. 
Transient e~-plt'ssion of mutant nctlIaminidase cDNAs 
To introduce the mutations found in the neuraminidase of sial-
idosis patients, into the full-length cDNA, small fragmcnts 
{-400 bpI, containing the identified mutations, were excised 
from the RT-PCR products described above and subcloned into 
the pSCTOP-neuraminidase cDNA construct. The plasmid, 
were then sequenced to ensure that the mutations had been 
correctly introduced. They were then transfected into COS-l 
cells and primary sialidosis fibroblasts as described above. 
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lysosomal neuraminidase (slaUdase) occurs In a high 
molecular weight complex with the glycosidase 
!}-galactosldase and the serine carboxypeptidase 
protective protein/cathepsin A (PPCA). Association of 
the enzyme with PPCA Is crucial for lis correct targeting 
and lysosomal activation. In man two genetically 
distinct storage disorders are associated with either a 
primary or a secondary deficiency of lysosomal 
neuramInidase: slalldosls and galactoslalldosls. In the 
mouse the naturally occurring Inbred strain SM/J 
presents with a number of phenotypic abnonnalltles 
that have been attributed to reduced neuraminidase 
acllvlty. SM/J mice were originally characterized by their 
altered slalylatlon of several lysosomal glycoprotelns. 
This defect was linked to a single gene, neu·t, on 
chromosome 17, which was mapped by linkage 
analysis to the H-2 locus. In addition, these mice have 
an altered Immune response that has also been coupled 
to a deficiency of the Neu-1 neuraminidase. Here we 
report the Identification In SM/J mice of a single amino 
acid substitution (l2091) In the Neu·1 protein which Is 
responsible for the partial deficiency of lysosomal 
neuraminidase, We propose that the reduced activity Is 
caused by the enzyme's altered affinity for Its substrate, 
ratherthan a change In substrate specificity or turnover 
rate. The mutant enzyme Is correclly compartment-
alized In Iysosomes and maintains the ability to 
associate with its activating protein, PPCA. We propose 
that it Is this mutation that Is responsible for the SM/J 
phenotype. 
INTRODUCTION 
Neuraminidases (sialidascs) constitute a large and important 
family of hydrol)·tic enzymes that cleave the tenninal sialic acid 
residues from a variety of sialoglycoconjugates [for a review see 
(10)]. This event influences many cellular proccsscs, including 
cell--cell interaction/adhesion, protcction from pathogens and 
antigen recognition (10-14). Some family members share certain 
characteristic fe.1tures, including the F{Y)RIP domain in the 
N-tenninal region of the protein, where the arginine is part of the 
active sitc, and two to five evenly spaced Asp boxes (Srr~X-D·X~ 
G·X·T-W/F), which are located C·temlinal of the F(y)RlP 
sequence (15,16). The three-dimensional structure of bactcrial 
and viral sialidases has shown thai these enzymes have acommon 
catalytic core of -40 kDa with a characteristic six·bladed 
p·propeller fold (17,18). Human lysosomal N-acetyl-a-neur-
aminidase is deficient or defective in Iwo distinct mctabolic 
storage disorders: siaiidosis, which is caused by structurollesions 
in the neuraminida~e gene; and galactosialidosis, in which 
neuraminidase deficiency is secondary to a primary defect in the 
serine carboxypeptidase protcctive protein/cathepsin A (PPCA) 
(1,4). Recently we and others doned the human neuraminidase 
eDNA and identified a number of independent mutations in the 
neuraminidase gene that we associated with different clinical 
variants of sialidosis (3, 19,20). The neunlIl\inidase locus maps to 
the HLA rcgion on chromosome 6p21 (3,21,22). 
In the mouse a partial deficiency of a neuraminidase was first 
identified in the naturally occurring strain SM/J (23). Thcse 
inbred mice had already been selected in the early 19-10s for their 
relative sma!! body size following cross matings with seven 
different inbred strains. Later, biochemical analysis demonstrated 
abnomlal sialylation of at least four lysosomal glycoproteins that 
showed an altered migration pattern on starch gel electrophoresis. 
This defect was corrcctcd by treatment with bacterial sialida'ie 
[reviewed in (5)}. This hypersialylation was attributed to a 
reduction in activity of a liver-specific sialidase (5,24,25), 
although some reports suggested that other organs were also 
affectcd (23,26). The responsible gene was designated /It'II·/ and 
mapped, by linkage analysis, to the histocompatibility locus on 
chromosome 17, in the region between H-2D and H-2Ea (6,7), 
which is syntenic to the human HLA locus on chromosome 6p21. 
Besides the abnonnal sialylation of lysosomal giycoproteins. 
SM/J mice also have an impaired immune response, which is 
thought to result from the altered processing of sialic acids pres· 
ent on cell surface molecules of subpopulations of T cells 
(8,9,27-31). An important step in the development of an immune 
response is differentiation of activated naive T cells into either 
IFN-'(producing (Thl) or IL-4·producing (Th2) cells [for a 
review see (32»). Although Sl\.1/J mice can stimulate a Thl-
mediated immune response, they cannot stimulate the conversion 
of naive T cells into Il...4-producing Th2 lymphocytes. This 
altered response has been attributed to reduced activity of Neu· I 
neuraminidase, which is thought to result in: (i) improper 
desialylation of surface antigens on Th2-committed cells; (ii) 
reduction in early IL-4 production; and (iii) abscnce of IgOl and 
IgE production by n cells aftcr ill vil'O immunization of S~I/J 
mice with pertussis toxin (31). T cell Neu·! neuraminidase has 
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also been implicated in conversion of vitamin D3 binding protein 
into macrophage activating factor (27). Together these data 
suggest an important role for Neu-I neuraminidase in processing 
of selected sialoglycoconjugates at either the plasma membrane 
or within intracellular compartments. 
In this paper we describe identification of a single amino acid 
sub~titution, L209I. in the lieu I-encoded lysosomal neuramini-
dase of SM/J mice. Analysis of the biochemical properties of this 
mutant enzyme demonstrates that its reduced neuraminidase 
activity is indeed caused by the presence of this mutation and not 
by improper compartmentalization of the protein, altered turn-
over or a lack of association with PPCA. 
RESULTS 
Isolation orthe murine neuraminidase cDNA and 
expression pattern or lleu-} in mouse tissues 
Two murine neuraminidase cDNAs (1.8 and 2.4 kb) were isolated 
using the human eDNA as probe. Both contained the same open 
reading frame, but the 2.4 kbclone lacked the first two codons and 
had an extended 3'-untranslated region (UTR). The deduced 
amino acid sequence of the mouse protein is 91 % 'similar to its 
human counterpart: the N-temlinus begins with a conventional 39 
amino acid signal sequence (33) and includes a FRIP domain as 
well as three conserved and two degenerated Asp boxes. The 
protein has four potential N-linked glycosylation sites; the first 
three are found at identical positions in the human neuraminidase, 
whereas the fourth, which is close to the C-temlinus, is only 
present in the mouse sequence (Fig. I). Northern blot analysis of 
multiple tissues, using probes spanning the cDNA (Fig. I) 
demonstrated two major and two minor transcripts, which vary in 
length from 1.8 to 4.0 kb (Fig. I). The 3'-UTR probe, unique for 
the 2.4 kb eDNA, recognized only the 2.4 and 4.0 kb transcripts, 
indicating that the four mRNAs use altemative 3'-lITRs. TIle 
hybridization results suggest that all four transcripts contain the 
same protein encoding sequence. The 1.8 and 2.4 kb mRNAs 
were the most abundant and displayed a differential pattern of 
expression which dosely correlated with expression of PPCA, 
which fonns a complex with the neumminidase protein (34,35). 
The murine gene coding for the isolated eDNAs contains six 
coding exom (Table I). The gene spanned a small region of4 kb 
and was mapped, using the 1.8 kb cDNA insert as probe, to the 
H+2 region of chromosome 17 (data not ShOV,l1), 
Phenotypic characterizallon orS~f/J mice and 
identifieallon of Ihe mutalion in the lIell-1 gene 
All four neuraminidase transcripts displayed similar pattems of 
expression in kidney, brain, liver and spleen RNA preparations 
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from S~-l/J mice (Fig. I). In addition, a single polypeptide was 
immunoprecipitated with anti-human neuraminidase antibodies 
(anti-neur) from radiolabeled Iysates of SM/J fibroblasts; this 
immunoprecipitated protein was comparable in size with the 
nonnal murine protein (data not shown). Although we found no 
overt changes at the RNA or protein level, we did find that 
neuraminidase activity of SM/J Neu-l differed from that of 
wild·type Neu+l. Using sodium 4-methyl-umbelliferyl-a-o-N+ 
acetylneuraminate (4-MU-NANA) as substratc, SM/J Neu-! 
activity was significantly reduced in lysosomal/mitochondrial 
extracts derived from several SM/! tissues and this partial 
deficiency wa~ clearly not restricted to anyone tissue (Fig. 2). 
S~I/J neurantinidase activity in kidney and liver extracts was also 
lower than that of control values when assayed with either a-2,3-
and a-2,6-sialyllaetose (a~2,3- and a-2,6-NANA-lactose) as 
substrate, thus demonstrating that the defective enzyme did not 
show altered specificity for either of the two linkages (Fig. 2), 
However, using fibroblast extracts we could demonstrate that 
Sl'I1/1 neuraminida~e assayed with substrate concentrations 
ranging from 0.110 1.5 mM 4-MU-NANA had an -3-fold lower 
V mH than the wild-type enzyme (Fig. 2). This suggests Ihat the 
L209I substitution influences the kinetic properties of the mutant 
enzyme. Furthennore, the mut:mt mice displayed an abnonnal 
pattern of urinary oligosaccharides (Fig. 2), indicative of 
oligosacchariduria, a condition commonly observed in galaclo-
sialidosis mice (2). Histological analysis of the SM/J mice 
showed evidence of stomge producls in specific cells, such as the 
Purkinje cells of the cerebellum and the glomerular epithelium, 
which appeared to accumulate over lime {data not ShOV,l1}. 
Because these parameters are commonly used in biochemical 
diagnosis of sialidosis and galactosialidosis patients (1,4), it is 
clear that SM/J mice share similar phenotypic abnonnalities with 
these two human diseases. 
To identify the underlying genetic lesion responsible for these 
abnonnalities we searched for a mutation(s) in the neuraminidase 
gene. Using RT-PCR on bmin and liver RNA derived from SM/J 
mice of different ages and from different litters we amplified four 
overlapping fragments that span the entire neuraminidase eDNA 
(Fig. 3). Three mouse strains, BALB/c, l29/Sv and FYB, were 
used as controls. Sequence comparison identified seven nucleo-
tide changes in the SM/J cDNA; four involved the wobble base 
of amino acid codons Lys93, Arg202, Thr295 and Ala316, Iwo 
were present in the 3'-UTR and one was a C-tA tnmsversion at 
nl 625 within exon IV of the gene. This transversion resulted in 
the amino acid change Leu209 to Ile (L209I). Because exon IV 
is present in all four neuraminida~e transcripts (Fig. I), we 
inferred that this point mutation must be present in all of the 
mRNAs and in the corresponding protein. 
Tuble I. Sizcs and locations of exons and introns and sequences at the e~onJinlron boundaries of the nell'} gene 
E~ons eDNA position inlrOru Inlron size 
Number Size 5' Iplice site 3' splice site 
17I -30 \0141 AGCCfGgIgagc g~gcagGTGCAG 365 (I) 
II 190 14210331 ACCAGGg\a.a~a \!ctagGTAGCA 453 (2) 
III 266 33210597 ATTCAGgltlca laacagAAACAG 1200 (l) 
IV 183 598 10 780 TGCCAGglcagg acgcagCCCTAC 97 (4) 
V 221 781 to lOOt AGTICCgtgagt tCClagGAGTGA 99 
'" VI 1365 1002102366 
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Flgure I, (A) CompanIon ofth~ amino add ;equences ofmou,e and human neuraminida,e,.ldemical residues Me sho\\TI in blad..: and similar residue, in gr;lY, The 
signal sequence is underlined; the FRIP !-e<juence and me «)n;~r\'ed Asp boxes (I-III) arc boxed; the deg~n~ratc Asp boxcs (IV and V) are double und~rlined. TI1C 
glycos}!ation sites are indicJted by an s<;teri,k above the !-e<juence. (B) Linear repre><,nL1tion of the tWO nrllr.l!llinid.1Se eDNAs: the coding region is indicated as an 
open bo:l:; the 5'·UTR, unique for the 1.8 kb dooe, and the pm of the 3'· UTR shared by both cD}lA dones are indicated by gr.l}' bo~e,. The p:l!t of the j'·UTR unique 
for the 2.4 kb clooe is sho\\TI as a smalkr bla,k bo~. f'.:umbers represent nucleotide rc',ition'. lhe different probe> Uled to h)bridize the nonhem blot are: I, nt-23 
to 491; II, nl601 to 780; III, nt 10-1910 1539; IV, ot 2072 to 216S. (C) Nonhem bl[lt anal)sis using the probes outlined in (Bland indicaled lmdereach panel. E~p'-~sure 
times were 3 days forblol'i probed "ith II and IV, 16h forblo\S probed \\ith I anJ III. The biOI b}bridizeJ \.ith probe II lias alsoe\rc'seJ for 16h IOresoll"c theJifferent 
transcript> in the kidney sample (sho\\TI as separate lane). Br, brain; He, heart; Ki, kiilile}~ U, EWr; l.u,lunll; Sm, smooth mlL<,Cle; Sp, sple.-o; Te, uSIis. (D) Nortll~m 
blot prepared with tOlal RI"A from S~"J-deril"ed tissues and b)bridi7ed \\ith a combination (If prot-e, I and III. E~po\ure time \\3-> 5 da}s 
Expression of L209I llIutant neuraminidase In deficient 
fibroblasts 
To a~sess the impact of the L2091 change on biochemical 
properties of the nonnal enzyme we engineered this mutation into 
the nonnal 1.8 kb murine eDNA. The resulting mutant done 
(Mo-smj) was completely sequenced to confiml correCI introduc-
tion of the mutation. This mutant eDNA was transiently 
expressed in Iwo human sialidosis type n fibroblasts. 1l1ese cells 
were chosen because, unlike SM/J fibroblasts, they totally lack 
neuraminidase activity (3). Mo-smj cDNA only partially cor-
reeled the deficient fibroblasts, genentting neuraminidase activity 
of between 40 and 65% of that of the wild·type murine ("Mo·neur) 
enz}me. Given the strict dependence of neuranlinidase on PPCA 
for full enzymatic activity (l ,2), we also tested the effect of both 
mouse and human PPCA on S.M/J neuraminidase. Co-transfec~ 
lion oflhe Mo-smj and Mo-neur cDNAs with either the mouse or 
human PPCA eDNA (Mo-ppca and Hu·ppca) resulted in a dear 
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increase in neumminidase aClivily for bOlh the nomlal and mulant 
prolein (Fig. 3). 11le induced SMJJ activity, however, remained 
lower thml that of the wild+type. The L209I mutation was also 
introduced into the human neumminidase eDNA (Hu-smj). 
Expression of this mutant clone alone or in combination with 
human or mouse PPCA again re~ulted in reduced neuraminidase 
activity (Fig. 3), unequivocally demonstrating that the L2091 
substitution is responsible for the enzyme defect. Immuno-
fluorcscence analysis of singly and doubly tmnsfected cells 
showed that the presence of the mutation in either the mouse or 
the human neumminidase molecule does not alter Ihe subcellular 
distribution of the enzyme, which maintained a typical punctate 
lysosomal staining (Fig. 3). The lysosomal localization of the 
mutant enzyme was confinned using Percoll density gradients 
with transfected COS-I cells (data not shown). Co-expression of 
either mouse or hum.m PPCA dearly enhanced the lysosomal 
signal, further indicating that PPCA has a stabilizing eHeet on Ihe 
mut.mt protein. 
Biosynthesis of the L2091 nmtant in COS·! cells and Its 
association with the PPCA precursor 
The increase in SM/J neuraminidase activity in cells co-expres-
sing mutant Neu-l neuraminidase and PPCA suggested that 
inlenlction between the two proteins was not affected by the 
L209l mutation. We tested this assumption by overexpressmg the 
Smj.neul and the PPCA eDNAs in COS-I cells and then 
immunoprecipitating radiolabeled proteins with anti-neur or 
anti-PPCA antibodies (Fig. 4). Although the anti-neur antibodies 
recognized the murine protein with lower afflllity than they did 
the human protein, more SM/J protein than wild-type mouse 
protein was immunoprecipitated from equally transfected cells 
(Fig. 4, lanes 2 and 3). Nevertheless, neuranlinidase activity in 
singly tmnsfected cells was again 50% of that of control values 
(data not shown). In co-tmnsfectoo cells both the .mouse and 
human PPCA precursors were co-precipitated with anti-neur 
antibodies, together with the S~Uj polypeptide (Fig. 4, lanes 8 
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acthity in edll}'.\ates of ele.:troporaled GM01718 lialidosil I)pe II fibroblasts ming 4·MU·NANA as submate. Values reprelenllhe average of four independent 
ele..-u-oporations. 11le diagram to the left moll 5 re'iUlrs ob!.iined II ith the murine n~ur.!ITlinidase cDi'l"As, \I hereas the diagr.ml to the right shOlH re~U!lS \I ith the human 
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cD:-'A containing the SMIJ mutation. (C) Inununofluorescence II ith antj·hum3ll neuranlinid.l>e antibodie, of fibroblasll ekawpora!ed \\ith the mOllIe neuranlinid.lSe 
cDNA (Illo-neur), the S~flJ eDNA (l'IIo-smj), human neuraminidase cD;..IA (fIu·neur) and human mutant cDi'l"A (Hu-smj).l.posome·lil..e punClated staining \\dS 
elidenced in the different e!ectmjXlfJ.ted fibroblasts. 
and II). The mutant protein, the wild-type mouse protein and 
human neuraminidase all co· precipitated the PPCA precursor 
equally efficiently (lanes 7, 9, 10 and 12). Therefore, the L209I 
substitution did not interfere with association between the mutant 
protein and either mouse or human PPCA, excluding the 
possibility that the SM/J mutation affects complex fonnalion. 
Sequential immunopredpitation of all samples with anti-PPCA 
antibodies explained the difference in the ability of the mouse and 
human PPCA to enhance neuraminidase activity (Fig. 3). The 
murine PPCA precursor in overexpressing cells was not as well 
processed to the mature two chain foml as the human PPCA 
precursor (Fig. 4, lanes 7-9 and 10-12). This reduced level of 
processing could have led to a smaller pool of mature PPCA 
available for 'protection' of the lysosomal neuraminida~e. 
Turnover of the SM/J neuraminidase was apparently not 
influenced by the L2091 substitution, as delennined by pulse-
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(Hu'PP'a) eDNA,. Molecular v.dghtl v.ere calculated 011 the basis of protein standard ... 
chase labeling of transfected COS-I cells (Fig. 4). Both the 
mutant and wild-type neuraminidase appeared to be stabilized 
upon co-expression of mouse PPCA, since immunopredpitable 
material could still be detected at the 3-6 h time points (Fig. 4, 
middle panels). The stabilizing effect was less apparent, but still 
recognizable, when human PPCA was co-expressed with mutant 
or wild~type neuraminidase (Fig. 4, lower panels), These results 
clearly correlate with the obserwd increase in enzyme activity in 
cells co-expressing mutant or wild-type neuraminidase with 
PPCA. 
DISCUSSION 
Overall the results we present here provide strong evidence that 
the subtle L2091 substitution is responsible for the altered 
neumminidase activity in SMjJ mice, Leu209 in the murine 
enzyme falls in an amino add streIch that is highly conserved 
among the different sialidases (10,36). This residue coincides 
with Leu22t and Leul99 of the Micromonospora viridifaciens 
and Salmonella /yphinwriwlI sialidases respectively, which are 
located in the three-dimensional structure of these enzymes in the 
vicinity of the active site (17,18). It is therefore conceivable that 
this amino acid substitution in the SM/J neuraminidase could 
affect substrate recognition, rate of substrate cleavage or release 
of the product, as evidenced by the altered Fma. .. of the mutant 
protein. Although Si\f/J mice present with some of the biochemi-
cal abnomlalities that are associated with the human lysosomal 
disorder ~iaHdosis, the relatively high residua.l neuraminidase 
activity prevents the occurrence in young mice of excessive 
storage in their tissues. Older mice, on the other hand, eventually 
develop visible cellular changes, especially in the CNS. There-
fore this animal model may be regarded as a mild fonn of 
sialidosis. 
111e residual SM/J activity varied slightly in different tissues. 
This could be attributed to the occurrence in some tissues, like 
brain, of neuraminidase 'isoenzymes' thought to be localized in 
the lysosomal (37,38) or plasma membrane (38-42) and the 
cytosol (16,38,43-45). However, the exislence of various 
lysosomal tleununinida.~es is questionable, since in PPCA-
deficient mice no residual neuraminidase activity is detected at 
acidic pH (2). The sanle holds true for human sialidosis patients 
with stnlcluml nlulations in the neuraminidase gene that result in 
complete los~ ofneunlminid3-~e activity (3). 
Modification of sialic acid residues, which lire present as 
tenninal sugars on various types of sialoglycoconjugates, is 
essential for regulation of many cellular activities. The Neu-I 
neuraminidase plays a key role in such modifications, for 
example in processing of cell surface molecules that are involved 
in modulating an immune response (9,27-31). T lymphocyte 
activation is nom13l1y accompanied by an increase in endogenous 
Neu-I neuraminidase (30,31), which, in tum, resull~ in hypo-
sialylation of glycoproteins on the surface of activated T cells 
(9,46-49). These surface glycoproteins lire required for T cell 
differentiation [for a review sec (32») and several of them are 
known to be internalized from the plasma membrane and 
subsequently re-exposed by a 'recycling' process. MHC elass I 
andelass II mole<'ules and the T cell receptor are examples of such 
molecules (50-53). Therefore, it may be that processing of the 
sialic acid residues on these and other glycoproteins present on 
the surface of specific T cells is mediated intracellularly by 
lysosomal neuraminidase. If this enzyme is part of the main 
mechanism for sialic lIcid processing in T cells then the altered 
t'ma., value of SM/J neununinidase would quite logically account 
for the abnonnal sialylation of these molecules. OUf data suggest 
that the mutant enzyme retains the capacity to recognize its 
substrate but that its rate of catalysis and/or release of product is 
impaired. The type of substrates that are cleaved by the enzyme 
may detennine whether or not a certain cell type can compensate 
for a reduction in activity of mutant neuraminidase. Again, this is 
besl exemplified in the T cell system, where the immune response 
in SM/J mice involves differentiation of naive T cells to Thl but 
not to Th2 cells. 
Interestingly, reduced neuraminidase activity has also been 
detected in rat strain KGH (54). TIle responsible gene, flel/-} , was 
mapped to the RTllocus (55), which is syntenic to the mouse H-2 
und human HLA loci. It is unclear whether this defect results in 
the same phenotypic alterations identified in ShUJ mice. It will be 
instructive to identify the molecular basis of the defective 
neuraminida~e activity in this rat strain and to compare it with that 
found in Shf/J mice. A second gene, IIcu-2, has also been 
described in both mouse and rat (54,56). However, the encoded 
enzyme is localized in the cytoplasm and docs not cleave the 
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fluorimetric substrate (57). Furthennore, linkage analysis dem-
onstrated that the IlclI-2 is not linked to the m'II-J locus (54). 
Once the three-dimensional structure of the lysosomal mam-
malian neuraminidase becomes available we could gain a better 
understanding of the impaci of the L209! mutation on structure 
and function of the enzyme. Our findings on SM/J mice will 
hopefully facilitate further genetic and immunological studies on 
this animal model. 
MATERIALS AND METHODS 
Isolation of the mouse eDNA 
A mouse BALEk cDNA librury was screened according to the 
manufacturer's instructions (Clontech). eDNA clones were 
sequenced with the Amersham thennocycler kit and subeloned 
into the mammalian expression vector pSCfOP (58). 
RNA isolation and Northern bioi allal~'sls 
RNA was prepared from Sr...f/1 mouse tissues by the LiCVurea 
melhod a.~ previously described (59). Total RNA was setxlIated 011 
1% agarose gels Ihat contained 0.66 M formaldehyde in MOPS 
buffer, was then blotted onto Zctaprobe membmnes (BioRad) and 
was fmally hybridized under standard conditions (60). The 
multiple ti~sue northern blot was purcha.~ed from Clontech and 
handled according to the manufacturer's instructions. 
Mutation analysis and mUhlgenesis 
Total Rt'l'A prepmtions from different S1'If}J mice and FVB controls 
were subjected to RT-PCR (3,61). The following primers were used 
in the reactions: 5'-CCCfAGGACACCGGGCCITC-3' (nntisense, 
primer R); 5'-CCfGGACAGGGATCGCCG-3' and 5'.{JTA-
GAGGCCACCfGGCAG-3' (fragment I); 5'-CGGACCAGGG-
TAGCACGTGG-3' and 5'-GGGTGTCACAGGCGTCATAG-3' 
(fragment II); 5'-GATGACCACGGTGCCfCC-3' and 5'-GOTOT-
ACCGGITCAGGCC-3' (fragment III); 5'-CCfGGCAGAAG-
OAGAGGG-3' nnd 5'-CfGITCArcrCfcCAGGG-3' (fragment 
IVJ. 
Amplified products were purified by phenoVchlorofonn ex-
traction, on Centricon-IOO columns (Amicon) and by ethanol 
precipitation. The purified products were directly sequenced with 
the fmol sequencing kit (Promega). The mutation was inserted 
into the wild-type eDNA by combining fragments II and III (Fig. 
3) and using the StuI restriction sites at positions 377 and 1168 to 
substitute the Stili fragment for the wild-type fragment. 
Cell cullure, eiectroporation of fibrobla~ts and 
transfection or COS-I cells 
Human skin fibroblasts were cultured in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with antibiotics and 
10% fetal bovine serum (FBS). CDS-I cells were maintained in 
DMEM supplemented with 5% FRS. Fibroblasts were electro-
poraled according to the manufacturer's instructions (BioRad) 
with the following modifications. Cells were han'estcd by 
trypsini7.ation and w3-~hed once in Iscove's medium. They were 
then counted and 25 )lg plasmid DNA were electroporated into 
I x 106 cells su_~pended in 500 )11 Iscove's medium using a 
BioRad Gene Pulscr sci at 0.32 kV and 500 J-lF. Eleclropomtcd 
cells were seeded in 6-well plates for 14--18 h before the medium 
was changed. They were han'ested 72 h later. Immunof1uores-
('enee of e!ectroporated fibroblasts was performed as described 
previously (3). COS-\ cells were transfected with Qiagen's 
Superfect according to the manufacturer's instructions and 
harvested 72 h post-transfection. Tran~fection efficiency was 
checked by immunofluorescence and the total amount of 
synthesized neuinminidase protein was estimated by western blot 
analysis of total ceillysates. Comparable transfection efficiencies 
were obtained among samples within each experiment and 
similar levels ofncuraminida~e protein were synthesized. ' 
LysosomaL/mitochondrial extract 
Mice were sacrificed by cervical dislocation and their tissues 
immediately isolated and placed in ice-cold 10 mi\I HErES, pH 
7.4,250 mM sucrose. After the tissues were washed several times 
in this' buffer they were weighed and homogenized in a 
tight-fllting dounce (Kanies) in 4 vols HEPES-buffered sucrose. 
A lysosomaVmitochondrial extract was prepared according to the 
procedure described by Gieselnumn (62). The resulting lyso-
somaVmitochondrial pellet was dissolved in HEPE..<';-buffered 
sucrose and analyzed for enzyme activity. 
Enzyme aclhities and urine analysis 
LysosomaVrnitochondrial extrncl~ and cell lysate from either 
trJIl'>fectoo COS-J cells or electroporated fibroblasts were a~sayed 
for neununinidase activity using the artificial substrnte 
4-11U-NANA according to Galjaard (63). Protein concentrations 
were delemlined using the BCA kil from Pierce Chemical Co. 
Neuraminidase activity also was assayed with «.-2,3- and «-2,6-
NANA-Iactose as substrates, according to the procedure described 
previously (64,65). Urine samples were collected and analyzed 
using a FACE® Urinary Carbohydrate Analysis kit purchased from 
Glyko Inc. following the manufacturer's instructions. 
Immunoprecipitalion 
TnlJl.Sfected COS-I cells were seeded in 6-well plates and labeled 
for J 6 h with 50 ~Ci [3Hj-4,5-leucine. Radiolabc!ed proteins were 
immunoprecipitated with anti-neur antibodies, as described 
previously (66). For the pulse-<:hase experiment transfected cells 
were labeled with 50 ~lCi [3HJ-4,5-leucine for I h and then chased 
in fresh DMEM over different lime periods (67). 
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Human lysosomal N·acetyl·a-neuraminidase is defi-
cient in two lysosomal storage disorders, slalidosis, 
caused by structural mutations in the neuraminidase 
gene, and galactosialidosls, In which a primary defect 
of protective protein/cathepsin A (PPCA) leads 10 a 
combined deficiency of neuraminidase and ~·D-galacto· 
sidase, These Ihree glycoprotelns can be isolated in a 
high moleculal· weight multi·enzyme complex, and the 
enzymallc activity of neuraminidase is contingent on 
its Interaction "ith PPCA. To explain the unusual 
need of neuraminidase for an auxiliary protein, we 
examined, in transfected COS·l cells, the effect of 
PPCA expression on post-translallonal modification, 
lurnover and intracellular localization of neuramini· 
dase, In puls{'-(:hase studies, we show thai the enzyme 
is synthesized as a 46 kDa glycoprotein, which is poorly 
phosphorylated, does not undergo major proteolytic 
processing and is secreted, Importanlly, its half-life 
is not altered by the presence of PPCA. Howe\'er, 
neuraminidase associates wUh the PPCA precursor 
shortly afler synthesis, since the latter protein co-
precipitates "ith neuraminidase using antl-neuraminl· 
dase antibodies, We further demonstrate by subcellular 
fractionation of transfected cells that neuraminidase 
segregates to mature Iysosomes only when accompanied 
by wild-type PPCA, but not by transport-impaired 
PPCA mutants, These data suggest a noyel role for 
PPCA in Ihe actiyaCion of lysosomal neuraminidase, 
that of an intracellular transport protein. 
Keywords: activation!lysosomes/neuraminidase/protective 
protein/transport 
Introduction 
Neuraminidases (sialidases) are exoglycosidases that cata-
lyze the removal of terminal sialic acid residues, 
a-ketosidically linked to mono- or oligosaccharide chains 
of glycoconjugates, In mammals, three distinct neuramini-
dascs have been identified in the cytoplasm, plasma 
membrane and lysosomes, These enzymes differ in their 
pH optimum, interaction with detergents, and stability 
(reviewed in Saito and Yu, 1995; Schauer et al., 1995). 
Lysosomal neuraminidase preferentially cleaves temtinal 
a(2,3)- and a(2,6)-linked sialic acid residues and has an 
acidic pH optimum. In man, deficiency of this enzyme is 
associated with two distinct genetic disorders of metabol-
ism: sialidosis, caused by structural lesions in the neur-
aminidase gene (Thomas and Beaudet, 1995), and 
galactosialidosis (GS), in which neuraminidase deficiency 
is secondary to a primary defect in the serine carboxypepti-
dase protective protein/cathepsin A (PPCA) (d' AZlO et al., 
1982). For both diseases, early onset forms with severe 
CNS pathology and systemic organ involvement, as well 
as milder late onset variants, have been identified, The 
lack of PPCA has also been shown to hamper neuramini-
dase activity severely in the mouse model of OS (Zhou 
et al .• 1995). 
The eDNA for human lysosomal neuraminidase was 
isolated recently (Bonten eJ al., 1996; Milner et al., 1997; 
Pshezhetsky et at., 1997). It encodes a protein of -45 kDa, 
with three potential N-linked glycosylntion sites, and 32-
38% sequence homology to several bacterial sialidases 
as well as to the cytosolic mammalian enzyme, These 
homologous sequences include the characteristic FRIP 
sequence, three conserved copies of an 'Asp box' [con-
sensus sequence Serffhr-X-Asp-(X)·Gly-X-1l1r-TrplPhe 
(Roggentin et al., 1993)] and two degenerated Asp boxes. 
Electroporation of the neuraminidase eDNA into sialidosis 
fibroblasts restores enzymatic activity (Bonten eJ al" 
1996), Furthermore, analysis of the neuraminidase eDNA 
from different sialidosis patients has identified six inde-
pendcnt mutations in the gene (Bonten et al., 1996; 
Pshezhetsky et aI" 1997), two of which were shown to 
render the protein non-functional (Bonten et al., 1996). 
These studies have thus defined Ihe molecular basis of 
sialidosis. 
Mammalian lysosomal neuraminidase is unique among 
other sialidases in that it requires the serine carboxypeptid-
ase PPCA for enzymatic activity (d'Azzo eJ 01" 1995; 
Thomas and Bcaudct, 1995). Neuraminidase shares this 
feature with a third lysosomal enzyme, p.D-galactosidase 
(d'Azzo et al., 1995; Suzuki et al., 1995). The dependence 
of these glycosidascs on the carboxypeptidase is evident 
in GS, where malfunctioning or absence of PPCA leads 
to the combined deficiency of neuraminidase and 
p-galactosidase (d' Azzo et al., 1995), These three Iysoso· 
mal enzymes can be co· purified in a high molecular weight 
complex with either p-galaetosidase or PPCA affinity. 
matrices (Verheijen etal" 1985; Yamamoto and Nishimura, 
1987; Pshezhetsky and Potier, 1994, 1996), Both neur-
aminidase and p-galactosidase activities in cultured GS 
fibroblasts are restored by the addition of exogenous PPCA 
precursor (54 kDa), which is intemaliled via the manJlose-
6·phosphate (M6P) receptor, routed to the lysosome and 
processed into its mature 32120 kDa two-chain fonn 
(Galjart et al., 1988: Zhou eJ aI" 1996), 
How PPCA influences the generation and maintenance 
of neuraminidase and {3-galactosidase activities is not yet 
clear, It is known that the half-life of mature p-galactosid-
0000000000 
ase is severely reduced in GS fibroblasts, and that treatmcnt 
with the protease inhibitor leupeptin increases the amount 
and activity of p-galactosidase (d'Azzo et al., 1982; van 
Diggelen et af., 1982; Pshezhetsky and Potier, 1996). This 
implies that PPCA protects p-galactosidase against rapid 
proteolytic degradation. In contrast, the neuraminidase 
activity of GS cells is hardly affected by leupeptin treat-
metlt (d'Azzo et al., 1982; Pshclhctsky and Potier, 1996), 
suggesting that this enzyme is influenced by PPCA in a 
different way. In this study, we have investigated whether 
neuraminidase requires the presence of PPCA for protec-
tion against intralysosomal degradation. for specific post-
translational modifications like proteolytic processing and 
phosphorylation. or for its intracellular transport. We also 
compared the effect of transport-deficient PPCA variants 
on the intracellular beha\'ior of neuraminidase. Our results 
offer a first e.xplanation for the PPCA dependence of 
lysosomal neuraminidase activity. 
Results 
Neuraminidase associates with PPCA and 
p-galactosidase precursors and has a short half-life 
To deternline whether the PPCA-dependent activation 
of neuraminidase is accompanied by specific structural 
modifications of the enzyme en route to the lysosome, we 
transfected COS-l cells with the neuraminidase cDNA 
either alone or in combination with the cDNA for PPCA 
and/or p-galactosidase. Transfected cells were pulse-
labeled for I h and then chased for different time periods 
in medium containing cold leucine. The cells were then 
lysed in buffer at pH 7.4 and immunoprecipitated with 
anti-neuraminidase (anti-Neur) antibodies. As shown in 
Figure 1. neuraminidase was recovered from single and 
co-transfected cells in multiple forms. migrating on SDS-
polyacrylamide gels either as a broad band or as discrete 
bands with molecular weights of .... 44-46 kDa. These 
multiple fOrolS represent different glycosylation states of 
the enzyme (Bonten el a/., 1996; Milner el al .• 1997). In 
both single and co-transfections. the size of the newly 
synthesized neuraminidase did not change during the chase 
periods, suggesting that post-translational processing of 
the enzyme was completed within 1 h and was not 
influenced by the presence of PPCA and/or p-galactosidase 
(Figure lA-D). Furthermore, in all transfected cells. the 
neuraminidase levels began to decrease after 3 h of chase. 
and the enzyme was largely degraded 24 h after synthesis. 
Therefore. co-expression of PPCA or p-galactosidase did 
not grossly alter the half-life of neuraminidase. After 
immunoprecipitation with anti-Neur antibodies, lysates 
from double- or triple-transfected cells were subjected to 
a second round of immunoprecipitation with anti-PPCA 
and anti-p-galactosidase antisera (Figure IE and F). PPCA 
and p-gaiactosidase precursors were converted slowly to 
their mature forms (32120 and 64 kDa, respectively) that 
were stable for >24 h after synthesis (see also Morreau 
et al., 1992; Zhou et al .• 1996). This clearly illustrates 
that the turnover of neuraminidase was more rapid than 
that of PPCA or p-galactosidase. From triple-transfected 
cells. both PPCA precursor and small amounts of its 
mature fonn were co-precipitated with p-galaetosidase. 
During the I h pulse labeling. both PPCA and 
p-gaiactosidase precursors were co-precipitated with neur-
64 
aminidase from double- and triplc-transfected cells (Figure 
IE-D). indicating that association of these three proteins 
occurred shortly after their synthesis. The mature forms 
of PPCA and p-galactosidase did not co-precipitate with 
neuraminidase under the neutral immunoprecipitation con-
ditions. However, by immunotitration with Staphylococcus 
al/rells-bound anti-PPCA antibodies, up to 60% of neur-
aminidase activity was co-precipitated with cathepsin A 
activity from co-transfected cells lysed in buffer at pH 5.5. 
From these results. we could infer that the majority of 
enzymatically active neuraminidase remains associated 
with mature PPCA (Figure 2). 
Neuraminidase ;s secreted into the extracellular 
space 
\Ve found overexpressed neurami-nidase in the medium of 
transfected cells, and the time course of its secretion was 
independent of PPCA and p-galactosidase co-expression. 
The level of secreted enzyme was maximal after 3-6 h 
and had diminished at the 24 h time point (Figure lA-D. 
lower panels). To compare the relative levels of secretion, 
the amount of neuraminidase immunoprecipitated from 
medium samples was quantitated by densitometry scanning 
and expressed as a percentage of the total amount immuno-
precipitated from pulse-labeled cell Iysates (Figure lA 
and B, lower panels). The secretion of neuraminidase. 
quantitated in this fashion. was clearly reduced when co-
expressed with PPCA, irrespective of p-galactosidase 
expression (Figure lC and D, lower panels). This variation 
was not the result of differences in the rate of synthesis 
of neuraminidase, because the intracellular levels of neur-
aminidase were similar in all transfected cells (Figure 1 A-
D. upper panels). Thus, the intracellular routing of the 
enzyme was influenced by the concomitant overexpression 
of PPCA. Extracellular neuraminidase, on the other hand, 
did not associate with PPCA or p-galactosidase, since we 
could not co-precipitate the three proteins from the medium 
of triple-transfected cells (Figure ID, lower panel); in tum, 
no neuraminidase activity was detected in concentrated 
medium samples from co-transfected cells, even though 
high activity was measured in the corresponding Iysates. 
Moreover, secreted neuraminidase was not activated when 
we mixed concentrated media from PPCA- and neuramini-
dase-overexpressing cells. in an altemptto promote in ~'itro 
association of the two molecules (data not shown). 
PPCA controls the intracellular routing of 
neuraminidase 
By using immunofluorescence. we and others have 
reported that when neuraminidase is expressed in COS-l 
cells it has either a punctate distribution or it is localized 
in the endoplasmic reticulum (ER)fGoigi region. Further, 
depending on the expression levels. the enzyme can also 
form small square crystals in the perinuclear area that 
stain strongly with anti-Neur antiserum (Bonten et at .• 
1996; Milner et al .• 1997). Here, we analyzed whether 
the proportion of cell populations showing a different 
subcellular distribution of neuraminidase was contingent 
on the level of expressed PPCA. In cells transfected with 
the same amount of neuraminidase cDNA but increasing 
concentrations of PPCA eDNA, neuraminidase activity 
increased in parallel with the number of cells exhibiting 
punctate staining (Figure 3A and B). In contrast, cells 
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Fig. 1. Pulse-cbase labeling. COS-I cells were transfected \lith vector alone [denoted M in (G)l or with cDi{As encoding neuraminidase (N), 
p-galactosidase (B) or PPCA (Pl, in various combinations (A~F), labeled with eHJleucine {or I h and chased \lith cold leucine for the time periods 
indicated. Ce!llysatcs and medium samples were immunoprecipitated \lith anti-Neur antiserum (A-D and OJ, and selected Iysates were used for a 
secondary round of immunoprecipitation with anli-PPCA antiserum (E) or anti-p.galactosidase antisera (F). Exposure was for 20 days (B and D 
upper panels, and E and F), 1 month (B and D, lower panels), 3 days (A and C, upper panels), 4 da)·s (A and C, lower panels) or 14 da>·s (0). 
transfected with different amounts of PPCA eDNA and 
no neuraminidase eDNA displayed slightly higher endo-
genous neuraminidase activity, which remained constant 
irrespective of the amount of PPCA cDNA added (Figure 
3A). This result demonstrates that PPCA affects the 
subcellular localization of neuraminidase, which in tum 
may influence its activation. 
To analyze the subcellular distribution of neuraminidase 
further, we separated the organelles of transfected cells 
on self-generating Percoll density gradients (Figure 4). 
This procedure separates mature dense lysosomes from 
lighter membranes such as microsomes and early and late 
endosomes, p-Hexosaminidase and horseradish peroxidase 
(HRP) were used as lysosomal and endosomal markers, 
respectively. In cells transfected with the p-hexosaminid-
ase eDNA <p-chain), enzyme activity peaked in both the 
dense bottom fractions (fractions 1 and 2) and in fraction 
5 (Figure 4A), After a 4 min incubation of the cells 
with HRP, the internalized enzyme was detected only in 
fractions 4-6, confirming the presence of endosomal 
vesicles in this part of the gradient (Figure 4B), During the 
3 h chase period that followed, however, the internalized 
enzyme shifted to the denser fractions (Figure 4B). In 
parallel experiments, we monitored the distribution and 
enzymatic activities of PPCA and neuraminidase. Neur-
aminidase expressed alone was detected on inununoblols 
with anti-Neur antibodies exclusi\'ely in the lighter frac-
tions (Figure 4C). Its activity was marginal throughout 
the gradient (Figure 4C). In contrast, blots probed with 
anti-PPCA antibodies showed the PPCA precursor in both 
the light and dense fractions, while its mature two-chain 
form was confined to the bottom of the gradient (Figure 
--+-Neur. 
--+-Cath. A 
4 6 10 
).11 anti·PPCA Staph. a. 
Fig. 2. Precipitation of neuraminidase acthily from co·transfected 
COS-I cells \lith anli·PPCA antibodies. Aliquots of lysates of COS-J 
cells overe.\pressing both neuraminidase and PPCA were incubated 
under acidic conditions v.ith inneasing amounts of lU:.ed S.OllrCIIS cells 
that had been pre-loaded with IgO from either pre·jmmune or anti-
PPCA antiserum. After removal of the bacteria by centrifugation, 
neuraminhlase and cathepsin A acthities were assayed in the 
supernatants. The data are e_,pressed as a percentage of the level 
mC;J..\urcd in samples incubated with pre-immune IgG·S.atITc'115. Error 
b~rs jodie,,!e s\JodJ.fd dCI'iation for duplicate c_lperimeolS, 
4D). In keeping with this finding, cathepsin A activity 
increased only in the fractions that contained the mature 
enzyme (Figurc 4D). When neuraminidase eDNA was 
transfected into COS-l cells together with PPCA eDNA, 
the two proteins co-distributed, and equal amounts of 
neuraminidase polypeptide were found in the light and 
dense fractions (Figure 4E and F). Howcver, enzyme 
activity was detected primarily in the mature lysosomal 
fractions, with only a moderate increase in fraction 5 
(Figure 4E and F). These results show that when the 
neuraminidase polypeptide is expressed alone it localizes 
in only light biosynthetic vesicles, but it reaches mature 
Iysosomes when accompanied by PPCA. The generation 
of neuraminida~e activity seems, therefore, to depend on 
the lysosomal localization of the enzyme. The interaction 
of neuraminidase with PPCA in an early biosynthetic 
compartment is sufficient merely for partial activation, 
which is fully unraveled in the lysosomal milieu. 
Effect of PPCA mutants on neuraminidase 
compartmentalization 
We next investigated the effect of different PPCA variants 
on the intracellular transport and activation of neuramini-
dase. Four mutants were selected, each carrying a single 
amino acid substitution that impairs its lysosomal compart-
mentalization to a different degree: PPCA-Leu208Pro (LP) 
and PPCA-Vall04Met (VM) were originally identified in 
a severe early infantile case of as, These mutant proteins 
are not transported out of the ER and persist as immature 
precursors in this compartment (Zhou et ai" 1996). In the 
patient with these mutations, neuraminidase activity is 
undetectable, In contrast, PPCA-Phe412Val (FV) and 
PPCA-Tyr22IAsn (YN), which are associated with the 
mild, late-infantile phenotype, are partially transported to 
Iysosomes, where PPCA-FV is degraded more rapidly 
than PPCA-YN (Zhou et ai" 1991, 1996; Shimmoto et ai" 
1993). The presence of small amounts of mutant PPCA in 
lysosomes supports the finding of residual neuraminidase 
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Fig. 3, Titration of nellraminidase. COS-1 cells Were IrJnsfected with 
vector alone (M), or \\ith in~reasing amounts of PPCA (P) cDNA (0.2, 
OA, 0.8 or 1.2 ~g per 3S mm dhh), alone or in combination with a 
fhed amount of neuraminidase (N) cDNA (0,2 ~g per 35 mm dish). 
Cells were (A) assayed for neuraminidase activity or (8) processed (or 
immunofluorescence using affinity-purified anti-NeUI antiserum. 
Enzyme actil'ity is expressed in nmollmglh. At least 70 cells were 
el<amined mlcrosc(lpkally and scored for neuraminidase staining. 
activity in patients with this phenotype. COS-l cells were 
transfected with neuraminidase cDNA or co-transfected 
with neuraminidase cDNA and a cDNA encoding either 
wild-type PPCA or one of the PPCA mutants, Cells were 
then metabolically labeled for 16 h, lysed, and the cell 
lysates were immunoprecipitated sequentially with anti-
Neur and anti-PPCA antisera. Figure 5 shows that all 
four mutant precursors co-precipitated with neuraminidase 
when treated with anti-Neur antiserum, demonstrating that 
the PPCA mutants associate with the enzyme as efficiently 
as the wild-type PPCA precursor does (lanes 5, 7, 9, 11 
and 13), As observed previously (Zhou et ai" 1991, 1996), 
all of the PPCA mutants accumulated in the precursor 
fonn, except for PPCA-YN which was partially converted 
to the mature fonn (Figure 5, lanes 6, 8, 10, 12 and 
14). The amount of PPCA precursor associated with 
neuraminidase was proportional to the level of unbound 
precursor that was not brought down by the anti-Neur 
antibodies but was precipitated with anti-PPCA antibodies 
(Figure 5, compare adjacent lanes). 
Fractionation of the COS-l cells co-expressing neur-
aminidase and PPCA-YN or PPCA-LP revealed that the 
mutant precursors localized in light organelles (Figure 68 
and D), This method was not sensitive enough to detect 
the small amount of mature PPCA-YN that could be 
immunoprecipitated from radiolabeled cells (see Figure 5). 
which also explains why we saw no increase over back-
ground levels in cathepsin A activity throughout these 
gradients (data not shown). In both sets of co-transfected 
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Fig. 4, Subcellular fra,tionation of COS-l cells on density gradients. (A) Density distribution of Percoll gradients, as detennined with dellSity marker 
beads (pharmada), and profile of p·he:<;osaminidase acthity (nmollhlml) In COS-l ce!ls O\'ere.~pressing p·he:<;osaminidase p.chain. (8) After pulse-
labeling .... ith HRP, COS·! ce11s were either stored ou lee (T) or chased for 3 h in HRP·free medium (B). Cells were then fractionated and the 
resulting gradient fractions assayed for HRP content (Jlglml). Altematively. COS-l cells. transfected with (C) neununinidase eDNA, (D) PPCA 
eDNA or (E and F) oo.trarufected with both cDNAs were homogenized and loaded onto Percoll gradients. Fractions were analyud for enzyme 
acth'ilies and used in Westem blots, which were probed with anti-Neur (anti-N) or antj·PPCA (anti-P) antisera. Neuraminidase acth'i!y (+) is 
e,~pressed in nmollhlml and cathepsin A acth"ity (0) in rnnollminlml. Blots were deYe!oped with colorimetric substrates. 
cells, most of the neuraminidase wa" found in light 
organelles (fractions 4, 5 and 6) (Figure 6A and C); 
however, a small portion of the enzyme was detected in 
the denser fractions (fractions 2 and 3) from cells co-
expressing PPCA-YN (Figure 6A). Consequently, only 
these cells displayed a low level of neuraminidase activity 
in both dense and light organelles (Figure 6A). 111ese 
data further support the concept that neuraminidase must 
interact with transport-competent PPCA for its lysosomal 
localization and activation. 
Neuraminidase Is poorly phosphorylated 
Soluble lysosomal enzymes are segregated to Iysosomes 
via the interaction of their M6P recognition marker with 
the M6P receptor (Hille-Rehfeld, 1995; Sabatini and 
Adesnik, 1995). We therefore investigated whether neur-
aminidase acquires an M6P recognition marker when it 
interacts with PPCA. COS-I cells, transfected with the 
neuraminidase cDNA, the PPCA cDNA or both cDNAs, 
were metabolically labeled with [32Plorthophosphate. Cell 
Iysates and media were immunoprecipitaled with either 
Neur. 
PPCA 
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Fig. s. Co-immufloprecipitation of PPCA mutants with neuraminidase. 
COSo! cells, tr.lllsfecled with the neuraminidase cD}JA alone, or in 
wmbinauon v;ith a eDNA encoding wild-type PPCA, PPCA· YN, 
PPCA·FV, PPCA-LP or PPCA·'n.I, were metabolicaUy labeled with 
eHJlcucine and used for $cquenliai immunoprecipitations v.ith anli· 
Neur (n) and antj·PPCA antiserum (p). E'posure was for 1 da)', 
anti-Neur or anli·PPCA antibodies, Figure 7 shows that 
in all of the transfected cells the level of phosphorylation 
of neuraminidase (lanes 5, 7, 13 and 15) was considerably 
lower than that of PPCA (lanes 3 and 11), to the extent 
that the neuraminidase signal from cell Iysates barely 
exceeded background levels even though both proteins 
were synthesized in comparable amounts in similarly 
transfected cells (see Figure I). A clearer 44f46 kDa 
band could be resolved when the neuraminidase was 
immunoprecipitated from samples of medium because of 
the higher signaVnoise ratio, which allowed a longer 
exposure time of this autoradiograph (Figure 7, lanes 13 
and 15). We know thaI neuraminidase was phosphorylated 
on one or more of its N-Iinked oligosaccharide chains 
because the phosphate label was lost after the cells were 
cultured in the presence of tunicamycin and after treatment 
with N-glycosidase F (data not shown). The phosphoryl-
ation of neuraminidase was not influenced by PPCA. 
Addition of the M6P marker to lysosomal enzymes 
is a two-step process; first, an N-acetylglucosamine-J-
phosphate residue is bound to the N-linked high-mannose 
oligosaccharide through the forotation of a phosphodiester 
bond; second, the terminal N-acetylglucosamine is 
remo\'ed by N-acetylglucosamine-I-phosphodiester a·N-
acetylglucosaminidase, leaving the M6P exposed 
(reviewed in von Figura and Hasilik, 1986; Sabatini and 
Adesnik, 1995), Because the efficiency of lysosomal 
transport depends on how accessible the M6P marker is 
to its receptor, we examined the extent to which the 
mannose-bound phosphate of neuraminidase is exposed. 
We incubated immunoprecipitated neuraminidase with calf 
intestinal alkaline phosphatase (Crp), which removes only 
terminal, monoester-bound phosphate from N-Iinked 
oJigosaccharides (lsidoro el al., 1991). After elP treatment, 
the PPCA was almost completely dephosphoryJated 
(Figure 7, lanes 4 and 12), whereas the neuraminidase 
retained a substantial proportion of its phosphate label 
(Figure 7, lanes 14 and 16). Furthermore. we found that 
neuraminidase from the culture medium of transfected 
a,,~-N 
A <,I 
1ilW111I1I 
anU-N 
C 
9 B 
=46144 
§ D 
anti-P 
2 3 4 5 
Fraction /I 
"'"' 
68 
§ U@ -04 
.. I 
!~D 
' " Z 10 
0, , 
Fraction /I 
=46144 
t 2 3 4 5 
Frac~O<lIl 
Fig. 6. Density fractionation of COS-l cells expressing neuraminidase 
and PPCA mutants. Follov.ing co-transfeetion of COS·1 cells \\ith 
neuraminidase cDNA and either (A and B) PPCA-Th' or 
(C and D) PPCA·LP eDNA. cenular organelles were separated on 
Per.;oll gradients. Fractions were used to assay for neuraminidase 
activity (+), expressed in nmol!hlml. and to prepare Western blots. 
which were probed I'.ith anti·PPCA antiserum (anti·P) or affinity-
purified anti·Neur antiserum (anti-N). For increased sensiti~ity. blots 
probed with anti·Neur antiserum were de\'eloped v.ith 
chemiluminescent substrates. 
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Fig. 7. Phosphorylation of neuraminidase. COS-1 cells were 
transfected as outlined in the legend to Figure 1, and metabolically 
labeled \\ilh rJ1Pjorthophosphate. Celllysates and media were used 
for immunopredpitation with anti·PPCA antiserum (lanes 3, 4, 11 and 
12) or anti-Neuc antiserum (all other lanes). The recovered proteins 
were di~ided into two aliquot, and incubated v.ith or without alkaline 
phosphatase (CIP). Signals arr- stronger in the medium samples 
because of II longer exposure time (4 days) compared \\ith celllysates 
(16 h). 
COS-I cells could not be internalized by deficient sialidosis 
fibroblasts (data not shown). 
Discussion 
Human lysosomal neuraminidase is the only member of 
the sialidase superfamily that needs another protein, PPCA, 
to be catalytically active. although influenza virus neur-
aminidase and some of the bacterial sialidases depend on 
Ca2+ for optimal activity (reviewed in Saito and Yu, 
1995). To explain this unusual requirement of lysosomal 
neuraminidase, we have studied the various biochemical 
properties of this enzyme in relation to PPCA. We show 
that most of the neuraminidase activity, generated through 
co-expression of neuraminidase and PPCA, is measured 
in mature dense Iysosomes, with only low levels detected 
in light organelles, although equal amounts of the neur-
aminidase polypeptide are present in these two compart-
ments. This apparent discrepancy indicates that it is the 
subcellular location of neuraminidase that detennines, to 
a large extent, its enzymatic activity. Moreover, in the 
absence of PPCA, neuraminidase is found only in light 
organelles and is completely inactive. These data suggest 
that PPCA activates neuraminidase first by interacting 
with it in a pre-lysosomal compartment, and then by 
mediating its transport to dense lysosomes. 
Various mechanisms govern intracellular transport of 
lysosomal proteins, which depends on their primary struc-
ture and solubility. Integral membrane proteins have a 
hydrophobic transmembrane domain and a specific Iyso-
sOl,11altargeting motif in their cytoplasmic tails, containing 
the characteristic 0-Y-X-X-hydrophobic sequence 
(rc\'iewed in Hunziker and Oeuze, 1996). If the cyto-
plasmic tails oflamp-I.lamp-2, limp-l and acid phosphat-
ase, for example, are introduced into integral plasma 
membrane proteins. the latter are re-routed to Iysosomes. 
Lysosomal enzymes without a transmembrane domain are 
tagged in the Oolgi with the M6P recognition marker 
(Hille-Rehfeld, 1995). Such proteins are dependent on 
their phosphomannosyl residues for intracellular transport, 
with the exception of the OM2 activator protein, cathepsin 
0, the sphingolipid activator protein (SAP) precursor and 
aspartylglucosaminidase that apparently can reach the 
lysosome even in the non-glycosylated state (Rijnboult 
et al., 1991b; Tikkanen et al., 1995; Vielhaber el al .• 
1996; Olombitza et al., 1997). For cathepsin 0 and the 
SAP precursor, transient membrane association is thought 
to playa role in lysosomal transport (Rijnboutl el ai., 
1991a). Hydropathy analysis of neuraminidase did not 
demonstrate a prominent hydrophobic domain besides the 
signal sequence (data not shown). Furthennore, it is 
unlikely that phosphorylation mediates routing of neur-
aminidase. since the enzyme is poorly phosphorylated, 
even in the presence of PPCA. Our data suggest that the 
oligosaccharide-linked phosphates on neuraminidase are 
only partially unmasked; in addition, those that are 
unblocked may not be sufficiently multivalent, a require-
ment for high-affinity binding to M6P receptors (reviewed 
in Hille-Rehfeld, 1995). This may explain why the M6P 
marker on neuraminidase is not functional in receptor-
mediated endocytosis of this enzyme. We also demon-
strated that neuraminidase is readily secreted from 
transfected cells. Thus, our results indicate that neur-
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aminidase does no! behave as a membrane-associated 
protein, contrary to what was suggested earlier 
(Pshezhetsky et al., 1997), and that it is co-transported with 
PPCA along the endosomalllysosomal pathway through its 
association with this protein. 
Evolutionarily, sialic acids are relatively young, occurr-
ing almost exclusively in vertebrates and higher inverte-
brates, and, apart from a few exceptions, not in plants or 
lower invertebrates (Schauer et al., 1995; Reuter and 
Oabius, 1996, and references therein). Sialidases, on the 
other hand, occur not only in species that synthesize 
neuraminic acid, but also in various microorganisms that 
do not make this monosaccharide. Many ofthese organisms 
have contact with sialic acid-synthesizing animals, and 
are thought to have obtained the neuraminidase gene 
through horizontal gene transfer (for reviews, see 
Roggentin el al., 1993; Saito and Yu, 1995). Considering 
the homology between lysosomal neuraminidase and 
various bacterial sialidases (Bonten et al., 1996), many of 
which are secretory enzymes (Corfield, 1992; Schauer 
el al., 1995), it is possible that all of these proteins derive 
from a common secreted precursor, and that the Iysosomlll 
enzyme has acquired the means to be intracellularly 
compartmentalized: through the help of another protein, 
PPCA. The use of targeting signals from a secondary 
protein is well documented in the case of MHC class II 
antigens, which rely on the cytoplasmic domain of the 
associated invariant chain for their endosomall1ysosomal 
localization (Wolf and Ploegh, 1995). The «-chain of 
lysosomal ~-hexosaminidase may need the p-hexosaminid-
ase p-chain for lysosomal localization (d'Azzo et al., 
1984); however, this has not been demonstrated directly. 
The molecular nature of the catalytic activation of 
neuraminidase is not clear. In pre-lysosomal compart-
ments, initial association of the enzyme with PPCA and 
mild acidification may induce confonnational changes that 
result in a low catalytic capacity. In mature lysosomes, 
partial processing by proteases may be needed for the 
acquisition of full enzyme activity, and this processing 
can only occur after lysosomal proteins have been segreg-
ated from the secretory pathway (Hasilik. 1992). The 
carboxypeptidase activity of PPCA itself does not seem 
to playa role in the activation of neuraminidase, because 
a catalytically inert mutant of PPCA retains the capacity 
to activate neuraminidase and p-galactosidase (Galjart 
et at., 1991); instead, cathepsin C and an unidentified 
acidic aminopeptidase have been implicated in this process 
(D'Agrosa and Callahan, 1988; Hiraiwa et al., 1993). 
Alternatively, structural rearrangements may occur, as has 
been described for influenza virus neuraminidase. This 
enzyme undergoes various maturation steps from an inact-
ive monomer to an active telramer (Hogue and Nayak. 
1992; Saito et at., 1995). Initial dimerization, intemlOlecu-
lar disulfide linking and Ca2+ binding are thought to 
be followed by a confonnational change that confers 
enzymatic activity to the oligomeric fonns of the protein 
(Bumleister et al., 1992; Saito et al., 1995). Since active 
neuraminidase remains associated with mature PPCA, this 
interaction apparently is needed to maintain catalytic 
activity, in agreement with previous purification studies 
(Verheijen et al., 1985; Yamamoto and Nishimura, 1987; 
Pshezhetskyand Potier, 1994). The relatively short half-
life of lysosomal neuraminidase, on the olher hand, may 
0<) 0<) 0<) 0<) 0<) 
be important to control neuraminidase activity in the 
endosomaillysosomal pathway. 
Surprisingly, the p-galactosidase precursor also co-
precipitated with the neuraminidase polypeptide, This 
interaction is intriguing because there is no genetic evid-
ence that it is required for the functioning of either protein. 
However, the direct interaction between neuraminidase 
and p-galactosidase may again provide a means of subtle 
regulation of the two enzyme activities, or it may enhance 
the stability of the multi-enzyme complex. 
We previously have reported that p-galactosidase in 
transfected COS-l cells depends on PPCA for intralyso-
somal stability, since the amount of its mature fonn is 
strongly reduced both in the absence of PPCA and when 
combined with a transport-incompetent PPCA mutant 
(J\1orreau et al., 1992). Our subcellular fractionation 
experiments have now confinued these results (unpub-
lished observation), In a recent report, Pshezhetsky and 
Potier (1996) have described the isolation of a 1.27 
MDa enzyme complex from human placenta that contains 
N-acetylgalactosamine-6-sulfate sulfatase (GALNS) in 
addition to p-galactosidase, PPCA and neuraminidase. 
Significantly, these authors noted a partial deficiency of 
GALNS in OS fibroblasts, It would be interesting, there-
fore, to investigate whether PPCA is required for the 
lysosomal transport or for the intralysosomal stability 
ofGALNS. 
Deficiencies of PPCA are the primary cause of OS, The 
pathology of this disorder. however, derives mainly from 
a secondary deficiency in neuraminidase and from the 
subsequent accumulation of undegraded substrates 
(d'Azzo et al .• 1995). Our findings allow us now to link 
these issues. In OS, either the PPCA gene is not transcribed 
or PPCA mutants are synthesized that are partially or 
completely impaired in their lysosomal transport. In both 
cases, lysosomal localization and subsequent activation of 
neuraminidase are affected, We can infer from our data 
that in paticnts' cells that synthesize transport-incompetcnt 
PPCA, neuraminidase is retained to a large extent in an 
early biosynlhetic compartment. On the other hand, the 
restoration of neuraminidase activity in as fibroblasts 
after internalization of exogenous PPCA precursor (Galjart 
et aT., 1988, 1991) implies that the two proteins can 
interact where the biosynthetic and endocytic pathways 
merge, In future studies. structural analysis of the PPCA-
neuraminidase complex should provide further insight into 
the role of PPCA in protein transport and in the activation 
of neuraminidase, 
Materials and methods 
Cell culture 
Normal and siaHdosis fibroblasts were obtained (rom the European Cell 
Bank, Rotteroam (Dr WJ.Kleijer). Flbroblasts were maintained in 
DuJbe<:<:o's modified Eagle's medium (DMEM) containing 10% (etal 
oo\'ine serum and antibiotics. COS-I cells (GluDIlan, 198 I) were grollTI 
in the same medium in 5% serum. 
Transfectlons and metabolic labeffng 
cDNAs encoding human lysosomal neur.uninidase (Donten il Ill .. 1996), 
~·galactosidase (Morreau (I al., 1989), PPCA (Oaljart il a/., 1988), 
PPCA-Phe4]2Va] (Zhou ela/., 1991), PPCA-Tyr22IAsn, PPCA-Va1104-
Met and PPCA-Leu208Pro (Zhou il a/., 1996), subdoned into the 
mammalian expression \'cctor pSC-TOP (fomerod (I aI., 1995), and 
~-hexosaminidase fi-chain, subdoned into pcDNAl.1 (Invitrogen) 
70 
(kindly provided by Dr R.Proia), were transfected into COSo] cells 
using calcium phosphate precipitation, as desnibed (Chen and Okayama, 
t 987). or the Superfect reagent, ac<:ording to the manufacturer's instruc-
tions (Qiagen). For steady-state labeling, at 48 h post-transfection cells 
were metabolically labeled with L-{4,5-3HJleucine (SO )lCi/ml culture 
medium) for 16 h, or at 64 h post-transfection cells were labeled \\ith 
e2PJorthophosphate (100 )lCi/ml culture medium) for 8 h. Pulse-<hase 
tabeling was performed as described (Morre-au (I a/., 1992). 
Immunopreclplt8tlon, d8gfycosylation and 
dephosphoryl8tion 
Trarufected and metabolically labeled COS-I cells were used for 
immunoprecipitation essentially as described (Proia (I a/., ]984; Zhou 
et a/., 1996), Celt Iysates were prepared according to the method o( 
Proia et a/, (1984). COS-I celt Iysates and medium samples were 
incubated with antiserum for 16--18 h, Irrununoprecipitations were done 
with rabbit antisera against ueur.uninidase (anti-Neur) (Bonten il aI., 
1996) and PPCA (Bonten (I of" 1995). 1\1,'0 antisera against 
~.galactosidase were combined: a.n64, raised against the mature form 
of the enzyme, isolated from human placenta, and anti·8S, raised against 
the ~-galactosidase precursor, overexpressed in insect celts. Reco\'ered 
proteius were resolved on 12% SDS-polyacrylamide gels under denatur-
ing and reducing conditions and \'isualized by autoradiography (for np_ 
labeled samples) or by f1uorography of gels impregnated with Amplify 
(Amersham) (for ]H-Jabeled samples). Apparent molecular weights were 
calculated by comparison with marker proteins (Life Technologies). 
Dephosphorylation of 32P_labeled proteins was carried out as described 
(Isidoro il a/., 1991), using EIA-grade CIP (Boehringer Mannheim). 
Densitometry scanning of autoradiographs was performed on a Biolmage 
Visage I JO system. 
Immunotitratlon 
Fixed S,aun'lIs cells. activated as described (Zhou el al .. 1996) and 
e,\teusil'el>' washed, were resuspended in phosphate-buffered saline 
(PBS), and loaded with IgO by iucubating the bacteria in an excess 
\'o!ume of either pre-imm'une rabbit serum or anti-PPCA antiserum for 
2 h at 4'C. The bacteria were then washed twice in PBS and tllice in 
extraction buffer (20 mM sodium acetate, pH 5.5, 150 mM NaCI and 
0.4% NP-40), and resuspended iu the lauer buffer to make a 20% (vlv) 
suspension, Trarufected COS-I cells were lysed in extraction buffer, and 
insoluble material was removed by centrifugation at 16000 g for 2 min. 
Immunotitration was performed by mixing 15 III of the COS-I cell 
e~tract {0,5 mg Protein/mll with increasing volumes of one of the IgO-
loaded S.ar/rell5 suspensions, in a totat \'olume of 25 Ill. Follo\\ing 
incubatiou at 4'C for 2 h, the reaction mixtures were spun at 16000 g 
for I min, and supernatant, were assayed for neuraminidase and cathepsin 
A activities. 
Subceffufsr fractIonation 
Transfecled COSO! cells were washed twice with PBS and ouce .,.,ith a 
HEPES·buffered sucrose solution [HBS: 250 rn}.{ sucrose, 10 mM 
HEPES-NaOH, pH 7.4, I m.\I EDTA (Gicse!mann et al .. 1983)1. Cells 
were haryested in HBS by scraping and were homogenized by 30 strokes 
in a tight-fitting dounce (Kontes). Nuclei and unbroken cells were 
removed by centrifugation at 600 g (or 10 min, and the post·nuclear 
supernatant (400 )ll) was loaded onto 8.6 ml of isotonic, HEPES-buffered 
PeKoJ[ [containing 29.74 ml Percoll (Pharmacia) per 100 ml, 210 m.\-f 
sucrose, 8.4 rn}.1 HEPES-NaOH, pH 7.4, and I m.\-f EDTAj, prepared 
according to the manufacturer's instructions and to Gieselmann it al. 
(1983) and Vincent and Nadeau (1984), Subcellular organelles were 
separated in self-generating deusity gradieuts, as described (Gieselmann 
el 01., 1983). Si>.: 1.5 ml fractious were collected (rom the bottom of 
each gradient, and Percoll was removed by dilutiug each fraction in 10 
vots of sucrose wash buffer 1250 m.\-I sucrose, 10 mM HEPES-NaOH, 
pH 7.4, I mglml bovine serum albumin (BSA)j and centrifugation for 
15 min at 20 000 g (Pisoni il 01 .• 1987). The pelleted material was then 
resuspended in 0.5 ml of sucrose wash buffer and spun for 12 min at 
15600 g. The final pellets were resuspended in 50)lt of 50 m.\i sodium 
acetate, pH 5.0, 0.25% gl>'codeoxycholate, 100 ffi!I.[ NaCl and I mglml 
BSA, and assayed for neuraminidase and cathepsin A activities (Kleijer 
il a/., 1996). Density was determiued using density marker beads 
(Pharmacia). Equal aliquots from each fraction were subjected to Western 
blot analysis using anti-Neur and anti-PPCA antisera, and developed 
I'oith either a colorimetric or a chemiluminescent substrate (Renaissance, 
Dupout) as described earlier (Donten (I 0/., 1995), 
Immunofluorescence 
COS-I cells were seeded in 6-well dishes at a density of IXIOS cells 
per well. Celts were tramfected \\ilh increasing amounts of PPCA eDNA 
(ranging from 0.25 to 1.5 ~g), or co-transfeCied with the eDNAs for 
both PPCA and neurJminidase, in which case the amount of neuramini-
dase plasmid was fued at 0.25 ).Ig while PPCA was added in increasing 
quantities from 0.25 to 15 ).Ig. For indirect immunofluorescence, the 
cells were tJ)"psinized 48 h p<lst-transfection and aliquots were seeded 
on SuperfrostlPJus microscope glass slides (Fisher). The ne;.;t day, the 
slides were processed according to the method of van Dongen el at. 
(1985), using affinity-purified anti-Neur antibodies (Bonten et al., 1996) 
and fluorescein isothiocyanate {FlTC}Nnjugated anti-rJbbit IgG second-
ary antibodies (Sigma). A minimum of 70 transfected cells per transfec-
tion were examined microscopically and scored for the presence of 
either a punctated, ERiGolgi or crystal-like staining pattern, as described 
earlier (Bonten el al., 1996). Tmnsfection efficiencies were delennined 
by counting both the tr;msfected and untmnsfected cens. Cell Ipstes 
were assayed for neuraminidase and cathepsin A actvities as described 
above. Total protein concentrations were quantitated using the BCA kit 
(Pierce Chemical Co.), follolling the manufacturer's guidelines. 
HRP Internalfzatlon 
Uptake experiments \\ith HRP were performed as desaibed by Thlp 
el al. (1993). Briefly, (onftuent COS-I cells were incubated for either 4 
or 10 min \\ith 2 mg/ml HRP (Sigma, 1)1'<.1 VI-A) in JO Ifu\t glucose, 
to mM HEPES~NaOH, pH 7.4, in DMEM. After the 4 min pulse, cells 
were tr.llliferred to ice. Alternatively, cells were washed thr~ times 
with PBS, dased for 3 h in DMEM containing 5% fetal bovine serum 
and antibiotics, and then IrJnsferred to ice. All cells were then fractionated 
on Percoll gradients as described above. Gradient fwctions were assayed 
for HRP content using o·phenylenediamine (Sigma) as a substrJte, 
according to Amigorena el al. (199..\). Following a I h incubation at 
room temperature, assays were read at 450 nm \\ithout terminating the 
reactions with HCI. A solution of HRP (5 ng/ml) was nsed as the standard. 
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Lysosomal protective protein/cathepsin A is a serine 
carboxypeptidase that forms a complex with p·galacto. 
sidase and neuraminidase. The enzyme is synthesized as 
a 54·kDa precursorlzymogen and processed into a cata. 
Iytically active 32· and 20·kDa two·chaln form. We have 
expressed in baculovil'us·infected insect cells the hu. 
man one-chain precursor as well as the two separate 
subunits in order to establish the mode of catalytic ac· 
Uvatlon of the zymogen and the assembly and activation 
of the two subunits. Infected insect cells synthesize 
large quantities of the exogenous proteins, which arc 
glycosylated and secreted but not processed. Co-expres' 
slen of the two subunits results in their assembly into a 
two-chain form of 34· and 20·kDa with negligible enzy· 
matlc IlcUvity. Limited proteolysis with trypsin of the 
54·kDa precursor and the reconstituted 34· and 20·kDa 
form gives rise to a fully active 32· and 20·kDa product. 
These results enabled us to map the sites of proteolytic 
cleavage needed for full activation of the cathepsin A 
zymogen, They further indicate that the 34· and 20·kDa 
form is a transient processing intermediate that is con· 
veried Into a mature and active enzyme by removal of a 
2·kDa ''lInker'' peptide from the COOH terminus of the 
34·kDa subunit. 
A primary defect oflysosomal protective protein/cathepsin A 
(PPCA)l in humans causes the metabolic storage disorder gal. 
actosialidosis (Ref. 1; reviewed in Ref. 2). This disease is char· 
acterized by severely reduced activities of the enzymes I3'D-
galactosidase and N·acetY]·Q·neuraminidase, secondary to 
absent or abnonnal PPCA. The reason for the additional com· 
bined deficiency relates tc one of the functions ofPPCA protein, 
which is to associate with and protect the two glycosidases, 
modulating their activity and stability in Iysosomes (1, 3-5). 
The primary structures of human, mouse, and chicken PPCAs 
are highly conserved (6-8) and bear homology to yeast and 
plant serine carboxypeptidases (Ref. 6; for reviews see Refs. 9 
and 10). Mammalian PPCAs have cathepsin A activity at lyso-
somal pH but maintain a deamidaselesterase activity at neu· 
• These studies were supported in part by the National Institures of 
Health Cancer Cenrer Support CORE Grant P30·CA21765, the Amer· 
ican ubanese Syrian Associated Charities, and the Foundation of 
Clinleal Genetics at the Erasmus Unlveraity. The cools of publication of 
this article were defrayed in part by the payment of page charges. This 
article must therefore be hereby marked ·ad~'f!rtisement~ in acrordance 
with 18 U.S.C: Section 1734 solely to indicate this fact. 
il To whom correspondence should be addressed: Dept. ofGenetleB, 8t 
Jude Children's Resesrch Hospital, 332 N. Lauderdale, Memphis, TN 
38105. Fax: 901·526·2907. 
1 The abbrevilltions used are: PPCA, protective protein/cathepsin A; 
BV, bllculovirus; DFP, diisopropyl fluorophospbate. 
tral pH (8, 11). Furthennore, the human enzyme, purified from 
platelets and lymphocytes, has been shown to function both in 
in vitro and in vivo assays on the inactivation of select~d 
neuropeptides, like substance P, oxytocin, and endothelin I 
(11-13). 
prCA is synthesized as a 54·kDa precursor that is glycosy. 
lated on two Asn residues and is enzymatically inactive (1, 6, 
8). The precursor dimerizes at neutral pH shortly after synthe-
sis and is likely to be transported as a dimer to the iysosomes 
(14). Once in the acidic lysosomal environment, the zymogen is 
cleaved into an enzymatically active 32· and 20·kDa two·chain 
fonn. However, the events involved in proteolytic activation 
have not been established until now. Here we have used bacu· 
loviros (BV).expressed human precursor and two separate sub-
units to map the sites of cleavage and prDcessing of human 
PPCA zymogen. We have identified a "linker" domain in the 
precursor molecule, located at the COOH tenninus of the large 
subunit, which needs to be removed for full catalytic activation 
of the enzyme. 
EXPERIMENTAL PROCEDURES 
Plasmid Construcls-AcMNPV transfer plasmids pJR2 lind pBC3 
are deri\'atiyeS of plasmid pAc373, which includes the entire p<Jlyhedrin 
gene (I5). They both contain a p<Jlylinker with multiple doning sitea, 
iIlBerted directly 3' of the polyhedrin promoter. In pJR2 the p<Jlylinker 
substitures a aa·nucleotide deletion spannlng the ATG, whereas in 
pBea only theATG codon Is mutated toACG. Full·length human PPCA 
~DNA, HPP54 (6), and the two deletion eDNA mutants, HPP32(t.20) 
and HPP20(t.32) (8), were subcloned either in pJR2 or pBC3 as EcoRI 
fragments, using standard procedures (16). The HPP20(t.32) deletion 
mutant was tagged v.ith the human PPCA signal sequence, as reported 
earlier (8). AIl eDNA fragments were engineered to hanl short 3'· and 
5' ·untransJated regions «10 base pairs). 
Genua/ion of Recombinant Bacu[ot,iruses-Spodoptera (rugiperda 
iIlBect «'lis (IPLB·SF21) were cultured in monolayers at 27·C in 
TIn.I·FH medium (17) supplemented with 10% fetal bovine serum and 
antibiotics (complete medium). Wild·type AeMNPV virus strain E2 (18) 
and recombinllnt baculoviruses were propagated on confluent monolay· 
era of Sf21 cells. Recombinant ba~uloviruses were generated by cc--
transfecting Sf21 «'lIs with 1 Jigofwild·type AcMNPV DNA and 10 Jig 
of plasmid DNA as described (19). They were selecred and purified by 
sequential plaque assays and verified by Southern blot analysis (19). 
Large quantities ofinoculum were produced by infection of insect ceUs 
st 25 ... SO% confluenoo with recombinant virus at II multiplicity orinfec· 
tion of < 1 plaque-fonning unltlcell. Mer 3--6 days at 27°C, when all 
cells Ilppeared infected, the medJum was harvested and centrifuged for 
5 min at 1000 rpm to remove detached cells. The titre of the inoculum 
was derermined by plaque assay analysis. 
Metabolic Labeling of Infected Cells-For biosynthetic labeling stud· 
ies, Sf2i cells were seeded in 6-well plares and grown until 80-90% 
confluen«,. Cells were Infeded with bacu10viruses at a multipl!city of 
infection of5-1O plaque.fonning units/cell and radiolabeled for4 h with 
50 JiCilml [3SS1methionine (Amersham C<lrpJ. Immunoprecipitations 
were carried out with anti·human PPCA precursor antibodies (anti-54) 
(8) and formalin·fixed Staphylococcus aureus cells (immunoprecipitin, 
BRL) as reported ell.1'lier (8, 20). Immunoprecipitsted proteins were 
resolved on 12.5% 80S-polyacrylamide gels under reducing or nonre· 
dueing conditions (2l) and visualized by fluorograpity of gels soaked in 
Amplify (Amersham Corp.). 
lmmunoe/edron Microscopy---Sf21 cells infected with r«ombinant 
baculovinlses were fiXed tW() days postinfection in 0.1 ~! phosphate 
buffer, pH 7.3, 1% acrolein, and 0,4% glutaraldehyde. Further embed-
ding in gelatin, preparation for uitracryotomy, and methods for immu· 
noelectron microscopy weTe as reported earlier (22). Ultrathin sections 
were probed 'with antibodies (anti·32) raised against the denatured 
32·kDa cha.in of human PPCA (6). 
Del'e/opment of Anti-peptide Antibodics-A IS-amino acid peptide 
{NH2·Cys.Met-Trp·His·G1n.Ala.Leu-Leu-Arg-St>r.G1y.Asp-Lys-Val-
Arg·CODAl based on the eOOH_terminal sNIuence of the 34-kDa sun. 
unit (amino adds 285-298) (6) was synthesi~ed on a peptide synthesizer 
(Applied Biosystems) and tOI'alentiy coupled via the NH2·tenninal C)'S 
residue to the carrier protein Keyhole Limpet Hemocyanin using the 
lmjet-adivated immunogen conjugation kit as recommended by the 
manufacturer (Pierce). Polyclonal antibodies (anti·pep) were raised in 
rabbits against the (onjugated product and tested on immunoblots or 
immunoprecipitations of BV-producM proteins. 
Limited Proteolysis with 'fr)psin-Infections with baculovirus con-
structs were perfonned as described abol'e. Medium samples were 
concentrated 5-20-fold by ammonium sulfate pI<'Cipitation and de-
salted on a Sephadex G50 column (20). Aliquots of 15 pI of medium 
concentrates were diluted to 200 pi Ilith 10 ffi!.1 sodium phosphate 
buffer, pH 6.8, and 1 mglml bovine serum albumin. Samples were 
subjected to limited proteolysis ""ith 1 ,.,g of trypsin (Sigma) for increas-
ing periods of time as described by Galjart ef al. (8). Reactions were 
stopped by the addition of 3 ,.,g of bOline pancreas trypsin inhibitor 
(Sigma). Aliquots of each reaction mixture (10 ,.,\) were as~ayed for 
cathep5in A acthily using the ,v·blocked dipl:'ptide benlyloxycarbonyl-
phenylalanyJ-alanine as described by Galjart ('/ al. (8), 20·,.,1 aliquots of 
trypsin-digested proteins were resoil·ed on SDS·polyaCf)'lamide gels 
and transferred from gels to lmmobilon polyvinylidene difluoride mem-
branes (Millipore Corp.) using a semi--dry blotter (W. E. P. Company). 
Blots were intubated for at least 12 h in blocking buITer (0,01 ~I Tris-
buITered saline, pH 8.0, 0.05% Tween 20, and 3<:', (wlv) bovine serum 
albumin) and subsequently probed 'vUn anti-54 or anti-pep antibodies 
followed by alkaline phospha.ta.se conjugate anti·rabbit IgG second an-
tibodies (Sigma). Proteins ""·ere stained using the colorimetric substrate 
for alkaline phosphatase (Sigma). For the DFP-binding assay, 40-,.,1 
aliquots were incubated for 1 h at room temperature with 1 ",Ci of 
[JH]DFP as described earlier (8). Radiolabeled proteins Wl:'re immune--
pre<:ipitated with anti·54 antibodil:'s and resolved by SDS-polyacryl-
amide gel electrophoresis and fluorography. 
RESULTS 
SF21 insect ceJls were infected with recombinant baculovi-
ruses AcHPP54, AcHPP32, and AcHPP20 separately or co-
infected with AcHPP32 and AcHPP20. Metabolic labeling and 
immunoprecipitation analysis showed that PPCA precursor 
was synthesized in large quantities and efficiently secreted but 
was not or poorly processed to the mature two-chain product 
(Fig_ 1, lanes 1 and 5). Its estimated molecular mass of-54 
kDa was similar to wild-type precursor from human cultured 
fibroblasts (1). Trace amounts of low molecular weight polypep. 
tides, visible both intra- and extracellularly, were products of 
aspecific proteolysis, because pulse-chase experiments showed 
no time-dependent conversion of the precursor into maturo 
protein (not shown). Single infections with AcHPP32 and 
AcHPP20 resulted in the production of truncated polypeptides 
with molecular masses of34, 20, and 18 kDa, respectively (Fig. 
1, lanes 2 and 3)_ Only the former, which was 2 kDa larger than 
the corresponding wild-type subunit, was secreted to some 
extent (Fig. 1, lane 6). The two chains of 20 and 18 kDa (Fig. 1, 
lane 3) were different glycosylation forms of the small subunit. 
Under nonreducing conditions the secreted large chain mi-
grated as a doublet, suggesting that within this polypeptide 
partial and/or different intrachain disulfide bridges may have 
formed (Fig. 1, lane 10). Co-infected cells synthesized a large 
subunit of34 kDa and three small subunits of20, 19.6, and 18 
kDa, respectively. The intermediate 19.5-kDa species was 
unique for co-infected celis (compare lanes 3 and 4) and was the 
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FIG. L Metabolic labeling of PPCA precursor and separate 
subunits in Insect eells. Smt teUs were either infected with baculo-
lirus construct AcHpp54 (54), AcHpp32 (32), or AcHpp20 (20), or co-
infeded \Iith AcHpp32 and AcHpp20 (32120). 2 days after infection 
newly synthesized proteins were labeled with [3~Slmethionine, LabelM 
proteins were immunoprecipitated from cells and media using anti-54 
antibodies. Proteins were sl:'paraled by SDS-polyacf)-lamide gel eledro-
phoresis under reducing (lanes 1-8) or nonreducing (lanes 9-12) con-
ditions and \isualized by fluorography, Exposure time was 24 h. MI)-
lecular sizes are indicated. DIT, dithiothreito!. 
only one of the small subunits found in the medium (Fig. 1, 
lanes 8 and 12). Co-expressed polypeptides were immunopre-
cipitated in larger quantities both intra- and extracellularly, 
compared v.-ith single infections and under nonreducing condi-
tions were resolved as one product of -54 kDa, similar in size 
to the wild-type precursor (Fig. 1, lanes 9 and 12). These results 
suggest an early intracellular association of the two separately 
synthesized polypeptides, which are secreted in an associated 
state. Although they assemble, the 34-kDa subunit remains 2 
kDa bigger (Fig, 1, lane B) and is not further processed to the 
mature size. 
To determine whether the subcellular localization of over-
expressed proteins could account for the lack of maturation, 
singly infected or co-infected cells were analyzed v.ith electron 
microscopy. Immunostaining of ultrathin sections demon-
strated an intracellular distribution that was similar for the 
different over-expressed proteins, Extensi\'e gold labeling was 
restricted to structures in the cytoplasm corresponding to swol-
len cisternae of the endoplasmic reticulum (Fig. 2A) and the 
Golgi c(lmplex (Fig. 28). Other subcellular organelles, includ-
ing multivesicular bodies and fibrous structures, llsU[llly ob-
served in insect cells infected with either wild-type or rewm-
binant viruses (23, 24), were totally devoid of gold particles. It 
appears therefore that none of the BV-expressed proteins reach 
a lysosome.like compartment, where proteolytic processing 
should occur. 
The amino terminus of the 20·kDa chain, isolated from hu-
man placenta and human platelets (6, 11), starts with 1\Iet·299, 
which is preceded in the amino acid sequence of the precursor 
by a C(lnsen'ed arginine. This residue likely represents the site 
of initial cleavage_ Circumstantial evidence has, however, in-
dicated that complete maturation of the precursor may require 
more proteolytic steps that could occur at Arg·284, Arg-292, or 
Lys-296. Here we have monitored the processing and catalytic 
activation of human PPCA precursor and reconstituted sub-
units by digesting BV-derived secreted proteins with trypsin. 
To ascertain the occurrence of sequential processing steps, we 
have used a polyvalent rabbit antibody (anti-pep) raised 
against a peptide of 16-amino acids, 14 of which are derived 
from the COOH tenninus of the large subunit. Concentrated 
medium samples containing either the precursor or the 34- and 
Fro. 2. Subcellular localization of 
BV·elIpressed proteins. Sf21 (ells were 
infected y,.-jth AcHPP54, AcHPP32, or 
AcHPPM + AcHPP32 and prepared for 
immunoelectron mitf(lscoPY 48 h after in-
fection. Cryosections were incubated with 
unti-32 antibodies followed by goat anti-
rabbit IgG gold labeling. A, in all three 
cases the over·expressed proteins were lo-
calized in swollen cisternae of the endo-
plasmic reticulum (R), which have the ap-
pearance of large vacuoles. B, gold 
particles were also clearly present in the 
Golgi complex (G). 0, nudeus; F, fibrous 
structures; MVB, multiveskular bodies. 
The magnifications were: 38,OOOx for A 
and 79,OOOx for B. 
20-kDa associated protein were incubated with a flxed amount 
of trypsin for increasing periods of time, and each reaction was 
stopped by the addition of trypsin inhibitor. Aliquots of each 
sample were tested on Western blots immunostained with an-
ti-54 and anti-pep antibodies and were assayed for cathepsin A 
activity. As seen in Fig. 3 (upper left panel), after 0.5 min of 
incubation with trypsin, part of the one-chain precursor WaS 
cleaved into a two-chain product of 34 and 20 kDa. Between 2 
and 5 min, the 34-kDa form was gradually converted into a 
32·kDa derivative, and complete maturation was achieved af-
ter 10 min, In contrast, the size of the 20-kDa chain did not 
vary. Prolonged digestion periods (16 and 30 min) led to aspe-
cifie degradation and lower yield of both subunits. Using anti· 
pep antibodies, only the 64- and 34·kDa polypeptides were 
detected, indicating that the COOH·terminal peptide (If the 
34-kDa species was lost upon conversion to the 32-kDa form 
(Fig, 3, middle left panel). Step-wise maturation of the precur· 
sor into a fully processed product was paralleled by a clear 
increase in cathepsin A activity, which was maximal after 15 
min of digesti<m (Fig, ;i, lower left panel). Similar maturation 
Catalytic activation of PPCA 77 
steps were observed for the reconstituted 34· and 20-kDa pro· 
tein, Upon trypsin cleavage, the large chain was again con-
verted from a 34- to a 32-kDa product, whereas the si~e of the 
small subunit did not change (Fig. 3, upper and middle right 
panels). However, the amount of both polypeptides, as detected 
on immunoblots, was significantly less than for wild·type pre-
cursor, resulting in an overall reduced cathepsin A activity, 
This was probably due to both a lower secretion of the recon-
stituted two·chain protein as well as a reduced stability. How-
ever, also in this case a clear increase in enzymatic activity was 
measured after digesti(ln (Fig, 3, lower right panel), 
Catalytic activation of precursor and reconstituted products 
was confinned by the ability of trypsin.processed proteins to 
bind the serine protease inhibitor DFP. As shown in Fig. 4 
(lanes 1-6), only the mature 32-kDa subunit, generated after 
trypsin digestion of the precursor, was recognized by the radio· 
labeled inhibitor. The 34·kDa form WaS apparently unable to 
bind DFP, although it was present at 0.5---5 min digestion time 
points (see Fig, 3). The inability to bind the inhibitor was 
particularly evident in the case of the undigested 34· and 
54 kDa prOOJrsor 34/20 Wa tWD·chai» 
0' 0.5 2. 5 10 15 3Q __ - 0 0.5 2' 5' 10 15 
FlO. 3. Limited proteolysis with trypsin of 5-t-kDa precuf.Sor 
Bnd 34· and 20·kDa reconstituted two·chain protein. Aliquot!! of 
medium concentrates containing the 54·kDa pr&Ursor and 34- and 
20-kDa associated protein Were incubated at 37"C ..... ith 11'-g of trypsin 
in the presence of bovine serum albumin (1 mg/ml) for the indicated 
periods of time. Readions Were stopped with 3 JAg of trypsin inhibitor. 
Samples in lanes 1 and 9 were untreated. At time 0 (lones 2 and 10), the 
samples were treated with trypsin inhibitor prior to the addition of 
trypsin. A portion oreach sample was separated by 8DS-polyacrylamide 
gel electrophoresis, followed by electroblotting nnd immunostaining 
with anti·54 and anti-pep antibodies. Cathepsin A acth'ity toward the 
acylated dipeptide benzyloX}'carbonyl-phenylalanyl-alanine was meas-
ured in each aliquot. One milliunit (mU) of ac!h'ity is defined as the 
enzyme acth'ity that releases ono nanonlo\e of alanine/minute. 
32- 32-
2 3 4 5 6 1 8 9 10 11 12 
FIG. 4. Binding of serine carboxypeptidase Inblbltor DFP to 
trypsin digested 54 kDa precursor and reconstituted two-chain 
protein. Trypsin digestions of precursor and 34- and 20-kDa two-chain 
product were performed as described in the legend to Fig. 3. 1 MCi of 
[>HjOFP was added to 40 MI of trypsin digest. followed by immunopre-
cipitation with anti-54 antibodies. Irnmunoprecipitated proteins were 
separated on SOS-polyacrylamide gels under reducing conditions and 
visuali~ed by Ouorography. Exposure times were 2 we(!ks for lane.'! 1-6 
and a monthB for lam's 7-12, Molc~ular SilC$ life indkated. Cathepsin 
A activity was measured as described ill the legelld to Fig. 3. 
20-kDa protein (lane 7), which showed no radioactive signal, 
confirming that it has only marginal enzymatic activity. How-
ever, this associated form was particularly susceptible to pro-
teolytic cleavage, because immediately after addition of trypsin 
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(time 0, lane 8), a substantial conversion to the 32-kDa product 
took place. For both wild-type precursor and reconstituted pro-
tein, the highest levels of cathepsin A activity were measured 
at digestion time points in which maximal binding was ob-
served (Fig. 4, lanes 3-5 and 9-10). As seen in the previous 
experiment, the overall amount of reconstituted and digested 
two-chain product was again considerably lower than trypsin-
cleaved precursor, All together these data point to the 34- and 
20-kDa product as being a processing intermediate, transiently 
occurring during proteolytic maturation of PPCA precursor. 
This process is probably mediated by a trypsin-like protease. 
Removal ofa COOH-terminal peptide from the 34-kDa subunit 
is essential for catalytic activation. 
DISCUSSION 
PPCA is a lysosomal serine protease with pleiotropic biolog-
ical properties. It binds in its normal state to the enzymes 
/3-galactosidase and neuraminidase, rendering them stable and 
active in lysosomes; it also hydrolyzes as carboxypeptidase 
and/or deamidaselesterase a variety of bioaclive peptides, de-
pending upon the pH conditions used in the assay. When defi-
cient or defective in humans, it causes the lysosomal storage 
disease galactosialidosis. Because its protective and catalytic 
functions are distinct (8), we and olhers have postulated a role 
for PPCA in the local inactivation of selected neuropeptides, 
with or without the aid of the Iwo glycosidases (8,11-13), The 
protein is synthesized in mammalian tissues and cultured cells 
as a one-chain precursor that is enzymatically inacth'e. Proteo-
lytic conversion toa disulfide-linked two chain product triggers 
catalytic activation. To investigate the process of z)'IIlogen ac-
tivation and to assess the capacity of the separately synthe-
sizcd subunits to assemble into an active enzyme, we have used 
the baculovirus system (for review see Ref. 25 and references 
therein) to express human PPCA in insect cells, either as 
one-chain precursor or as two separate subunits. 
BV-encoded proteins are synthesized in large amounts and 
transported from the endoplasmic reticulum to the GoJgi com-
plex but do not seem to be targeted 10 a lysosome-like organelle. 
It is conceivable that this transport step either requires a 
recognition marker on lysosomal proteins specific for insect 
cells or the process is saturated by the high concentration of 
newly synthesized proteins. The subcellular distribution of 
both PPCA precursor and reconstituted subunits could how-
ever explain their inadequate intracellular maturation, which 
may depend on a lysosome-associated protease. Although it is 
known that the degree of proteolytic processing varies among 
heterologous proteins expressed with the baculovirus system 
(25), identical results were obtained by us with mouse PPCA 
and human /3-galactosidase expressed in insect cells2 and by 
others with human ,a-galactosidase, ,a-gluoosidase, and ,a.hex-
osaminidase (26-29). Of the three separately synthesized pro-
teins, mainly the wild-type precursor is secreted in a large 
quantity. Interestingly, however, the co-expressed subunits are 
able to form interchain disulfide bridges and nre secreted only 
in the associated state. They evidently require confonnational 
changes for their secretion, acquired only when both domains 
are present. Using baculovirus co-expression vectors, other in-
vestigators have demonstrated appropriate fonnation of func-
tional immunoglobulin heterodimers, which are efficiently se-
creted, and of disulfide-bridged interleukIn 5 homodimers 
(30,31). 
The focus of the experimental work presented here is the 
process of enzymatic activation of human PPCA zymogen, 
which enabled us to map the linker domain between the two 
chains, whose removal is required for activation. Both wild-
2 Erik J. Bonten, unpublished data. 
type precursor and reconstituted two-chain form can be sub-
jected to partial proteolysis v.ith trypsin, and the cleaved prod-
ucts have maximal cathepsin A activity. Our results suggest 
that the in vitro activation ofBV-produced precursor mimics its 
in vivo processing taking place in at least two steps; an endo-
pr(lteolytic cleavage resulting in a transient intermediate of34-
and 20-kDa, followed by trimming of the last 14 amino acids at 
the COOH terminus of the large chain. Furthermore, we pro-
vide evidence that the 34· and 20-kDa reconstituted product is 
probably identical to the partially processed intermediate, 
which is a naturally occurring catalytically inactive form. A 
similar processing pattern was observed earlier for PPCA pre-
cursor over.expressed in COS-I cells (8, 14). In this case the 34-
and 20-kDa intermediate is seen only transiently, indicating 
that its half-life may be too short and its quantity too low to be 
detected in nonnally expressing cultured fibroblasts. There is 
an interesting analogy between the processing and activation 
ofPPCA and that of other serine carboxypeptidases. This fam-
ily of proteases comprises single- and two-chain enzymes that 
are present in different species, ranging from yeast to fungi, 
plants, and humans (9,10). Some of the plant peptidases have 
been purified in an active form composed of tW(I chains that 
have been sequenced at their NHz termini (32). In the case (If 
barley carboxypeptidase I, the two mature subunits of the 
enzyme originate from a single-chain precursor that in addition 
CDntains a stretch of amino acids separating the two chains 
(33). This closely resembles the processing of PPCA zymogen 
and provides another verified example in a homologous car· 
boxypeptidase of COOH-terminal trimming after the initial 
endoproteolytic step. The analogy in maturation events might 
indicate a similar function for the linker domain in the plant 
carboxypeptidase and PPCA precursors, namely to keep these 
forms in an inactive state. In yeast carboxypeptidase Y such an 
inactivation function resides within its propeptide segment, 
which must obstruct the access of a substrate to the preformed 
active site (34). Limited proteolysis with trypsin removes this 
inactivating segment and exposes the active site. Removal of 
the linker domain during maturation of the PPCA zymogen 
may induce major conformational changes on the protein nec-
essary to uncover its active site. Alternatively, this peptide may 
only mask the active site on an already correctly folded 
polypeptide. These hypotheses aTe currently verified on the 
basis of the three-dimensional structure of the uncleaved pre-
cursor molecule. 
Ackrwu:ledgmenls-We are indebled 10 Prof. Hans Galjaard (Erasmus 
University, Rotterdam) for support. We thank Dr. Gerard GroS','eJd for 
stimulating discussions and critical reading ofilia manUS(:ript. We grate-
fully acknowledge the help of Dr. Richard Pr{)ia (NIDDK, NIH, Bethesda, 
MOl, who has synthesized for us the synthetic peptide used in these 
studies. We also thank Peggy Burdick for editing the manuscript. 
Catalytic activation of PPCA 79 
REFERENCES 
1. d'Azzo, A, HoogEYHm. A.. Rem<'r. A J,. Robin.own, D .• and Galjaard, R (1982) 
Proc. Nat!. ACQd. Sci. U. S, A 79, 4535-4539 
2. d·Ano. A, Andria. G,. Struciuglio. P., and Galjaard. H. (1995) in T1o~ M~ta. 
bolie and Mol,~ular Ba«$ o(Inherilfd Disease (S~ri\'et. R. Ile",udet. A 1:... 
Sly. W. S., 1I1ld Valle. D,. e<h) Vol. 2, pp. 2825-2838. McGraw.HiII IM., New 
York 
3. Verheijen, F., Bro<smet, R, and Galjaard, U. (1982) Bioch€m. Biophys. R€.l 
Commun.. 108,868-875 
4. Hoogel'een,A T., Verheij~n, F. W., and Galjaard, H. (1983)J. Bioi. Chem. 258, 
12143-12146 
5. \'an der HOlOt, G., Galjart. N. J., d'Az.o. A-, Galjurd. R, and Vnheijen, F. W. 
(I9S9)J. BioI. Chem. 264, 1317-1322 
6. Galjart. N. J., Gillemam, N~ HQrri~, A, van der HalOt. O. T. J., Verheij~ll. F. 
W .• OaljMTd. H., and d·Allo. A. (1988) Coli 54, 765-76--1 
7. Galjart. N. J., Gilleman~, N .• Meijer, D" and d·Azw. A (1900) J. Bioi. C~.m. 
265, 4678~4684 
8. Galjart. N. J .• MaTTuu. H" Willem,en. R.. Gillemaru. N.. Bonterl. E. J., and 
d·AzlO. A (1991) J. Bioi. Chem. 266, 14754-14762 
9. Ilreddam. K. (1986) Carisb"g Re<. CommuM . .51,83-128 
10. Rawling;!. N. D,. and Barrott, A J. (1994) M'lhods Enzymol. 244, 19-61 
11. Jackman. H. 1:... Tan. F .• Tamei.H.. Iluerling_HarbUlj', C,. li. X. Y .• Skidgel. R. 
A. 1I1ld Erdo". E. G. (1990) J. BioI. Chem. 26.'i, 11265-11272 
12. Jackman, IL h. 1!orrU. P. W., Deddiili. P. A-. Skidgel. It A-. and Erdo". E, G 
(1992) J. Bioi. Chem. 261, 2872-2875 
13. Hanna, W. 1:... TurlxlV, J. :lol.. Ja~kman, JL h, Tan, F., and Froelioh, C, J. (19S4) 
J. Immuno!. IS:), 4663-4672 
14. Zhou, X. Y., Galjart, N. J., W,lIemsen, R, Gil\emans. n, Galjaard. H., and 
d·Azzo. A- (l99\) EJIBO J. to, 4041-4048 
15. Smith. G, E., Ju, G., Eric.;on, 8, 1.., Mosthera,J., J.,ahm, R W., ChilZonit<', R, 
and Summerll. M. D. (1985)Proc. Nail. Mad. Sci. U. S. A 82, 8404-8-l0a 
16. Sambrook, J,. Fritsch. E. F., and Manisth. T. (1989) MoIr.:u/ar CIMing; A 
lAJbQmlory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, 
NY 
17. Hink. W. F. (1970) Trichoplusia ni, Nalur~ 226, 466-467 
18. Smith. G. E" and Summer3. M. D, (1978) Virology 89, 517-,527 
19. Summer.. M. D .• 1I1ld Smith. G. E. (1987) Ta. Itgrle. Exp. SIn.. Bull. 1555 
20. Proia. R. L. d'Azzo, A. and Neufeld. E, F. (l984) J. Bioi, Chern. 259, 
3350-.3354 
21. H .... i1ik, A. and Neufeld. E. F. (l9S0) J. BioI. Chtm. 255, 4937-4945 
22. Wi1Iem..o;<,n, It. HoogevH'n. AT .• Sip5. H. J ..... an Dongen, J, M,. and G~lj~STd. 
II. (1986) Eur. J. Cdl Bioi. 40,9-15 
23. \an der Wdk. F., \'an un!, J. W. M., and VIal, J. 11. (19S7)J. o"n. Viral. 68, 
2615-2623 
24. VIal<, J. M., KJinkenberg. A, Zul, K J. M., U,rnAny, 1L, Klinge-Roode. E. C,. 
(kenliet,J. Il. F., Roossieu, J., and ,'an Lent,J. W. M. (l9881J. Gen.. Virol 
69,765-716 
25. O'Reilly, D. R, MIller, h K, and Luckow. V. A- (1994) Bac~lodru$ Expnmion 
\'cclor;;: A Labora/ory Manual, Oxford Unlvenity Press. New York 
26 Martin. B. M., Tsuji, S., La.\!arra, 11. E., Mal'sak, K, Eliason, W., and Ginn;;, 
E. I. (1988) DNA (N. Y.) 7, 99~106 
27. Grabowski, O. A., White, W. R, and Grate. M. E, (1989) Enl)me (E1l,d) 41, 
131-142 
28. [toh, K, Oshima. A-. Sakuraba. R, and Suzuki, Y. (1990) Bioch.m. Biophys 
Res. Cornmun. 167,746-753 
29. Boo5e. J. A, Tim. C. J., Prob. R 1:... and M)'erowitz. R (1990) Prolein 
E:qmssion Purif. 741, 111-120; C()rr"ctian (1991)Proldn E:rpre$Sio~ Pu,if. 
2,228 
30 Hagemann. C. A. and Capra. J. D. (1990) Prr:-~ Natl. A,~d. Sci, U. S. A. 87, 
3942-.3946 
31. [ngl"y. E .• Cutler. R. 1... Fung. M. C., Sandelllon. C. J., and YOllllg.1. G, (1991) 
Eur. J. Bioch~m. 196,623-629 
32. Sorensen. S, 8.. Svends~D. I,. and Bredd,~m. K. (1939) Carlsberg Res. Commun. 
54,193-202 
33. Doan. N. P., and Fincher. G. B. (1988)J. BioI. Chem. 263, 11100-11110 
34. Endrilri, J. A. Breddam. K, and Remington, S. J. (1994) Biochemistry 33, 
11100-11120 

Lysosomal neuraminidase: catalytic activ ion in 
insect cells is controlled by the protec ive 
protein/cathepsin A. 
Bonten EJ and d'Azzo A. 
J. Bioi. Chern., accepted for publication 
00 00 0<1 0<1 0<1 0<1 0<1 82 
Catalytic activation of neuraminidase 83 
Lysosomal Neuraminidase 
CATALYTIC ACTIVATION IN INSECT CELLS IS CONTROLLED BY THE PROTECTIVE 
PROTEIN/CATHEPSIN A 
Erik J. Bonten and Alessandra d'Azzo 
SI. Jude Chlldren's Research Hospital, Department of Genetics, 332 N. Lauderdale, 
Memphis, TN 38105, USA 
Lysosomal N-acetyl-a-neuramlnldase Is 
active In complex with the protective 
protein/cathepsin A (PPCA) and ~.galactosldase. 
The Interaction with PPCA Is essenUal for the 
correct Intracellular routing and lysosomal 
localization of neuraminidase, but the 
mechanism of Its catalytic activation Is unclear. 
To Investigate this process, we have used the 
baculovlrus expression system to co-oxpress 
neuraminidase and PPCA precursors In Insect 
cells, which ensued high enzymatic activity of 
neuraminidase. Both the 34· and 20·kOa PPCA 
subunits were required for the activation. We 
further demonstrated that when expressed alone 
the neuraminidase precursor remained dlmerlc 
(114 kDa) and had tow enzymatic activity, but 
when co-expressed with PPCA and ~. 
galactosidase, multlmerlzed In a complex of 
"1350 kOa, together with the other two proteins. 
The fully active neuraminidase co·preclpltated 
with full·length PPCA and ~.galactosldase 
precursors. However, when co-expressed with 
the Individual PPCA subunits, neuraminidase co-
precipitated only with the small 20·kDa 
polypeptide, which therefore must contain a 
neuraminidase-binding site. Our nndlng 
suggests a model of activation of neuraminidase 
dependent on Its oligomerization at acidic pH 
that Is mediated by Interaction with PPCA. 
Lysosomal neuraminidase (EC 3.2.1.18) 
catalyzes the intralysosomal degradation of 
slaloglycoconjugates by releasing terminal sialic acid 
from their oligosaccharide side chains. The human 
enzyme Is Involved In two genetically distinct 
lysosomal storage disorders: s/alidosls, which is 
caused by mutations In the lysosomal neuraminidase 
gene (1,2), and galactoslalldos/s, which Is the 
combined deficiency of neuraminIdase and ~­
galactosidase, caused by a primary deficiency of the 
protective proleln/cathepsln A (PPCA) (3-5). 
In mammalian tissues, neuraminidase Is 
present In a high molecular weight mullienzyme 
complex wilh PPCA, and ~·galactosldase, and 
copurifies with these enzymes on affinity 
chromatography columns for either ~·galactosldase 
or PPCA (6-12). Pshezehtsky and coworkers have 
reported that also N-acetylgalactosamine-6-sulfate 
sulfatase can be present in the multlenzyme 
complex, although confirmation of this finding or a 
follow-up has not yet been reported (6). Only a small 
percentage of PPCA and ~·galactosldase activities 
are consistently measured In the multlenzyme 
complex (1-2% of total), which Instead contains all of 
the neuraminidase activity. Apparently, PPCA and~­
galactosidase are active also outside the complex, 
while neuraminidase Is not (6-15). VerhelJen et al 
have shown that human neuraminidase purified from 
placenta was inactive at neutral pH, but could be 
reactivated In vitro by concentrating the preparation 
at 370 C and acidic pH, which resulted In a four fold 
Increase In activity for every two fold of concentration 
(8). On sucrose density gradients the 'stabilized' 
enzyme coprecipilated with the 32-kDa PPCA 
subunit and fl-galactosldase, suggesting that 
assembly Into a multlenzyme complex 
stabilized/protected the neuraminidase activity. In 
galactosialldosls fibroblasts, In the absence of 
PPCA, the 10-15% residual ~·galactosidase activity 
Increased upon addition to the cullure medIum of the 
protease inhibitor leupeptin, which pointed to a 
protective role of PPCA against proteolytic 
degradation of ~-galaclosidase (6,16,17). In contrast, 
neuraminidase activity remained undetectable after 
leupeptln treatment, unless PPCA was added 
(6,16,17), suggesting a dlfferenl way for PPCA to 
Influence neuraminidase activity. 
We have previously shown that human and 
mouse lysosomal neuraminidase expressed In COS-
1 cells and fibroblasts from patients with sialidosls 
associate with PPCA shortly after syntheSiS, and 
segregate to mature Iysosomes, only when 
accompanied by wild-lype PPCA, bul nol by 
Iran sport-Impaired PPCA mulants (18). Early 
Interaction Is needed because neuraminidase is 
poorly phosphorylated, even In the presence of 
PPCA, and lis mannose-six phosphate-marker 
(M6P) Is not functional In receptor-mediated 
endocytosis of Ihe enzyme (18). Thus, PPCA 
functions as an auxiliary transport protein for 
neuraminidase, and neuraminidase acquires full 
enzymatic activity in mature Iysosomes, only when 
bound to PPCA. In contrast, others have reported 
that In galactoslalldosis fibroblasts neuraminidase 
does reach the Iysosomes, but Is rapidly degraded 
because of the absence of functional PPCA (19). 
Thus, the exact mechanism by which PPCA controls 
both the catalytiC activation of neuraminidase, and 
the maintenance/regulation of its enzymatic activity 
is unknown. 
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We have utilized the baculovirus (8V) 
expression In insect cells to study the mechanism of 
catalytic activation of PPCA and demonstrated that 
the one-chain zymogen Is cleaved into a two-chain 
mature enzyme by a trypsin-like protease, removing 
a IInker·peptide between Ihe two subunils (20), The 
structural basis of this activation mechanism were 
assessed after the determinalion of the 3D structure 
of human PPCA precursor that showed that the 
active site is preformed In the zymogen. but is 
blocked by a 'maturation subdomaln' (21), Removal 
of the linker peptide causes conformational changes 
of the maturation 5ubdomain, exposing the active 
sile (21), 
Here we have developed a similar approach 
to elucidate the mechanism of catalytic activation of 
neuraminidase In Insect cells, When using 
baculovlrus constructs, several factors can Influence 
the level of protein expression In Insect celis, 
Including the type of baculovlrus vector, the type of 
insect cells, the multiplicity of infection (M,Q,I), the 
type of culture medium. the time of Infection, and the 
stability of the overexpressed protein (22,23), When 
high expression levels are achieved the recombinant 
protein Is usually clearly visible on Coomassle 
stained SDS-gels containing total celllysates, Taken 
this into account we expressed neuraminidase In 
insect cells and studied the In vivo and In vitro 
interactions with co-expressed PPCA and p-
galactosidase. Our results Indicate that 
neuraminidase Is catalytically activated by 
conformational changes that occur when the enzyme 
shifts from a 114-kOa dimeric form to an oligomeric 
complex of -1350 kOa. ThIs activation occurs 
exclusively at acidic pH. and Is triggered by its 
Inleractlon with PPCA. 
EXPERIMENTAL PROCEDURES 
Cell Culture and Generation of Recombinant 
Baculovirus Constructs - Spodoptera fruglperda 
insect cells (/PLB-SF21) were cultured in monolayers 
al27'C In TNM·FH medium (24), supplemenled wilh 
10% fetal bovine serum and antibiotics. 
Recombinant baculovlrus (BV) constructs encoding 
mouse and human neuraminidase (Moneur and 
Huneur). hUman p-galactosidase Wgal) and mouse 
PPCA (MPP54), were generaled Ihrough 
homologous recombination in insect cells. of wild-
type BV DNA (AcMNPV) and Ihe respeclive eDNA's 
(20,25,26), which were subcloned Inlo the BV· 
Iransfer plasmids pJR, and pBC, (20,27), The 
generation and characterization of BV-construcls 
encoding human PPCA (HPP54) and Ihe two 
separate hUman PPCA subunits (PP32 and PP20) 
was described earlier (20), 
Development of Antibodies - Polyclonal 
antibodies were raised in rabbits (Rockland) against 
BV-expressed 85-kDa human p-galactosidase 
precursor (anli·~gal), 54·kDa hUman PPCA 
precursor (antl·hPPCA), 20·kDa human PPCA 
subunit (antl·PP20), and 54·kDa mouse PPCA 
precursor (anti-mPPCA). All secreted recombinant 
proteIns were affinity purified from the Insect cell 
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culture medium on Concanavalin sepharose columns 
(Con A; Pharmacia Biotech), prior to Injection in 
rabbits, with the exception of the 20-kDa PPCA 
subunit. The latler polypeptide was excised from a 
preparative SOS-polyacrylamlde gel containIng PP20 
infected celHysates, The generation of anti-human 
neuraminidase antibodIes (anti-Neur) was described 
earlier (2), 
Metabolic Labeling of tnfected tnsect Cells -
For blosynthetic labeling studies Sf21 cells were 
seeded in 6-well dishes and grown until 80-90% 
confluence. and infected with BV at a multiplicity of 
infection (M,O,I.) of 5 plaque fonnlng unils/cell 
(pfu/ceU), Two days after infection the cells were 
radlolabeled for 16 h with 50 ~Cllml 35S-methionine, 
Immunoprecipltations were carried out as described 
earlier (20,28,29). immunopreclpitated proteIns were 
resolved on 12.5% SDS·PAGE, and visualized by 
fluorography of Ihe gels soaked In Amplify 
(Amersham Corp,), 
Purification of Neuraminidase - Sf21 cells 
were propagated In 3D bottles (Nunc) until 80-90% 
confluence and infected at M,Q.!' 5 wIth Moneur. The 
cells were dislodged two days after infection by 
tapping the bottles firmly. AU steps were carried out 
at 4°C unless Indicated otherwise. The cells were 
washed In Phosphale buffered Saline (PBS) and 
pelleled by centrifugation at 1000 rpm, The cells 
were lysed In waler and 1% Nonldet P40 (NP40; 
Calblochem) for 30 min, Tns Elhano! Amine (TEA 
stock solution: 0,2 M. pH 8.75) and water was added 
to the lysate to obtain final concentrations: 20 mM 
TEA pH 8.75, 0,1% NP40, The Iysale was ullra· 
centrifugated (Beckman SW28 rotor, 25000 rpm, 1 
h), and the supernatant was filtered through a 0,2 
flm filter. Neuraminidase was FPLC-purified on a 
Resource Q column (Pharmacla BioteCh.) and eluted 
with a sail gradient of 0·150 mM NaCI (20 mM TEA 
pH 8,75), The neuraminidase eluled al-80 mM NaC! 
and was concentrated in Centriprep 10 units 
(Amlcon) to 1-3 mg/mt. Neuraminidase was further 
purified on a Sephacryl S300HR column (Pharmacla 
Biolech,) In 20 mM TEA pH 8,75/100 mM NaCI. The 
neuramInidase containing fractions were pooled and 
concentrated as described above. The column was 
calibrated with molecular weIght markers (Pharmacla 
Blolech,), 
In vitro activation of neuraminidase - Fixed 
amounts of purified mouse neuraminidase were 
mixed with increasing concentrations of Con A 
purified mouse PPCA. human PPCA, human p. 
galactosidase. or bovine serum albumin (BSA) In 50 
mM sodium acelale pH 5,0 or pH 6,8 and 100 mM 
NaCI, and incubated at room-temperature (RT) for 1 
h. Neuraminidase activity was assayed with the 
artificial 4-methylumbelliferyl substrate (Sigma) 
according to Galjaard (1980), Atiquots of In vitro 
activated neuraminidase with and without PPCA 
were resolved on a Sephacryl S300HR column (50 
mM sodium Acelate pH 5,0/100 mM NaGI), Eluled 
fractions were separated on 12.5% SOS-PAGE, 
blotted on PVOF membranes (Immobllon, Millipore). 
and Incubated with anti-Neur and antl·PPCA 
antibodies, 
In vivo activation of neuraminidase and 
gelfillration - Sf21 cells were Infected in 6-well dishes 
with fixed amounts of Moneur, and increasing 
amounts of either MPP54, HPP54, PP32, PP20, and 
PP20 plus PP32 (as described above). Two days 
after infection the cells were harvested and the 
neuraminidase activity assayed. The cell-Iysates 
were separated on a Sephacryl S300HR gelfiltration 
column (50 mM sodium Phosphate pH 7.0/100 mM 
NaCI) and the eluates were analyzed by SOS-
PAGElwestern-blottlng, and neuraminidase activity 
assays (as described above), 
RESULTS 
Baculovirus expression in Insect cells of 
neuraminidase, PPCA, and (i-galactosidase, for In 
vivo catalytic activation of neuraminidase, - In 
mammalian cells neuraminidase depends on Its 
association with a transport-competent PPCA for 
lysosomal iocalizatlon (18), In insect cells, instead, 
PPCA does not reach the vacuole, but accumulates 
In the endoplasmic reticulum (ER) and Golgi 
compartments, and Is hardly processed Into the 
mature and catalytically active two·chaln fonn (20). 
Using BV-Infected Insect cells to co-express 
neuraminidase with PPCA and/or (i-galactosidase 
we could now test whether PPCA Influences 
neuraminidase activity In a manner that Is 
independent from its intracellular 
compartmentalization, For co-expression studies it 
was crucial to obtain comparable levels of 
expression of the different components, Previously 
we over-expressed in Sf21 cells three baculovlrus 
constructs that encode the human PPCA (HPP54), 
and the two separate PPCA subunits (PP32 and 
PP20) (20). The expression levels of these proteins 
were comparable as demonstrated by Immuno-
precipitation, Western-blotting, and Coomassie 
staining of SOS·gels (20). We now made baculovlrus 
constructs that encode human neuraminidase 
(Huneur), mouse neuraminidase (Moneur), mouse 
PPCA (MPP54), and human p·galactosldase (pgal). 
To select the best expressing clones, up to 10 
baculovlrus clones were screened for each protein 
by infecting the virus in S121 cells, and analyzing the 
recombinant proteins on Coomassie-stained SOS-
gels, before and after Can A sepharose purification 
(Experimental Procedures), Furthermore, the best 
expressing clones were also tested In metabollcally 
labeled Insect cells Infected Individually with 50 ~I of 
Moneur-, MPP54-, HPP54-, pgal·, HPP32·, and 
HPP20-recomblnant baculovlruses. Two days after 
Infection, cells were labeled for 16 h with 3SS_ 
methionine. Radiolabeled proteins were Immuno-
precIpitated with specific antibodies (anli-Neur, anti-
PPCA, anti,pgal), and subjected to SOS·PAGE (Fig. 
1A). The molecular weights of the expressed and 
immuno·preclpltated proteins are summarized In 
table 1. The 18·kOa and 75·kOa polypeptides (Fig. 
1A, lanes 5 and 8) represented non-glycosylated 
fonns of the small PPCA subunit and the p. 
galactosidase precursor respectively, sInce 
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treatment with N-glycosidase F, or InhIbition with the 
N·llnked glycosylatlon Inhibitor tunlcamycln did not 
alter their mobility on SOS·PAGE ((20) (data not 
shown)). These results confirmed that all proteins 
were expressed at similar levels, with the exception 
of human neuraminIdase (Huneur), which was 
expressed at considerably lower levels than the 
other proteins (FIg. 1A, lane 2), For this reason we 
chose to use the mouse (Moneur) rather than the 
human neuraminidase construct (Huneur) in co-
expression experiments, This approach was further 
justified by earlier studies demonstrating that 
interaction of the three enzymes Is not species-
specific, but each of the human enzymes can be 
substituted by its murine counterpart In the enzyme-
complex (26,30,31). 
Table 1. Summary of Immunopreclpitations. 
BV-construct antibody Mw Flg.1A 
(kOa) 
Huneur anti-Neur 46 lane 2 
Moneur antl-Neur 46 lane 3 
PP32 anti·hPPCA 34 lane 4 
PP20 antl·hPPCA 20/18 lane 5 
HPP54 anti·hPPCA 54 lane 6 
MPP54 antl·mPPCA 54 lane 7 
p·gal antl·pgal 85(75 lane 8 
Insect cells were co-infected with a constant 
amount of Moneur (50 ).!I), and increasing virus 
concentrations of either MPP54, HPP54, or ~gal) 
(50·300 !II). The cells were harvested two days after 
Infection, and assayed for neuraminidase activity, 
80th human and mouse PPCA were able to Increase 
the neuraminidase activity in a concentration 
dependent manner, although mouse PPCA was 
somewhat more effective In this function (FIg, 1 B), 
whereas (i-galactosidase had no effect at all on the 
neuraminidase activity (Fig. 1 B), AI/quots of the 
different cell-Iysates, analyzed on Western-blots 
probed with anti-Neur antibodies, showed that the 
amount of the 46-kDa neuraminidase protein was 
comparable In all samples, Small variations in 
expression levels and stability of the human and 
mouse PPCA might account for the differences In 
neuraminidase activity. Both human and mouse 
PPCA did not affect the level of expressIon or the 
stability of neuraminidase, as shown on Western-
blots (FIg. 18, Insert), but their interaction with 
neuraminidase clearly activated the enzyme. 
To determine whether a full·length PPCA 
was needed for thIs process or either of the two 
PPCA subunits (PP20 and PP32) would be sufficient 
for neuraminidase activation, Insect cells were co-
infected with a constant amount of Moneur Inoculum 
(50 /.ll), and increasing concentrations of PP20, 
PP32, or a combination of the two. Two days after 
infection, cells were harvested and assayed for 
neuraminIdase activity. The separate subunIts did 
Fig.1. Baculovlrus expression In Insect 
cells of neuraminidase, PPCA, and ~. 
galactosidase, for in vivo activation of 
neuraminidase. (A) 8f21 cells were single 
infected with Maneur, Huneur, PP32, 
PP20, HPP54, MPP54, and ~gal. Newly 
synthesized proteins were radio-labeled 
with 35S-methlonlne, two days after 
Infection, followed by immunopreclpilation 
with either ant·Neur, anti-PPCA. or anti-
pgal antibodies. Proteins were separated 
on 80S·PAGE and visualized by 
Huorography (eposure time 5 h). (8) 8f21 
cells were co-infected with constant 
amount (50 Ill) of mouse neuraminidase 
inoculum (Maneur) and increasing 
concentrations of either mouse PPCA 
precursor (MPP54), human PPCA 
precursor (HPP54), or human ~gal 
precursor (50, 100, 200, 300 ~I). Two days 
after Infection the cells were harvested 
and assayed for neuraminidase activity 
(nmol/hlml). The activities are an average 
of three experiments. Cell-lysates were 
analyzed for expression of neuraminidase 
on western-blots, Incubated with anU-Neur 
antibodies (insert). (C) Insect cells were 
co-infected with a constant amount (50 !-tIl 
of Moneur, and increasing concentrations 
of the two human PPCA subunits (PP20 
and PP34), or the combination of both (0, 
50, 100, 200, 300 ~I). Two days after 
infection the cells were harvested and 
assayed for neuraminidase activity 
(nmolfhlml). The activities are an average 
of three experiments. The cell-lysates 
were analyzed for expression of 
neuraminidase on western-blots Incubated 
with anli-Neur antibodies (Insert). 
Fig.3. Metabolic labeling and co-
precipitation of BV-expressed 
neuraminidase, PPCA, fl-
galactosidase, and the two separate 
PPCA subunits. Sf21 cells were co-
Infected with Moneur and flgal, MPP54, 
PP32, PP20, and PP32 plus PP20. 
Newly synthesized proteins were radio-
labeled with 35S-methionine, two days 
after infection, followed by 
immunoprecipitation with either ant-
neur, anti-PPCA, anli-PP32, or anti-
~gal antibodies. Proteins were 
separated on SOS-PAGE and 
visualized by f1uorography (eposure 
time 5 h). Co-precipitated polypeptides 
are indicated with a white asterisk 
(righl panel). 
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Fig,2, Gel filtration of av-
expressed neuraminidase. Insect 
cells were elther (A) sIngle infected 
with Moneur, or co-infected wlth 
Moneur and: (8) HPP54 and pgal; 
(C) PP32 and PP20; (0) pgal. Two 
days after Infection the cells were 
harvested and the Iysates were 
loaded on a Sephacryl S300HR 
gelfiUration column (Phannacia 
Biotech.), Eluted fractions (90-210 
ml) were subjected to SOS-PAGE, 
blotted on PVOF membranes, and 
probed with antibodies (indicated at 
the right). The gel fiftratlon column 
was pre-calibrated with molecular 
weIght standards (Pharmacla 
BIotech). Molecular weights of the 
eluted proteins (native), and 
molecular weight standards are 
IndIcated at top. Molecular weights of 
the proteins after SOS-PAGE 
(denatured) are indicated at left. 
Elution volume is indicated at 
bottom. (E) All gel filtration fractions 
were assayed for neuraminidase 
aclivity (nmoUh/ml). 
Fig.4. In vitro multlmerlzatlon and 
catalytic activation of 
neuraminidase. (A) Increasing 
amounts of Con A purified HPP54 and 
MPP54 were added (0, 1, 3, 5 ~I) to 
purified dimeric mouse neuraminidase 
and subsequenlly incubated at room 
temperature for 4 h, at either pH 5,0 or 
6,8, After incubation the samples were 
assayed for neuramInidase activity 
(nmol/h/ml). (8) Catalytically activated 
neuraminidase (5 III HPP54 added to 
dimeric mouse neuraminidase for 
optimal activation) and mock activated 
neuraminidase (BSA added instead of 
PPCA) were resolved on a Sephacryl 
S300HR gel filtration column at pH 5,0. 
Eluted fractions were separated on 
SOS-polyacrylamide gels, blotted on 
PVDF membranes, and probed with 
anti·Neur antibodies, Molecular 
weights of eluted proteins (native), and 
molecular weight standards are 
indicated at top. Molecular weights of 
proteins after 8DS-PAGE (denatured) 
are indicated at left. Elution volume Is 
indicated at bottom. 
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not affect the enzyme activity (Fig. 1C). However, a 
significant increase in activity was observed when 
both PPCA subunits were co-expressed with 
neuraminidase (Fig. 1C), The levels of the 46·kOa 
protein on western-blots were comparable In all 
samples (fig. 1C, insert). Thus, a full-Ienglh PPCA 
protein. In form of the one-chain precursor or the 
two-chaIn mature enzyme, is needed for catalytic 
activation of neuraminidase. 
Complex (ormation of neuraminIdase with 
PPCA and p-galactosidase. - OU( results have 
shown that PPCA by itself has the ability to activate 
neuraminidase. We further investigated whether the 
three-enzyma-complex could assemble also In 
insect cells, and whether neuraminidase activity 
would change In the context of this complex. We 
first analyzed by gel filtration the native molecular 
weight of mouse neuraminidase alone, or in 
combination either with the 85-kOa ~-galactosldase 
precursor, the 54-kOa PPCA precursor, or both 
PPCA subunits, Total cell-Iysates from BV-Infected 
insect cells were resolved on a Sephacryl S300HR 
column, and the eluted fractions were analyzed on 
western-blots, probed with polyclonal antibodies 
specific for either of the three proteins (Experimental 
Procedures), Neuraminidase expressed alone eluted 
at a molecular weight of -114 kOa, probably as a 
dlmer (Fig. 2A). When co-expressed wilh PPCA and 
p-galactosldase, a small amount of neuraminidase 
oUgomerized and eluted from the colUmn In fractions 
corresponding to a molecular weight of -1350 kOa 
(Fig, 28, upper panel), These fractions also 
contained small amounts of PPCA and 13-
galactosidase, suggesting that the three enzymes 
were in complex (Fig. 28, middle and lower panel). 
However, most of the neuraminidase, PPCA, and 13-
galaclosidase eluled al 114-85 kDa (Fig. 2B, 3 
panels), and were not associated. When co-
expressed with both PPCA subunits, a small 
percentage of neuraminidase again eluted at -1350 
kOa (Fig. 2C), However, neither of the two subunits 
was resolved together with neuraminidase In these 
fractions, suggesting that they were either only 
transiently associated with neuraminidase, but just 
enough to trigger the oligomerization of the enzyme, 
or they were still In complex with neuraminidase, but 
their amount was too low to be detected on the 
western-blot. Co-expression of neuraminidase with 
only l3-galaclosidase did not promote oligomerizatton 
of the enzyme (Fig. 20), confirming that p-
galactosidase was not directly involved in this 
process. 
The gel filtration eluates were also assayed for 
neuraminidase activity (Fig. 2E). The dimeric 
enzyme had very low activity (Fig, 2E, upper-left 
panel). The neuraminidase that was eluted at 1350 
kDa, logelher wilh PPCA and ~-galaclosldase, was 
also calalytically aclive (Fig. 2E, upper-righl panel). 
Given that only a small percentage of neuraminidase 
was resolved in these high molecular weight 
fractions, this oilgomeric neuraminidase had a 
substantially higher specific activity (10~20x) than 
the dimeric form (28, lower panel), In contrast, the 
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-1350-kDa oligomeric neuraminidase, resolved on 
gel filtration after co-expression with the separate 
PPCA subunits, was catalytically Inactive (Fig 2E, 
lower-left panel), despite the relatively high amounts 
delecled on weslern-blols (Fig. 2C). Thus, Ihe 
oligomerization of neuraminidase Is not sufficient for 
its catalytiC activation, which apparently requires 
stable association with PPCA. 
Co-precipitation of BV-expressed 
neuraminidase with PPCA and p-galactosidase, -
To demonstrate that neuraminidase was indeed 
associated with PPCA and p-galactosidase, Insect 
cells were co-Infected with the BV-constructs listed 
In table 1. Two days after infection, cells were 
metabolically labeled for 16 h with 35S-methlonine. 
The radiolabeled proteins were preCipitated with 
specific antibodies (anti-Neur, anli-PPCA, anti-PP20, 
antl-pgal), and the immunopreclpltated products 
were subjecled 10 SDS-PAGE. The 54-kDa PPCA 
precursor was readily co-lmmunopreclpltated with 
neuraminidase using antl-Neur antibodies (Fig. 3, 
lane 2). Surprisingly, only the 20·kOa and not the 
34-kDa subunll of PPCA co-preclpllaled wilh 
neuraminidase (Fig. 3, lane 3 and 4), suggesting 
that this subunit contains a neuramlnldase-
Interacting domain. It Is not clear at this moment 
whether the large PPCA subunit did not bind at all to 
neuraminidase, or whether this Interaction was too 
weak to withstand the Immunopreclpilatlon 
conditions, The 34-kOa subunit did co-preCipitate 
with the 20-kOa polypeptide using antibodies that 
are specific for the small subunit (Fig. 3, lane 6). 
Neuraminidase also co-preCipitated efficlently with 
the p-galactosldase precursor using antl-pgal 
antibodies (Fig. 3, lane 1), indicating that the two 
proteins did interact strongly, although 13-
galactOSidase did not appear to Influence the activity 
of neuraminidase (Fig. 1 and 2). Mouse 
neuraminidase assoclated equally well with the 
human and mouse forms of PPCA and p-
galactosidase (31) (data not shown). As shown in 
Figure 3 (lane 2), PPCA precursor co-precipitated 
with neuraminidase only with anti-Neur and not with 
anti-PPCA antibodies, while neuraminidase co-
precipitated with ~-galactosidase only with antl-pgal 
and not with anti-Neur antibodies (Fig. 3, lane 1). 
This was probably due to the inability of some of the 
antibodies to recognize the associated proteins, 
which may no longer expose the epitopes against 
which the antibodies were raised. Together, the 
results indicate that neuraminidase, PPCA, and 13-
galactosidase can physically associate in insect 
cells, forming a -1350-kOa enzyme-complex (Fig, 
28). 
In vitro catalytiC activation of neuraminidase. 
- The ability to produce In Insect cells, and purify 
large quanliUes of neuraminidase, PPCA and ~­
galactOSidase (Experimental Procedures), allowed 
us to test in vitro the catalytic activation of 
neuraminidase. Oimerlc mouse neuraminidase (pH 
8.75) was mixed with Increasing amounts of either 
mouse or human PPCA, and Incubated for 1 h at 
room temperature at pH 5.0 or 6.8. Afterwards the 
samples were assayed for neuraminidase activity. 
Incubation with both mouse and human PPCA 
(MPP54 and HPP54) resulled in Ihe Increase of 
neuraminidase activity, but only under acidic 
condllions (Fig. 4A), while ~-galaclosidase or BSA 
had no effect on the activity (data not shown). This 
demonstrated that PPCA controls the catalytic 
activation of neuraminidase in a pH dependent 
manner. To determine whether catalytic activation 
had any effect on the molecular weight of 
neuraminidase, we separated neuraminidase, either 
PPCA-activated or mock-activated, on a Sephacryl 
S300HR gelfiltralion column. The eluates were 
analyzed on westem- blots probed with anti·Neur 
antibodies (Fig. 48). PPCA-activated neuraminidase 
was recovered in two separate pools, as oligomers 
of -600 kOa, and as oligomers of -1100 kOa. In 
contrast, mock-incubated neuraminidase was mainly 
recovered in fractlons ranging from 100 to 300 kOa 
(Fig. 4B, lower panel), These results Indicate that 
also in vitro PPCA was able to promote the 
oligomerization of neuraminidase. This process 
appeared to take place In two steps. Initially, 
oligomers of -600 kOa were formed, that probably 
consisted of 6 dimers, that further mullimerized in an 
-1100-kOa form. We conclude that the interaction 
between PPCA and neuraminidase is required for 
both the oligomerization and catalytic activity of 
neuraminidase. and the two events cannot be 
separated. 
DISCUSSION 
Lysosomal neuraminidase shares significant 
homology with other bacterial and mammalian 
members of the slalJdase superfamily (2). Most 
neuraminidases are monomeric. but higher 
oligomeric states have been reported (Taylor, 1996). 
The crystal structures of bacterial and viral 
slalJdases revealed that the fold topology of these 
enzymes Is Identical. and consists of a six-bladed 13-
propeller around an axis that passes through the 
aclive sile (30-33). II Is likely Ihal lysosomal 
neuraminidase shares the same fold. Nevertheless. 
it is the only member of the sialidase superfamily to 
require an accessory protein (PPCA) for its 
transport, catalytic activity and stability in Iysosomes 
little is known about the mechanism of 
complex assembly between neuraminidase. PPCA 
and j3-galactosldase. We have used the baculovirus-
expression system to co-express neuraminidase In 
insect cells, with PPCA and jl-galactosidase 
precursors, and the two separate PPCA subunits 
(20). BV-encoded PPCA precursor, and Ihe two 
separate subunits were synthesized in the Insect 
cells In large amounts. and transported from the ER 
to the Golgi compartment. but were not segregated 
to the vacuole, which explains their lack of 
maturation {20}. In mammalian cells we could not 
separate the effect that PPCA had on the transport 
of neuraminidase to Iysosomes (18), from the actual 
activation event. Since PPCA and neuraminidase 
likely Jack the appropriate signals for vacuolar 
sorting in insect cells, we were able to test the 
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influence of PPCA on the catalytic activation of 
neuraminidase. Independent from its intracellular 
transport. 
Many lysosomal hydrolases. after 
segregation to Iysosomes, undergo partial 
proteolytic processing, resulting in the removal of 
either C-terminal or N-terminal fragments, leading to 
the mature, active forms of the enzymes (34). 
Recently we reported the mechanisms of catalytiC 
activation of lysosomal jl-galactosidase and PPCA, 
showing that both are two-subunit enzymes, The 85-
kOa j3-galactosldase precursor is C-terminally 
processed by the cleavage of a 24-kDa domain. 
which remains non-covalently associaled to the 64-
kOa N-terminal polypeptide (35), The one-chain 
PPCA zymogen is processed by a trypsin-like 
protease. removing a -20 amino acid linker-peptide 
between the two subunits. The two subunits are 
linked by disulfide bridges. resulting in a 32/20·kDa 
two-chain active enzyme (20), The crystal structure 
of BV-expressed PPCA precursor indicated that the 
removal of the linker-peptide triggers conformatfonal 
changes /n a subdomaln of the PPCA. that /n tum 
expose Ihe calalytic pockel (21). Unlike PPCA and 
j3-galactosidase precursors neuraminidase is 
catalytically activated by a different mechanism thai 
requires the Interaction with PPCA. A pool of 
neuraminidase, PPCA, and fl-galactosidase. when 
co-expressed In insect cells. assembled Into a high 
molecular weight complex. The exact stOichiometry 
of this mulUenzyme complex Is unknown, but Its 
molecular weight In insect cells (1350 kOa) Is similar 
10 Ihe 1000-1300 kDa molecular welghl of Ihe 
mullienzyme complex Isolated from human 
fibroblasts and various other mammalian tissues (6-
9,13,36-39). Our In Vi/fO sludles Indlcale Ihal Ihe 
complex probably contains 12 neuraminidase 
dimers, The number of PPCA and j3-galactosldase 
molecules in the complex remains uncertain, The 
multimerization of neuraminidase occurs only at 
acidic pH. which Implies that in mammalian cells the 
high molecular weight complex Is assembled in 
Iysosomes. 
We have shown earlier that In absence of 
PPCA, neuraminidase formed crystals when over-
expressed In COS-1 cells. However, co-expression 
of neuraminidase with PPCA prevented crystal 
formation, and promoted its transport to the 
Iysosomes, and catalytic activation (18,20). 
Association with PPCA appeared to mediate correct 
folding and oligomerization of the enzyme, 
preventing aggregation of partially folded or unfolded 
molecules. A similar mechanism has been 
described for the coagulation proteins Von 
Willebrand Faclor (vWF) and Faclor VIII (FVIII) (40). 
Factor VIII needs to associate with vWF for correct 
folding and segregation Inlo the secretory pathway. 
In Von Willebrand patients. which are deficIent for 
vWF, FVIII aggregates and Is subsequently 
degraded. The dependence of a molecule on the 
association with a partner may be an important 
mechanism to regulate at the protein level its 
biological activity. Especially for neuraminidase this 
principle could hold true, Sialic acid residues. being 
0<1 0<1 0<1 OQ OQ 00 0<1 
the terminal sugars on carbohydrate chains. are the 
first targets for hydrolysis. Thus, It may not always 
be beneficial to have catalytically active 
neuraminidase In the Iysasames. An equilibrium 
between neuraminidase and PPCA could maintaIn 
the required level of neuraminidase activity. In tum. 
this could explain the 'Instability' of neuraminidase 
during enzyme purifications, which is caused either 
by dissociation from the complex, andlor 
delachmenl from PPCA (6-10,12). Given Ihe 
biological integrity and functionality of BV-expressed 
neuraminidase, including its association with PPCA 
and ~-galactosldase, this expression system can be 
of great value not only for biochemical analysis, but 
also for the crystallization and 3D-structure 
determInation of this enzyme and ultimately of the 
multienzyme complex. 
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Lysosomal neuraminidase is the key 
enzyme for the Intra lysosomal catabolism of 
slalylated glycoconjugates, and Is deficient 
In two neurodegenerative lysosomal 
disorders, slalldosls and galactoolalldosls. 
Here we report the Identification of ten novel 
mutations In the neuraminidase gene of 11 
slalldosls patients with various degree of 
disease penetrance. Comparison of the 
primary structure of human neuraminidase 
with the primary and tertiary structures of 
bacterial slalldases Indicated that most of 
the single amino acid substitutions 
occurred In functional motifs or conserved 
residues. On the basis of the subcellular 
distribution and residual catalytic activity of 
the mutant neuramlnldases we assigned the 
mutant proteins to three groups: (I) 
catalytlcalty Inactive and not lysosomal; (II) 
catalytically Inactive, but localized In 
lysosome; (III) catalytically active and 
lysosomal. In general, there was a close 
correlation between the residual activity of 
the mutant enzymes and the clinical severity 
of disease. Patients with the severe Infantile 
type II dlsea.e had mutations from group I, 
whereas patients with a mild form of type I 
disease had at le.st one mutation from 
group III. Mutations from the second group 
were mainly found In juvenile type II patients 
with Intermediate clinical severity. Ovorall, 
our findings expl.ln the clinical 
heterogeneity observed In slalldosls and 
may help In the assignment of existing or 
new allelic combinations to specific 
phenotype •. 
INTRODUCTION 
Neuramlnldases or slalldases are exoglycosidases 
that catalyz. tho cleavage of a·glycosldlcally linked 
terminal N-acetyl neuraminic acid from slalylated 
glycoconjugates (1). They are widely spread In 
nature occurring in viruses, bacteria, fungi, protozoa, 
birds and mammals (2-8). Together the 
neuraminidases form a family of hydrolases that 
share a conserved active site and similar sequence 
motifs (9-11). Three types of neuramlnldases are 
found In mammals that are defined as lysosomal, 
plasma membrane and cytosoUc on the basis of their 
biochemical properties and subcellular distribution 
(3-8, 12-14). Lysosomal N-acetyl-a-neuramlnidase 
has significant primary structure characteristics of 
other mammallan and microbial sialidases with 
similar substrate specificity. However, unlike other 
members of thIs family, lysosomal neuraminidase 
requIres the carboxypeptidase protective 
protein/cathepsin A (PPCA) for Intracellular transport 
and lysosomal activation (15); the enzyme is 
catalytically active only when it is bound to PPCA, 
and is a component of a high molecular weight, 
multi-protein complex containing PPCA, p-
galactosidase and N-acetylgalactosamine-6-sulfate 
sulfatase (16-21). A primary or secondary deficiency 
of lysosomal neuraminidase is associated with two 
neurodegenerative disorders of lysosomal 
metabolism, slalidosls and galactoslalidosls. 
SiaUdosls Is an autosomal recessive dIsease 
caused by lesions In the lysosomal neuraminidase 
gene on chromosome 6p21 (12,14). Distinct clinical 
phenotypes are recognized, varying In the onset and 
severity of the symptoms. Type I slalldosls, whIch Is 
also referred to as the cherry-red spoUmyoclonus 
syndrome, Is a relatively mild dIsease that occurs in 
the second decade of life and results In progressive 
loss of vision associated with nystagmus, ataxia. 
and grand mal seizures but not dysmorphic features 
(22). Type II slalldosls, 15 the sever. form of the 
disease, characterized by the presence of abnormal 
somatic features, Including coarse facIes and 
dysostosis multiplex. On the basis of the age of 
onset of the symptoms, type II sialldosls is divided 
Into thr.e subtypes: (I) cong.nilal or hydropiC (In 
utero), (II) Infantile (0·12 months), and (III) juvenile 
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(2-20 years) (reviewed In (22)). The congenital form 
Is associated with either hydrops (etalls and stillbirth 
or neonatal ascites, and death at an early age; 
features include facial edema, inguinal hernias, 
hepatosplenomegaly, stippling of the epiphyses, and 
periosteal cloaking. Type II patients with longer 
survival develop a progressive 
mucopolysaccharidosis-like phenotype; signs 
include coarse faCies, visceromegaly, dysostosis 
multiplex, vertebral deformlties, mental retardalton 
and cherry-red spoUmyoc!onus (22-25). 
A primary defect of PPCA causes the 
lysosomal disorder gafactosialldosls (GS), which 
presents with clinical signs strikingly Similar to those 
of slalidosls (reviewed In: (26». The absence or 
Impairment of PPCA leads to the secondary, 
combined deficiency of f3-0-galactosldase and 
neuraminidase. Residual neuraminIdase activity In 
patients with slalldosls or GS is typically less that 1 % 
of normal levels. As for slaUdosls patients, GS 
patients are diagnosed with either an early Infantile, 
late infantile, or a juvenile/adult form of the disease, 
based on age of onset and severity of clInical 
manifestations. The early Infantile form of GS Is 
clinically very similar to the congenital type II form of 
sialidosls; both are characterized by visceromegaly, 
hydrops fetalis, ascites and early death. The late 
InfanWefchildhood forms of GS and sialidosls are 
also simifar, with the exception of mUder neurological 
involvement in the GS patients. At the other end of 
the spectrum, similarities also exist between patients 
with adult type I sialldosis and juvenile/adult GS, 
both characterized by the absence of visceromegaly. 
However, juvenile /adult GS In contrast, 
Juvenile/adult GS patients have dysmorphlc features 
but milder neurological involvement (reviewed In: 
(26». The biochemical and clinIcal similarities 
between sialldosis and GS suggest an important role 
for neuraminIdase in the pathogeneSiS of these 
diseases. 
Several mutations have been identified in 
the neuraminidase genes of unrelated patients with 
slalidosls (12, 14, 27). The mutations analyzed to 
date Include poInt mutations, single nucleotide 
deletions, and small insertions (12, 14, 27). Those 
slaUdosis patients that were also tested for the 
presence of the neuraminidase mRNA, were found 
to have normal amounts of transcript (12, 14). 
Here we report the identification of eight 
novel and five previously Identified mutations In 
eleven patients with slalidosis (nine unrelated and 
two siblings). Collectively these patients exhibit the 
full range of severity of the disease. Expression of 
the mutant enzymes In slalidosis fibroblasts enabled 
us to classify the mutations according to the level of 
functional neuraminidase they support, and to 
Identify functional domains or amino acid residues in 
the protein. From these studies we found a 
correlation between specific combinations of mutant 
alleles and the severity of the disease. 
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RESULTS 
Cllnlcat Phenotypes 
We have studied 11 patients with sialldosls (nine 
unrelated and two siblings) of different ethnic origins 
and with heterogeneous clinical presentations. The 
type I form of the disease was diagnosed in six 
patients (patients 1, 2, 4, 5, 6, and 7); the type II 
juvenile phenotype, in one (patient 3); the type " 
Infantile form in three (patients 8, 9, and 10); and the 
type II congenital/hydropic form in one patient (11). 
Clinical reports have been published only for 
patients 9 and 10 (28-30); the other patients were 
newly diagnosed, or their cases had never been 
reported In the literature. Table 1 is a summary of 
the maIn clinical features, sex, ethnlclty, and 
biochemical data of these patients. The patients with 
the mildest form of slalidosls (patients 7, 5 and 6) 
had slowly progressing disease. The two siblings, 6 
and 5, presented with identical symptoms, but only 
for patient 5 had the disease affected the eyes 
(Table 1). Oespite the relatively mild clinical 
manifestations, serious central nervous (CNS) 
disorders, such as ataxia and epilepsy, developed in 
these patients, whereas patients with mild form of 
GS have no relevant signs of neurological disorders 
(31). The other patienls with type I or type II 
slalldosis experienced severe CNS symptoms, 
Including epilepsy, ataxia, dysmetria, hypotonia, 
deafness and mental retardation. 
The neuraminidase activities of the fibroblast 
Iysates were compared within one experiment to 
allow for the reliable calculation of residual enzyme 
activity of each patient. The differences in residual 
activity among patients were small, ranging from 0.5 
to 1.5% of the normal values, and did not reflect the 
broad spectrum of clinical manifestations. These 
findings Indicate that even small variations in 
residual catalytiC activity can greatly Influence 
disease severity and progression (Table 1). 
Biochemical characteristics of the slaUdosls 
patients 
All patients Included in this study expressed 
neuraminidase mRNA as determined by Northern 
blot analysis (Figure 1, upper panel) (12, 14). To 
compare the quantity and quality of the different 
RNA samples, the Northern blot was also hybridized 
with a PPCA cDNA probe (Figure 1, lower panel). 
The presence of the 1.9·kb neuraminidase and 2.0-
kb PPCA mRNAs was detected In all the patient 
samples. 
Western blots of total homogenates of the 
cultured fibroblasts were analyzed with affinity 
purified antl-neur antibodies (12). The size of 
neuraminidase detected In the patients' fibroblasts 
(46 kD) was the same as that In wild-type fibroblasts; 
however, the amount of neuraminidase In the 
Table 1. Clinical features of patients with sialidosis 
InitialS 1 (female) 2 (male) 3 (female) 4 (female) Sand $(12) 7 (female) 8 (male) 8 (female)(3(I) 10 (female)(2I..2II) 11 (female) 
(sex) (female/siblings) 
Clinical I I II juvenile I I I II infantile II infantile II infantile II congenital! 
type hydropic 
Neuracl 0.71 0.'" 0.76 0.49 0.65 1.02 0.50 0.'" 0.42 0.98 
(nmoUhlmg) 
Y.nonnal 1.0 0.82 1.1 0.72 1.0 1.5 0.72 1.3 0.62 1.4 
Origin African African· Italian G,_ German 0_ Hispanic· Unknown Unknown Italian . 
American American American (caucasian) (caucasian) 
Ooset 11 years 8,..", 12 years 10 years 17 and 15 years 13 years At birth 6 months At birth Gestational 
age of 20 
weekS 
Presen· MUSCle weak· MUSCieaches Generalized Seizures, Cerebellar Gait disturbance, Coarse facies! Strabismaus, Coarse facies! Hydrops 
tatlon ness. atrophy, 
-"" 
myoclonus atrophy stumbling & falling hepatospleno- nystagmus hepatospleno- fetalis, joint 
,...,,"" meg.aly megaly contracrures 
Growth Nonnal Nonnal Nannal Nonnal Nannal Nannal Short Nannal Weightllength 
stature underthe3n:1 
percentile 
Skeleton Nannal Nannal Dysostosis multiplex; Coarse laeles.mlld Nannal Normal Coarse facies; Coarse facies, Coarse facies, DysostOSis 
skull, vertrebal dysfrorphlc features, aaniosynostosis dolichocephalic dysostosis multiplex nystagmus, wheelchair bodles,hlps 
age 16 years slcull multiplex Uv.,., Nannal Nannal Nannal Nonnal Normal Normal Hepatospleno- Hepatospleno- Hepatospleno-
spleen megaly megaly megaly 
HeaR Nonnal Munnur ECG aspeonc aIt_~ns Nannal Nonnal cardiomegaly cardiomyo-of rnpIolar\l:allon; 
unrasoul"ld 00I'TT\a1 palhy 
N""", ... SeIzures. alaJda. Mode_ AtaxLa. Spad'City, Heanng loss, rnyodonus , Ataxia, dysarthria. Ataxia. pytarrridal ~gns, Developmental Mental Mild mental """'e 
systom slurTed speech, d""""'P- ~orOelay, mild hyP010flk3. cerebelta myoclonic epilepsy. dys.artMa, myoclonus, detay,ortital retardation, retardartion, psychomotor m'~y. Signs, dysattl'ma. dydiadochol<lnesla p;JJnful3)(On31 
-. mental delay dysphag'a. ~rlirle IQ. polyneuropathy, hypoplasia hearing loss, hearing loss, retardation, m""","~ rIOlurosel\SQl'1al de3l'ness, in language dysmatna. myoclonus EEGa:1Jnon'r1al~1es $pjlepsy,EEG abOO1'm_, hypotonia hypotonia hydrocephalus 
"" ..... ,,'/"1 
eM">,",ed Cheny-ffid Ch'rry-<ed Cherry-<ed I ~ eny-c:e~_ Bilateral cateracts, Nannal Macular Normal Nocomeal 
~ spotS. visual 'PO~ spots, OCCIJlar spots (5) and prolonged lalendes cheny· opacity Eyes 
acuity lens opacities, normal (6) on visual evoked red spots 
diminution impaired vision 
potentials. 
Intolerance for Hghl 
VIIheeIchalr and 0ihenMse SlOWly wheelchair age 16 Alive at 33 & 32 "owly Progressing at wheel chair at Progressing at exit1..Isat18 
Cou,,", slowly progressing normal health progressing at years, dead at 24 years; slOWly progressing; 4moo1h, 9 years,dead 24 months rnamh, 
al20 years ate years 28 years _ ,..'" - ~qgressing __ dead at ag~ 44 '-- at30~_. --- ---_ .. --
Figure 1. Neuraminidase mRNA expression, 
Radiolabeled full-length neuraminidase eDNA (upper 
panel) and PPCA eDNA (lower panel) were used to 
probe a Northern blot containing RNA (10 lJ,9) isolated 
from the cultured fibroblasts of a healthy person (WT). 
four patients with type I slalldosis (patients 1, 2. 4, and 
7), and four patients with type" sialidosls (patients 3, 
8, 9, and 11). 
Table 2. Neuraminidase mulations in sialidosis patienls 
Patient Clinical Nucleotido Exon 
phenotype mutation 
C878>T 5 
T690>A 4 
2 C878>T 5 
G654>C 4 
3 II juvenile G677>A (27) 4 
G677>A 4 
4 G677>A 4 
G677>A 4 
5 and 6 G159>A 2 
Gl127>T (12) 6 
7 G980>A (27) 5 
dupM 196 ACCACT 6 
8 II infantile A1107>G 6 
A1107>G 6 
9 II infantile T777>A (14) 4 
T777>A 4 
10 II infantile T777>A 4 
T1086>C (14) 6 
11 II congenital! C836>P 5 
hydropic Cl002>A 5 
a mutation only detected in genomic DNA 
98 
Amino acid 
change 
Arg294Ser 
Leu231 His 
Arg294Ser 
Gly218Ala 
Gly227 Arg (27) 
Gly227Arg 
Gly227Arg 
Gly227Arg 
Val54Met 
Gly378stop (12) 
Gly328Ser (27) 
dupl399HisTyr 
Tyr370Cys 
Tyr370Cys 
Phe260Tyr (14) 
Phe260Tyr 
Phe260Tyr 
Leu363Pro (14) 
Arg280stop 
Pro335Gln 
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Figure 2. Detection of neuraminidase in fibroblasts of patients. (A) Affinity·purified anti-neur (upper panel) and anti-
PPCA antibodies (lower panel) were used to analyze Western blots containing protein (5J.tg) from fibroblast Iysates of a 
healthy person (WT), five patients with type I slalidosis (patients 1, 2, 4, 6, and 7) and five patients with type II slalidosls 
(patients 3,8,9, 10, and 11) (B) lmmunocylochemlcallocalizatlon of neuraminidase in fibroblasts from a healthy person 
(WT) and from ten patients as Indicated. Affinity·purified anti-neur antibodies and FITC-conjugated secondary antibodies 
were used. The nudel were stained with DAPJ. The magnification is 400x. 
0<10<100000<100000<1 
WT 8 
+ + 
2 3 4 
Figure 3. In vitro stability of neuraminidase from 8 
fibroblasts of patient 8. Fibroblast Iysates (5 119 of 
protein) of a healthy person (WT) and of patient 8 
were incubaled for 15 min at 37 (Ie In the absence 
(-) or presence (+) of protease inhibitors. After 
incubation, the samples were subjected to SDS· 
PAGE (12.5% acrylamide gel). subsequently 
transferred to a PVOF membrane, and incubated 
with affinitv-ourified anli-neur antibodies. 
samples of all patients except one was markedly 
less than that In wild-type fibroblasts (Figure 2A). 
Only patient 8 had a normal amount of the 46-kD 
neuraminidase (Figure 2A; lane 11, upper panel). 
When the same blot was analyzed with an anti-
PPCA antibody that recognizes the 32-kD subunit of 
the enzyme, similar quantities of fully processed 
PPCA were detected in wild-type fibroblasts and In 
fibroblasts of aU patients (Figure 2A; lower panel). 
To further ascertain whether the different 
neuraminidase varianls were localized to aberrant 
subcellular regions, we used anti-neur antibodies to 
perform immunocytochemical analysis of the 
patients' fibroblasts. The wild-type fibroblasts 
displayed a punctated staining-pattern that is 
characteristic of Iysosomes (Figure 28; WT). In 
contrast, this punctated staining was not detected in 
any of the patients, with the exception of 8 (Figure 
28). In this patient's cells the protein appeared to be 
distributed in Iysosomes in a pattern similar to that of 
wild-type fibroblasts, but the signal intensity was 
somewhat lower than In the wild-type fibroblasts 
(Figure 2B). A normal subcellular distribution of 
PPCA was detected in all patient samples (data not 
shown). These results indicated that the biochemical 
phenotype of patients in this study, with Ihe 
exception of that of patient 8, fit the profile of 
sialidosis. 
The normal quantity of neuraminidase 
detected by Western blot analysis and the punclated 
immunoslaining in fibroblasts raised the possibility 
that patient 8 were affected by another lysosomal 
disorder. We excluded GS since the patients' 
fibroblasts had normal levels of cathepsin A and p-
galactosidase activities, and showed a normal 
punctated lysosomal localization of PPCA (data not 
shown). Moreover, we have shown earUer that In 
absence of a functional PPCA neuraminidase is not 
transported to the Iysosomes (15). We analyzed the 
in vitro stability of neuraminidase in this patient's 
fibroblasts. We Incubated homogenates of the 
patient's fibroblasts and those of wild-type 
fibroblasts at 37"C for 15 minutes, in the absence or 
100 
presence of protease inhibitors to allow the partial in 
vitro degradation of neuraminidase by endogenous 
proteases that are present in the cell Iysates. After 
Incubation, total proteins were subjected to Western 
blot analysis with antl·neur antibodies. The 46·kD 
wild-type neuraminidase was almost unaffected after 
the incubation at 3?OC (Figure 3; lanes 1 and 2). and 
only minor degradation was observed In the sample 
without the protease inhibitors (Figure 3, lane 1). In 
contrast, only a small amount of the 46-kD 
neuraminIdase was present in the samples of patient 
8 (Figure 3; lanes 3 and 4). A degradation product of 
approximately 20 kD was detected in the presence 
and in the absence of protease InhibItors. In 
conclusion, the mutant neuraminidase in this patient 
is apparently competent for transport to the 
Iysosomes but is more susceptible than the wild·type 
protein to (In vitro) proteolytic degradation (Figure 2). 
The protease(s) responsible for the degradation of 
neuraminidase in this experiment may not be 
lysosomal, since under physiological conditions 
neuraminidase stability does not seem to be 
affected. Nevertheless, the increased in vitro 
instability of neuraminidase in combination with the 
absence of catalytic activity in fibroblasts of patient 8 
does Imply a defect in the neuraminIdase gene. 
Molecular analysis of neuraminidase from the 
patients 
The cDNA and genomic DNA from the 11 patients 
were analyzed as described earlier (12). We 
identified 13 mutations, 8 of which novel. A 
compendium of the mutant aUeles from all patients is 
presented In Table 2. Most of the mutant aUeles 
contained point mutations that resulted In sIngle 
amino acid substitutions. Heterozygous mutations 
occurred In seven patients, and homozygous 
mutations occurred in four (Table 2). Three of the 
mutations were shared by more than one patient 
(Arg294Ser, Gly227Arg, and Phe260Tyr). Patients 1 
and 2, who shared a C> T transition at nucleotide 
878, are African Americans. A G>A transition at 
nucleotide 677 was present in patients 3 and 4, both 
of Mediterranean origIn. Despite having the same 
mutation, patients 3 and 4 were diagnosed at the 
onset of the disease as type II and type I sialidosis 
respectively. The same mutation was also present in 
two unrelated type II sialidosls patients from the 
USA and Mexico, both of Caucasian origin (27). 
The presence of this mutation in 4 patients from 
European ancestry suggests that this may be a 
founder allele that originated in Europe. Future 
molecular analysis of additional patients may 
establish the existence of more founder mutations 
and their migration Into different populations. 
Genomic DNA analysis by PCR from patient 11 
showed the presence of a second mutation, a C> T 
transition at nucleotide 836, resulting In a premature 
stop codon. Because this mutation was not detected 
in the patient's mRNA we can infer that the mutation 
caused instability of the neuraminidase mRNA 
transcribed from this allele. 
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Figure 4. (A) Conserved amino acid residues within the slalidase superfamily thai are mutated In sfalidosis. Selected 
regions of human lysosomal neuraminidase (Hu.Lys) are compared with those of other mammalian and bacterial 
members of the slaUdase superfamily: Chinese hamster cytosoUc (Ch.h. Cyt), Micromonospora vln'difaclens (M.v.), 
Streptococcus pneumonfae (S.p.), Clostridium perfnngens (C.p.), Closln'dium septicum (C.p.), Safmonelfa typhimurium 
(S.t.) and BacteroIdes fragills (8.1.). Mutated residues In lysosomal neuraminidase of slatldosis patients are Indicated 
above the aligned sequences. Regions without significant homology are indicated (-). (8) Schematic representation of 
neuraminidase mutations within the primary structure of neuraminidase. Conserved Asp-box motifs are numbered I 
through V. and amino acid positions are Indicated. The five strictly conserved active site residues are indicated In bold 
print. The 8 novel mutations are indicated In bold print. The slanal pepUde (SP) Is indicated bv a black box. 
Primary structure analysis of the mutant domain that Is fully conserved among siatidases 
neuraminidase. (Figure 4A) (12). 
We compared the predicted amino acid sequences 
of the mutant neuraminldases with those of wild-type 
mammalian and bacterial slalldases (Figure 4A). In 
particular. Tyr370, which Is replaced by a Cys in 
patient 8. Is fully conserved In all slatldases. It Is 
noteworthy that the three-dimensional structures of 
the active sites of bacterial and viral neuramlnldases 
have identified Ihe tyrosine. corresponding to Tyr370 
In the human enzyme. as one of the five active site 
residues (9, 11. 32, 33). The presence of a normal 
amount of correctly localized enzyme In fibroblasts 
of patient 8 that Is nonetheless catalytically Inactive 
suggests that the mutated Tyr370 Is one of the 
active site residues of lysosomal neuraminidase. 
Several mutations that are located within or 
near Asp-box motifs are also conserved in other 
slalldasas (Figure 4A: Ser182Gly. Leu231Hls, 
Ala296Val, Thr301slop) (27). with Ihe exception of 
Arg294. which Is adjacent to Ihe Asp box IV but Is 
not conserved. The mutation Leu91Arg, Identified 
earlier In a patient with Infantile type II slalldosis. 
involves a residUe that is part of a 9-amino acid 
Figure 48 shows a schematic representation of the 
neuraminidase protein and the relative position of 
the mutations (21 in total) Identified to date by us 
and other investtgators. Approximately 50% of all 
mutations either affect conserved residues within 
conserved domains or are located within or near an 
Asp-box motif (Figure 4A and B). This finding 
strongly suggests that Asp motifs are essential for 
neuraminidase function, and that mutations within or 
near such domains are detrimental to the activity of 
the protein. 
Mutant neuraminidase proteins In slalldosls 
fibroblasts 
The Individual mutations were engineered In the full-
length wild-type neuraminidase eDNA, and the 
resulUng mutant eDNAs were then subcloned into 
the mamma1/an expression plasmid pSCTOP (12). It 
Is well established that wild-type neuraminidase 
must bind to PPCA to be transported to the 
/ysosomes and to become catalytically active (15). 
To create an optimal intracellular environment for 
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Figure 6. Immunocytochemical localization of neuraminidase overexpressed In slaUdosls fibroblasts. Sialidosis 
fibroblasts were elther Iransfected with the wild-type PPCA and neuraminidase eDNA expression constructs (WT) or 
with the wild-type PPCA and mutant neuraminidase eDNA expression piasmids as indicated. Cells were seeded on 
slides and incubated with affinity-purified anti-neur antibodies and FITC-conjugated secondary antibodies. The 
nuclei were stained with DAPI. Tile magnification is 400x. 
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Figure 6.Western bioi and catalytic analysis of mutant neuraminidase overexpressed in sialidosis fibroblasts. 
Sialidosls fibroblasts were transfecled with wild·type PPCA and neuraminidase cDNA expression constructs or with 
wild-type PPCA and mutant neuramInidase cDNA expression plasmlds. (A) Western blots containing Iysates (5 ~lg of 
protein) of fibroblasts Iransfected with the indicated mutant plasmids were incubated with affinity-purified anti·neur and 
anti·PPCA antibodies. An asterisk indicates the absence of 54·kD PPCA precursor in lanes 4,5, and 15. (8) 
Neuraminidase activity in the indicated cell Iysates, measured 4 days after transfection. Activities are expressed as 
released nmol sialic add per mg of protein per h and normalized for the transfeclion efficiency (nmollhfmg). 
the determination of the localization and residual 
activity of the mutant proteins, we transfected the 
mutant neuraminidase and wild-type PPCA 
expressIon plasmids into defielent fibroblasts. These 
fibroblasts were derived from a type /I slaHdosis 
patient with less than 1 % resIdual neuraminidase 
activity and absence of immunofluorescent staining 
with anti-neur antibodies (12). An expressIon 
construct containing the lac Z gene was used as an 
Internal control for transfection efficiency (Male rial 
and Methods). Three days after electroporal1on, the 
cells were subjected to Immunocytochemical 
analysis using affinity-purified antl-neur antibodies 
(12). No puncta ted staining was observed In four 
sets of cells expressIng mutant proteins (Figure 5; 
Leu363Pro, Pro335Gln, Gly218Ala, and Leu231His), 
a finding indicatfng that these mutant proteins were 
unable to reach the Iysosomes. This staining pattern 
was indicative of an endoplasmic reticulum (ER) and 
Goigi localization, probably due to protein mlsfolding 
(31). Surprisingly, most of the mutant proteins were 
apparently partially transported to the tysosomes, 
because the expressing cells showed, besides an 
ER and Goigi staining (nol shown), also some 
punclaled slalnlng (Figure 5; Tyr370Cys, 
Phe260Tyr, Gly227Arg, Ar9294Ser, Va154Mel, 
dpL399HisTyr, and Gly328Ser), 
AU neuraminidase variants appeared to have 
the same molecular weight as the wild-type protein, 
but the amounts of the mutant proteins differed, 
probably because of variations In stability (Figure 
6A), The ,blots were, subsequently, analyzed wi!h 
antl·PPCA antibodies; all samples contained uniform 
amounts of the 32-kO PPCA subunit (Figure 6A). 
However, It was surprising that tn all mutants, with 
the exception of Gly328Ser and Tyr370Cys, we 
could still detect the 54·kD PPCA precursor (Figure 
6A, lanes 6-14). This precursor is usually not 
detected by Western blot analysis when the PPCA 
eDNA Is expressed either alone or with wild-type 
neuraminidase, because the precursor is rapidly and 
efficiently processed into the two-chain mature 
enzyme (Figure 6A; lanes 2 and 4). The fact that 
PPCA precursor was still detected when 
coexpressed with neuraminidase mutants (Figure 
6A; lanes 6-14) suggested that it was retained In 
part in a prelysosomal compartment, probably 
because of association with the mutant 
neuraminidase proteins. 
Seven of the mutant neuramlnldases failed 
to generate any detectable enzyme activity (figure 
6S). This result was expected for Leu363Pro, 
Pr0335Gln, Gly218Ala, and Leu231His mutants 
because they did not locaUze to Iysosomes. 
However, despite the punctated subcellular 
distribution of Tyr370Cys, Phe260Tyr, and 
Gly227Arg (Figure 6A), these proteins appeared to 
be catalytically Inactive. Thus, these mutations 
probably affect the catalytic machinery of 
neuraminidase. In contrast, four of the mutant 
proteins (Arg294Ser, Val54Met, dpl.399HlsTyr, and 
Gly328Ser) exhibited substantial residual 
neuraminidase activity (Figure 68) and thus could be 
considered mild mutations, These mutations may be 
selective for the mUd clinical phenotypes In patients 
with type I slalldosls. It Is noteworthy that the 
residual activities of the mutant enzymes were 
higher than the endogenous enzyme activities in the 
corresponding mutant fibroblasts (table 1), This is 
likely an effect of the high expression levels in 
transfected cells, that may either activate 'ER stress-
response' proteins, facilitating folding of normal as 
well as mutant proteins or promote oligomerization 
and complex formation of the mutant proteins (34). 
response will retain the improperly folded proteins in 
the ER (34). 
DISCUSSION 
We have Investigated the properties of 
neuraminidase mutants Identified in 11 patients with 
slalldosls (nine unrelated patients and two siblings). 
The phenotypes of these patients represent the 
complete spectrum of cUnical severity. This number 
of cases Is significant, given that the frequency of 
diagnosed slalidosls In the population (1 In 
approximately 4 million live births) Is much lower 
than that of olher lysosomal disorders (35). To date 
all of the patients for whom mutations In the 
neuraminidase gene have been Identified expressed 
neuraminidase mRNA (12, 14). This finding Is In 
contrast with those reported for GS (26) and 
suggests that a complete absence or deficiency of 
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lysosomal neuraminidase is lethal during 
development or at birth. 
On the basis of their biochemical properties, 
the neuraminidase variants can be divided into three 
groups. In the first group, the mutant enzymes are 
catalytically inactive and do not localize to 
Iysosomes, in the second group, the variants reach 
the Iysosomes but are catalytically Inactive, and in 
the third group the enzymes have residual activity 
and localize to the Iysosomes. Most Importantly, we 
found a correlation between the Impact of the 
individual mutations and the clinical severity of 
slalldosis. All four pattents with type I sialldosls have 
at least one of the 'mild' amino acid substitutions 
from the third group; pattent 7, who died at the age 
of 44 years, had two 'mild' mutations (dpl399HlsTyr 
and Gly328Ser). In contrast, two pallents with 
infantile type tI disease (patients 9 and 10) had 
mutations belonging to the first or second group of 
catalytically Inactive enzymes. Both unrelated 
patients with juvenile type \I sialidosls (patients 3 
and 4) were homozygous for the mutation 
Gly227Arg, which belongs to the second group. 
Because these mutant proteins localize to the 
Iysosomes, they may stii[ retain in vivo a low residual 
activity. which could account for the differences In 
clinical severity among the patients with type II 
disease. The Tyr370Cys mutation Is associated with 
a very severe slalldosls phenotype. Thus, residual 
amounts of mutant enzyme In Iysosomes are clearly 
not sufficient to cause a m1lder phenotype, unless 
part of the catalytIc machinery Is retained. It is 
conceivable that environmental factors, including 
diet, prophylactic therapies, or genetic factors 
besides neuraminidase mutations, may Influence the 
penetrance of the disease or phenotype. This Is 
most evident in patients 3 and 4, who were 
diagnosed with type tI and type I slalldosls 
respectively, but are homozygous for the same 
mutation (Gly227Arg). Moreover, patient 3 has a 
higher residual neuraminidase activity (Table 1), 
milder symptoms, and a longer lifespan. In addition, 
because sialidosls is a very rare disease with 
varying degrees of severity, there may be 
differences in the classification of patient's 
phenotypes at the Urne of diagnosis of the disease. 
The amino acid substitution Tyr370Cys Is of 
special interest, because it affects one a residue that 
was shown In other siaUdases to be one of the five 
active site residues (9, 11, 32, 33). This, together 
with the fact that this renders the enzyme Inactive, 
suggests that the catalytiC machinery of lysosomal 
neuraminidase Is similar to that of other sialidases 
(15), despite the dependence of the lysosomal 
enzyme on PPCA (12, 15). Crystal structure 
analyses of several viral and bacterial sialidases 
revealed that all of them have a conserved slx-
bladed propeller fold and identical catalytiC pocket. 
Although it is likely that the structure of lysosomal 
neuramInidase will be very similar to that of other 
siaHdases, it Is risky to make assumptions about the 
structural effects of the different neuraminidase 
mutations without the crystal structure of the 
mammalian enzyme (27). However, as mentioned 
earlier, the active sites of both viral and bacterial 
neiJraminidases are strictly conserved, Therefore, 
we can predict the impact of the Tyr370 change on 
the 3D structure of the Salmonella Typhimurium 
siafidase, which is the closest In primary structure to 
the lysosomal enzyme (9). In this structure, the 
tyrosine (Tyr342) approaches the sugar ring of the 
slaUc acid and stabilizes the carbonium transition 
state intermediate (9), The substitution of Tyr342 
with a Cys does not create steric clashes or loss of 
bonds with neighboring amino acids, Therefore, the 
sialic acid substrate could still enter the catalytic 
pocket. However, the smal/er Cys residue Is unable 
to interact with the sugar ring of the sialic acid, and, 
consequently, hydrolysis of the substrate cannot be 
achieved. This model would fit with our biochemical 
analysis that showed the synthesis of a normal 
amount of enzyme without catalytic activity. 
The Asp-box motif Is an 8-amlno acid domain 
(SIW)xDxGx(SIT)(W/F» that Is repealed two to fIVe 
times in all members of the sialldase superfamily, 
with the exception of the viral sialidases (3, 10, 36, 
37). The regions adjacent to the Asp-box motifs, 
although without an obvious consensus sequence, 
show a high degree of conservation. Asp-boxes are 
located at equivalent positions In the fold of the 
protein, far from the active site, with the aspartic acid 
residue exposed to the solvent. Their peripheral 
position indicates that they are not involved in the 
catalytic mechanism (9). However, they may have a 
function in maintaining the f3-propeller fold of the 
enzyme, and they may be involved In the initial 
recognition and binding of the substrate. Six of the 
mutations are either within, directly adjacent to, or 
near an Asp-box motif. These mutations may affect 
the function of the Asp box, In thai they may 
compromise the structural Integrity of the domain or 
Indirectly hamper the catalytic properties of the 
enzyme. The future determination of the cryslal 
structure of lysosomal neuraminidase will provide 
the structural basis for these and other 
neuraminidase mutations. 
The determination of the 3D structure of PPCA 
has already been of great value in understanding the 
mechanisms of maturation and catalytic activation of 
the enzyme, and has given insight Into the Impact of 
specific mutations on the protein structure {38, 39}. 
In this report we show indirect evidence that the 
characterized amino acid substitutions did not 
prevent the binding of neuraminidase to PPCA. It is 
conceivable that the two proteins have multiple 
attachment sites for each other. Thus, the 
association between neuraminidase and PPCA will 
be abolished only if multiple amino acid residues are 
changed, In contrast with our findings, others have 
postulated that several neuraminidase mutations in 
sialidosls patients affect tho binding with PPCA, 
which In turn promotes rapid intra-lysosomal 
degradation of the mutant proteins {27}. A 
biochemical and structural understanding of the 
mode(s) of Interaction between the two enzymes 
could clarify the differences and facilitate the design 
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of novel therapeutic approaches for patients with GS 
or slalldosis, 
Material and Methods 
Cell culture 
Human skin fibroblasts from a healthy person and 
from patients 9 and 7 were obtained from the 
European Cell Bank, Rotterdam (Dr, W.J. Kleijer), 
Sialidosis fibroblasts GM01718A (patient 10) were 
obtained from the 'NIGMS human genetic mutant 
cell repository', Camden, NJ. Fibroblasts of patients 
1, 2 and 8 were obtained from Dr. O. Wenger, 
Jefferson Medical College, Division of Medical 
Genetics. The other fibroblasts strains were Isolated 
in the laboratories of the clinicians who diagnosed 
the cases (3, 4, 6, and 11). The primary fibroblasts 
were maintained in OME medium, supplemented 
with antibiotics and 10% FBS, 
Northern blot analysis 
Total RNA and polyAt RNA were Isolated from the 
cultured fibroblasts by using Ol/golex and RNAeasy 
mRNA purification kits (Olagen). RNA was 
separated In a 1 % agarose gel containing Q.86M 
formaldehyde, After electrophoresis, the RNA was 
blotted onto a Zeta-Probe-GT membrane (8io Rad) 
and hybridized In ExpressHyb (Clontech) al 68'C 
with the full-length human neuraminidase cONA (12) 
or human PPCA eDNA (40). The blots were washed 
according to manufacturers' protocol (Clontech) and 
exposed to x-ray film overnight. 
Western bloHlng, Immunocytochemistry, and 
enzyme assays 
For Western blottfng, fibroblasts grown to confluence 
in 85·mm Petri dIshes were harvested by 
trypsinization and lysed In milli·O water (MlIllpore). 
Fibroblast Iysates (5 ~g of protein) were subjected to 
SOS-PAGE and transferred to polyvinylidene 
fluoride (PVDF) membranes (Mlilipore). To assay the 
in vitro stability of neuraminidase, cell Iysates (5~g) 
were incubated at 37°C In PBS in the presence or 
absence of a protease Inhibitor cocktail (,Complete 
protease inhibitors', Boehringer Mannhelm). The 
samples were subjected to SOS-PAGE and to 
Western blotting. Western blots were Incubated for 
16h with affinity-purified anli·neuraminldase (anti-
neur) antibodies (12) and with an affinity-purified 
antl·PPCA antibody that Is specific for the 32·kD 
mature subunit (anll-32) (12) as described eartler 
(41). After washing, the blots were Incubated with 
peroxidase-conjugated anti-rabbit IgG secondary 
antibodies (Jackson Immuno Research) and the 
bound antibodies were detected by using 
chemlluminescent substrate (Renaissance, DuPont 
NEN). 
For immunocytochemical analysiS, 
fibroblasts were seeded onto SuperfrosVPlus glass 
slides (Fisher) and processed as described by 
Cullen (42) using anll-neur antibodies {16h at room-
temperature) and File-conJugated secondary 
antibodies (Sigma), The nuclei were staIned with 
4',6-Dlamidino-2-phenyllndole, dlhydrochloride 
(DAPI; Sigma-Aldrich), which was added to 
Vectashield mounting medium (Vector labs). 
For enzyme assays, fibroblasts were 
harvested as described above. Neuraminidase 
activity was assayed by using the synthetic 4-
methylumbelliferyl-Neuramlnlc acid (4MU) substrate 
(Sigma-Aldrich) as described (43). Total protein 
concentrations were measured with the 
blcinchonlnlc acid {SeA} assay (Pierce Chemical 
Co). 
peR analysis 
The amplification of mutant neuraminidase cDNAs 
was perfomed with peR primers as previously 
described (12). Four overlapping eDNA fragments 
(approximately 500 bp each) that encompassed the 
entire coding region of the neuraminidase gene, 
were amplified by RT-PCR (Titan RT-PCR, Roche). 
The peR products were purified with the Qiaqutck 
Spin PCR purification kit (Olagen) and subjected to 
automated direct sequencing by using internal 
neuraminidase-specific primers. Mutations were 
verified by PCR-ampliflcatlon of the corresponding 
exons and automated direct sequencing. 
Transient expression of mutant neuraminidase 
cDNA. 
To Introduce neuraminidase mutations into the full. 
length cDNA, fragments (400-600 bp) containing the 
mutation of Interest, were excised from RT·PCR 
products by using two restriction endonucleases, 
each of which has only one recognition site In the 
neuraminidase cDNA (Bsml, Ps~ and Smal). After 
electrophoresis In 1 % agarose gels the DNA 
fragments were purified with Qlaex II (Qiagen). The 
mammalian expression plasmid pSCTOP (44), 
which contained the wild-type neuraminidase cDNA 
(12), was restricted at two of the three unique 
endonuclease sites to excise the corresponding 
wild·type fragment. The fragment carrying the 
mutation was then ligated into the plasmid. The 
constructs containing the full-length mutant 
neuraminidase cDNAs were then sequenced to 
ensure that the mutations had been correctly 
introduced. 
Thirty micrograms of plasmid DNA 
(pSCTOP-neur, pSCTOP-neur mutants and 
pSCTOp·PPCA) was transfected by eleclroporation 
Into fibroblasts as described (12). As an Internal 
control for the eiectroporation efficiency, 3 ,lg of the 
plasmid CMV·LacZ was co-transfected. Three days 
after eleclroporalion the cells were harvested and 
lysed In water. Neuraminidase activity was assayed 
as described above, and neutral p-galactosidase 
activity (10 mM Tris-HCI pH 7.5; 100 mM NaCI) was 
assayed by using the synthetic 4-MU substrate 
(Sigma-Aldrich). To adjust for differences In 
transfection efficiencies, the neuraminidase values 
were normalized on the basis of neutral p-
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galactosidase activity calculated In each transfected 
sample. SuperfrosVplus sUdes contaIning 
transfected fibroblasts were Incubated with affinity-
purified anti·neur and antl·PPCA antibodies and 
processed for immunocytochemical staIning as 
described above. The absolute transfection 
efficlencles were determined by counting positively 
stained cells versus cells lacking staIning. The 
transfeclion efficiencies ranged between 20 and 
30%. 
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Discussion 
The results presented in chapters 3-8 demonstrate Ihat human lysosomal neuraminidase is 
encoded by a gene that is localized on chromosome 6p21 within the HLA locus (Chapter 3). 
Mouse lysosomal neuraminidase was -90% identical to the human enzyme and its gene, 
neu·l, was mapped to the H-2 locus on chromosome 17, which is syntenic to the human 
HLA locus (Chapter 4). Both human and mouse proteins were synthesized as -46-kDa 
Asn-glycosylated, catalytically inactive polypeptides that needed to associate with the 
PPCA to be transported to the lysosomal compartment (Chapters 3-5). 
Structural lesions in the neuraminidase gene were responsible for both the 
lysosomal storage disorder sialidosis and the neuraminidase deficiency in the SM/J mouse 
strain (Chapters 3, 4 and 8). We established reliable phenotype-genotype correlations in a 
large number of sialidosis patients (Chapter 8). In addition, we identified an active site 
mutation in the neuraminidase of a severe type It sialidosis patient. The catalytically inactive 
mutant protein was present in the patients' fibroblasts in normal amounts and correctly 
localized in Iysosomes (Chapter 8). In contrast, 'mild' type I sialidosis patients apparently 
had small quantities of catalytically active mutant neuraminidase in their Iysosomes 
(Chapter 8). Thus, the amount of residual catalytically active neuraminidase in the 
Iysosomes is the major factor that determines the severity of the disease. The impact that a 
mutation has on the folding of the protein will ultimately determine whether it will escape the 
'ER quality control', which retains improperly or parially folded proteins (reviewed in: (1». 
These polypeptides are usually targeted for degradation by either the proteasome or 
aggresome pathways (2). By preventing the release of misfolded proteins, the cell 
diminishes the risks posed by defective protein products. However, mutant proteins that do 
manage to exit the ER may still be able to reach their final destination and excert partial 
function. 
Not only mutant proteins are subjected to the 'quality control' In the ER. Bip, an ER 
'quality control' chaperone, associates with Immunoglobulin heavy-chain molecules and 
prevents their secretion in the absence of appropriate light-chain molecules (3). This 
mechanism Is reminiscent of the interaction between PPCA and neuraminidase in the ER. 
Neuraminidase was retained in the ER in the absence of PPCA and formed aggregates 
(crystals) in over-expressing COS-1 cells (front cover, bottom-right). In turn, this could 
trigger the activation of the aggresome pathway for the degradation of the misfolded protein 
(2). The ER-retention of neuraminidase in the absence of PPCA was not complete, since it 
was secreted in part and also reached the endosomal compartment (Chapter 5). 
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The bleeding disorder von Willebrand's disease resembles biochemically the 
combined PPCAIneuraminldase defiCiency in galaCtosialidosis. In plasma, factor VIII' (FVIII) 
was associated and stabilized by non-covalent interactions with Von Willebrand Factor 
(vWF), which also regulated FVIII activity. Von Willebrand's disease patients' have a 
combined deficiency of vWF and FVIII, which resulted from a primary defect in the vWF 
gene. In the absence of vWF, FVIII was retained in the ER and degraded (Kaufman, ASHG 
annual meeting 1999; (1)). Thus, 'quality control' for protein-partners may be a common 
mechanism to prevent proteins, which are dependent on a partner for their function, to 
leave the ER. 
Evolution of neuramlnldases 
The absence of a functional mannose-6-phosphate recognition marker on lysosomal 
neuraminidase could mean that this enzyme was originally not a lysosomal protein or that it 
has lost its ability to independently reach the Iysosomes. We can speculate that the 
neuraminidase, like most bacterial sialidases, was originally a secretory protein. Indeed, 
when the enzyme was over-expressed in COS-1 cells, in the absence of PPCA more 
neuraminidase Was secreted. However, unlike most other secreted lysosomal hydrolases, 
the secreted neuraminidase could not be re-internalized by the cells. The presence of 
lysosomal neuraminidase in a multi-enzyme complex and Its dependence on PPCA has 
been conserved in vertebrate species (mammalian and avian) (4). However, 
neuraminldases appear to be absent in plants and yeast, while the PPCA has two 
homologs in yeast, the KEX-1 gene product and yeast carboxypeptidase Y (CPY) (5). The 
analysis of DNA sequences that have been deposited in the DNA-databases reveals that C. 
elegans and isome insect species do have PPCA homologs (E Bonten, unpublished 
database searches). However, neuraminidases were not found in these species. Thus, it is 
possible that higher eucaryots have acquired lysosomal neuraminidase, whereas PPCA 
has evolved from a carboxypeptidase to become a transporter/chaperone/activator of 
lysosomal neuraminidase and t\-galactosidase. 
The widespread distribution of neuraminldases in higher organisms, as well as in 
diverse micro-organisms, but the absence in plants, insects, and yeast, has led to 
speculation about the existence of a possible common neuraminidase ancestor (6-9). 
Initially a short sequence of 8 amino acids, 5 of which highly conserved (SerlThr-X-Asp-X-
Gly-X-Thr-Trp/Phe), was found repeated at 4 positions in several bacterial neuraminldases 
(6). This domain was called 'Asp-box', since the aspartic acid residue appeared to be the 
most conserved amino acid (7). Asp-box motifs were eventually also found in 
neuraminidases and trans-sialidases from non-bacterial species, including Trypanosoma 
and Macrobdella decora (leech), as well as in mammalian speCies (7, 8, 10)(this thesis). It is 
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now evident that Asp-box motifs, in combination with a short N-terminal domain (FIY)RIP, 
are presenHn ali neuraminidases;wlth the exception 01 most 01 the viral enzymes (7; 8). 
The arginine in the (FIY)RIP domain is one of the five strictly conserved catalytic site 
residues (7,11-15). Neuraminidases have 2 to 5 Asp-boxes and the distance between the 
(FIY)RIP domain and the first Asp-box (35-41 residues) and the spacing between the other 
Asp boxes are highly conserved (Figure 4). 
Some neuraminidases, belonging to the group of high molecular weight enzymes, 
have additional domains positioned either at the N-terminus (B. fragilis), the C-termlnus (M. 
viridivaciens) or in the middle of the protein (V. Cholerae). These domains, which lack Asp-
box motifs (Figure 4), are not essential for the catalytic activity and may reflect additional 
function(s) of these neuraminidases. Besides the Asp-boxes and the (FIY)RIP domain, nine 
other amino acids are strictly conserved among the neuraminidases (Figure 4), six of which 
are also conserved In the viral enzymes (7). 
The function of the Asp-boxes has been much debated In the literature, since the 
absence of these motifs in most viral neuraminidases Indicates that they are not involved In 
the catalytic mechanism of the enzyme. However, site specific mutations within the Asp-
boxes of Clostridium perfringens neuraminidase showed changes In Km, V max and K, values, 
which suggest that these residues could be involved in substrate binding (11). Interestingly, 
Asp-boxes were not exclusively found in neuraminidases, but were also identified In 
proteins with other functions, including Xanthus hemagglutinin (4 Asp-boxes), S. cerevisiae 
Invertase (3 Asp-boxes), B. subtilis levenase (2 Asp-boxes), E. coli penicillin G acylase (1 
Asp-box) and spinach oxidoreductase (2 Asp-boxes) (9). The occurrence of these 
sequences In proteins that are probably unrelated to neuraminidases suggests a more 
common function for these motifs. The only property that these proteins share is the ability 
to bind carbohydrates (9). This supports the hypothesis that Asp-boxes are involved in the 
recognition and binding of carbohydrates/substrates, rather then in the catalytic 
mechanism. The broad range of sialic acid containing substrates and the diverse substrate 
specificity of neuraminidases, could explain the differences In the number of Asp-boxes and 
the differences in their amino acid composition (Figures 4 and 5). 
This brings us to the Interesting topic of the evolution of neuraminidases. Did the 
neuraminldases evolve from a common ancestor, and if so, was this common ancestor a 
protein equiped with Asp-box motifs? Did all Asp-box containing proteins evolve from a 
common ancestor, or did the neuraminidases and other proteins independently acquire 
Asp-box motifs? The existence of these motifs in plant and yeast proteins, which do not 
synthesize sialic acids and do not have neuraminidases, implies that Asp-box motifs are 
evolutionary older than neuraminidases. However, several lines of evidence suggest that 
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the neuramlnidases did evolve from a common Asp-box containing neuraminidase ancestor 
andlhatthe neuraminidase superfamily has been spread by horizontal gene transfer; It has 
been speculated that bacteria, as well as other microorganisms, have acquired the 
neuraminidase gene from their hosts and that the neuraminidases have originated within 
higher organisms (7). 
Could a mammalian neuraminidase be the common ancestor to microbial 
neuraminldases? We found that lysosomal neuraminidase is more homologous to bacterial 
neuraminidases than to the mammalian plasma membrane and cytosolic enzymes (this 
thesis). In contrast, the cytosolic and plasma membrane neuraminidases are homologous 
to each other (-40%), more than to lysosomal and bacterial neuraminidases (-19%). 
Several amino acids in the potenlial trans-membrane domain of the plasma membrane 
enzyme are conserved within the cytosolic enzyme. Moreover, both enzymes lack an N-
terminal signal sequence (10, 16, 17). Thus, the plasma membrane neuraminidase is In 
essence a cytosolic protein that may have acquired the capacity to become associated with 
the plasma membrane. 
Overall, these data suggest that the genes encoding cytosolic and plasma 
membrane neuraminidase are a result of a 'recent' gene-duplication event and that 
lysosomal neuraminidase is a more distant cousin of these two enzymes. In conclusion, the 
common neuraminidase ancestor probably was a eucaryotic enzyme equiped with Asp-
boxes. The exchange of genomic material between microbial species and their hosts is an 
essential element that aids their evolution and adaptation to changing environments. Thus, 
it is likely that several Independent events have been responsible for the transfer of 
eucaryotic neuraminidase genes to microbial species. 
Tertiary structure of neuraminidase 
The first published crystal structure of a neuraminidase, that of the influenza virus 
enzyme, revealed a tetrameric association of identical monomers, whose fold was 
described as a superbarrel or p-propeller (18). Each monomer consists of six four-stranded 
antiparallel p-sheets, which are arranged as the blades of a propeller around a pseudo six-
fold axis (Figure 6A). Structural analyses of the neuraminidases from influenza A virus N2, 
N6, N8, and N9 subtypes, as well as from two influenza B viruses, have revealed a 
conserved structure, despite overall low sequence identities (40%). The active site is highly 
conserved and consists of a rigid catalytic center (19). Several 3D-structures of bacterial 
neuraminidases have also been solved. The neuraminidases from M. viridifaciens (Figure 
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1. Hli'Ljis. 
2. Bov-PM 
3. CHO-Cyt. 
4. S.1. 
5. M.v. 
6. B.t. 
7. V.c. 
8. T.c. 
100 residues 
Figur. 4. Comparison of the primary structures of neuraminidases: (1) Human lysosomal, (2) 
Bovine plasma-membrane, (3) Chinese hamster cytosolic, (4) Salmonella typhimurium LT2, (5) 
Micromonospora viridifaciens, (6) Bacteroides Iragilis, (7) Vibrio cholerae, (8) Trypanosoma cruz, 
TCNA, (9) Avian influenza A tern N9. Conserved Asp-box motifs are numbered I to V, indicated 
by their amino acid position, and a gray box. Conserved residues and their positions are 
indicated in the protein-bars. The five active site residues that are conserved in all 
neuraminidases are printed in bold. Amino-terminal signal-peptides (SP); trans-membrane 
domain (TM); stalk-domain (SO). 
Hu-Lys. 
CHO·Cyt. 
Bov·PM 
S.t. 
M.v. 
B.I. 
V.C. 
T.c. 
" 
III 
Ie., .. 0 L , G F 1(: 
IV v 
Figure 5. Alignment of the FRIP domains and Asp-box motifs I to V of selected neuraminidases: 
Human lysosomal (Hu-Lys.), Chinese hamster cytosolic (CHO-Cyt.), Bovine plasma-membrane 
(Bov-PM), Salmonella typhimurium LT2 (S.I.), Micromonospora viridilaciens (M.v.), Bacteroides 
Iragilis (B. I.), Vibrio cholerae (V.c), Trypanosoma cruzi (T.e). 
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Figura 6. Crystal 3-D structures of neuraminidases: Avian inftuenza A virus Tern N9 
(A), Micromonospora viridifaciens small form (8), Salmonella Iyphimurium LT2 (C). 
Micromonospora viridilaciens large form (D), Vibrio Cholerea (E). Catalytic domains 
of D. and E. are indicated by number 1, and non-catalytic domains by numbers 2 and 
3. Images are created with the program RasWin molecular graphics (RasMol) Version 
2.6. coovrioht © 1993-1995 R. Savle. 
68 and D), S. fyphimurium (Figure 6C), and V. cholerae (Figure 6E) showed a high degree 
of structural similarity to the viral neuraminidase structures, with conserved six-bladed fl-
propeller (12-15). However, the neuraminidases from M. vlridilaciens and V. cholerae have, 
besides the catalytic domain, two additional separately folded domains (Figure 6D and E). 
These domains either have lectin-like or immunoglobulin-like folding characteristics. Their 
functions are yet unclear, but they are not essential for the catalytic activity. In common with 
the viral neuraminidases, the active site of the bacterial enzyme also consists of an arginine 
triad, a hydrophobic pocket and a key-tyrosine and glutamic acid (12). The tyrosine at amino 
acid position 370 in human lysosomal neuraminidase corresponds to the key-tyrosine in the 
viral and bacterial neuraminidases (Chapter 8). The substitution of this residue for a 
cysteine, as found in the neuraminidase from a severe type II slalidosis patient, leads to the 
complete loss of catalytic function. The Asp-boxes are located at equivalent positions in the 
fold of the protein, far from the active site, with the aspartic acid residues exposed to the 
solvent. Their peripheral position confirms that they are not involved in the catalytic 
mechanism, but they may determine the fold and the integrity of the propeller (12). It is 
noteworthy that several mutations map near or at the Asp-box motifs of lysosomal 
neuraminidase in sialidosis patients (Chapter 8). The impact of these mutations on the 
structure of the enzyme is yet unknown. However, they most likely do not directly affect the 
catalytic machinery, but instead may cause misfolding or interfere with substrate 
recognition. 
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The ability to produce large quantities of lysosomal neuraminidase in insect cells 
(Chapter··7) could potentially be used to crystallize theenzymeamj determine its tertiary 
structure. It will be interesting to compare its structure with those of the bacterial and viral 
neuraminidases. These studies may lead to the identification of structural elements that are 
unique for lysosomal neuraminidase, and that potentially are involved in the interaction with 
PPCA and j3-galactosidase. 
The work presented in this thesis has contributed to a better understanding of the 
properties of lysosomal neuraminidase, including its Interactions with PPCA and 13-
galactosidase for the transport to Iysosomes and its mechanism of catalytic activation. We 
also gained insight into the role that neuraminidase mutants play in the lysosomal storage 
disorder sialidosis. The generation of murine models for both type I and type II sialidosis will 
be essential to obtain a further understanding of the clinical impact of a lysosomal 
neuraminidase deficiency. 
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Summary 
Neuraminidase is the first hydrolase that is· needed for the step-wise degradation of 
oligosaccharides, on which its substrate, sialic acid, is terminally positioned. The lysosomal 
storage disorder (LSD) sialidosis is caused by lesions in the neuraminidase gene. Patients 
that are affected by this disease present, depending on the severity, with mUlti-systemic 
manifestations, which may include retinal cherry-red spots (loss of vision), deafness, coarse 
facies, skeletal abnormalities, organomegaly, myoclonus, seizures and mental retardation. 
Many of these symptoms are also commonly seen in other lysosomal storage disorders. A 
primary genetic deficiency of lysosomal protective protein/cathepsin A (PPCA) results in a 
secondary deficiency of neuraminidase and f3-galactosidase, which in turn leads to 
galactosialidosis (GS). GS patients share many clinical features with sialidosis patients, 
likely as a result of the secondary neuraminidase deficiency. 
A cDNA encoding for a neuraminidase was identified in the dBEST database 
because of its homology to other bacterial and mammalian sialidases (Chapter 3). 
Electroporation of this cDNA into sialidosis fibroblasts restores the neuraminidase activity 
and gives a puncta ted lysosomal-like intracellular distribution. In contrast, the expression of 
this cDNA in GS fibroblasts does not restore neuraminidase activity. The co-expression of 
PPCA with neuraminidase is needed to generate catalytic activity in these cells. These 
experiments show that the dBEST cDNA clone is encoding lysosomal neuraminidase. 
Furthermore, we identified three mutations in the neuraminidase cDNA of sialidosis 
patients. Overexpression of these mutations result in a complete abolishment of both the 
catalytic activity and lysosomal localization of the mutant enzymes (Chapter 3). 
In Chapter 4 we present the cloning of the cDNA and gene encoding murine 
lysosomal neuraminidase, and the identification of a point mutation (Leu20911e) In the 
neuraminidase gene of the mouse strain SM/J, that causes a partial neuraminidase 
deficiency in these mice. We show that the mutation interferes with the efficiency of the 
enzyme to cleave natural substrates, but it has no effect on the substrate specificity. 
In Chapter 5 we describe in detail the interaction between neuraminidase and PPCA, 
co-expression them in COS-1 cells. We show that association of neuraminidase with PPCA 
in an early biosynthetic compartment is essential for the routing of neuraminidase to 
Iysosomes, and that the enzyme lacks a functional mannose-6-phosphate recognition 
marker that is required for routing to the Iysosomes. When neuraminidase is expressed in 
COS-1 cells In the absence of PPCA, it accumulates in the ER, while co-expression with 
PPCA restores the lysosomal localization. In contrast, when neuraminidase Is co-expressed 
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with transport-incompetent PPCA mutants, it is unabte to reach the tysosomat 
compartment. 
In chapters 6 and 7 we utilize the baculovirus expression system to express the 
PPCA precursor, the two separate PPCA subunits, the p-galactosldase precursor, and 
lysosomal neuraminidase. The PPCA precursor is catalytically activated in vitro by the 
proteolytic removal of an internal linker-peptide. The activated mature PPCA is a two-chain 
molecule that is non-covalently associated through disulfide bridges. When co-expressed, 
PPCA, neuraminidase and p-galactosidase are present as a multi enzyme complex of 
>1000 kDa. PPCA associates with neuraminidase through the C-terminal 20-kDa PPCA 
subunit, promoting oligomerization and catalytic activation of neuraminidase, but only at 
acidic pH. Neuraminidase is also associated with p-galactosidase but, in contrast, this 
association has no effect on either the oligomeric state or catalytic activity of 
neuraminidase. 
Finally, in Chapter 8 we identified several novel mutations in the neuraminidase 
cDNA and gene of eleven sialidosis patients, belonging to different clinical subtypes. The 
properties of the mutant proteins were analyzed by over-expression in deficient sialidosis 
fibroblasts. We studied the impact of the mutations on the subcellular localization and 
catalytic activity of neuraminidase. We are able to divide the mutant enzymes into three 
groups. The first group includes mutant proteins that lack residual activity and show no 
lysosomal localization. Mutants in the second group show lysosomal localization but no 
residual catalytic activity, while proteins in the third group show both lysosomal localization 
and significant residual catalytic activity. One of the identified mutations involves one of the 
five strictly conserved active site residues (Tyr370Cys). The patient that was homozygous 
for this mutation had a normal amount of correctly localized neuraminidase that however 
was completely inactive. As a result this individual is a severe type II sialidosis patient. We 
can establish reliable phenotype-genotype correlations for all sialidosls patients. Mutations 
belonging to the first group are present in severe type II sialldosis patients. In contrast, 
mutations from the third group are sufficient to give a mild type I phenotype. Thus, the 
phenotype correlates with the amount of residual neuraminidase activity and presence or 
absence of lysosomal localization. 
The studies presented In this thesis have provided new understanding about the 
characteristics of lysosomal neuraminidase, including Its interactions with PPCA and p-
galactosidase, and its involvement In the lysosomal storage disorders sialidosls and 
galactosialidosis. The genotype-phenotype correlation in sialldosis patients may provide a 
belter understanding about the clinical manifestations of these patients. The increased 
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knowledge about neuraminidase and Its impairment in slalidosis patients may become 
valuable for the future development of therapeutic strategies forsialfdosis. 
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Samenvatting 
Neuraminidase is het eerste enzym dat benodigd is voor de stapsgewljze afbraak van 
koolhydraatketens, waarop het substraat, siaalzuur, een terminale positie heeft. De 
Iysosomale stapelingsziekte (LSZ) sialidosis wordt veroorzaakt door mutaties in het 
Iysosomaal neuraminidase gen. Afhankelijk van de ernst van de ziekte lijden de patienten 
aan meervoudige gebreken waarbij ondere andere de ogen, het gehoor, het skelet, het 
centrale zenuwstelsel en de viscerale organen betrokken zijn. De LSZ galactoslalidosis 
(GS) wordt veroorzaakt door een defect van het Iysosomale protective protein/cathepsin A 
(PPCA). Ais PPCA niet goed functioneert kunnen neuraminidase en p-galactosidase het 
Iysosoom niet bereiken, omdat zij afhankelijk zijn van PPCA voor hun transport naar het 
Iysosoom. Dit heeft tot gevolg dat het GS ziektebeeld veel lijkt op dat van sialidosis 
pati~nten. 
Op grond van de homologie met andere bacteri~le neuraminidases werd het cDNA 
dat codeert voor het Iysosomale neuraminidase geidentificeerd in de dBEST database 
(Hoofdstuk 3). De electroporatie van dit cDNA in de gekweekte fibroblasten van sialidosis 
patienten herstelt de neuraminidase activiteit en vertoont een typische Iysosomale 
lokalisatie van het eiwit. Dit is in tegenstelling tot de electroporatie in GS fibroblasten 
waarbij de activiteit van dit enzym niet hersteld wordt. Aileen wanneer ook PPCA wordt 
geexpresseerd in deze cellen kan de neuraminidase activiteit hersteld worden. Deze 
experimenten tonen aan dat het geidentificeerde cDNA codeert voor het Iysosomale 
neuraminidase. Vervolgens von den we drie mutaties in de neuraminidase cDNAs van 
sialidosis patienten. Overexpressle van deze neuraminidase mutanten in zowel COS-1 en 
sialidosis fibroblasten veroorzaakt een volledig gebrek aan enzym activiteit en Iysosomale 
lokalisatie (Hoofdstuk 3). 
In Hoofdstuk 4 beschrijven we de klonering van het cDNA dat codeert voor het 
Iysosomale neuraminidase van de muis en de identificatie van een mutatie (Leu209I1e) in 
het betreffende gen in de muizenstam SM/J. Deze aminozuur verandering veroorzaakt een 
verlaging van de enzymactiviteit. We tonen aan dat de mutatie de verwerking van 
natuurlijke siaalzuur substraten negatief beinvloedt maar dat het geen invloed heeft op de 
specificiteit van dit proces. 
In Hoofdstuk 5 beschrijven we de interactie tussen neuraminidase and PPCA waarbij 
we gebruik maken van expressie in COS-1 cellen. We tonen aan dat deze interactie plaats 
vindt direct na de eiwitsynthese en dat dit benodigd is voor het transport van neuraminidase 
naar het Iysosoom. De koolhydraatketens van neuraminidase hebben geen functionele 
mannose-6-fosfaat determinant dat benodigd is voor het transport naar het Iysosoom, 
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waardoor overexpressie van neuraminidase in COS-1 cellen leidt tot accumulatie van het 
etwitinher endoptasmatische reticulum (ER): De cO'expressiemefPPCAhersteltCle 
Iysosomale localisatie van neuraminidase. Echter, de co-expressie van neuraminidase met 
PPCA mutanten, die zelf niet tot correct transport in staat zijn, heeft geen effect op het 
Iysosomale transport van dit enzym. 
In de hoofdstukken 6 en 7 expresseren we neuraminidase, j3-galactosldase en 
PPCA in insekten cellen middels baculovirus constructen. De PPCA precursor wordt in vitro 
geactiveerd door de enzymatische verwijdering van een intern peplide. Het enzymatisch 
actief PPCA bestaat uit twee eiwit ketens die niet-covalent verbonden zijn door disulfide 
bruggen. Door de gelijktijdige expressie van PPCA, neuraminidase en j3-galactosidase 
wordt een multienzym complex gevormd (>1000 kDa). De PPCA precursor bindt 
neuraminidase via het C-terminale 20-kDa PPCA domein en bevordert de oligomerisalie en 
activatie van neuraminidase. Neuraminidase kan ook blnden aan j3-galactosldase maar dit 
heeft geen effect op de enzym activiteit en de oligomerische staat. 
Tenslotte, In Hoofdstuk 8 beschrijven we de identificatie van nieuwe mutaties in 
neuraminidase van elf pati6nten met de verscheiden klinische vormen van sialidosis. De 
biochemische eigenschappen van deze gemuteerde enzymen worden bepaald door de 
overexpressie in sialidosis fibroblasten waarbij vooral gekeken wordt naar het effect op de 
subcellulaire localisatie en de enzym activiteit. Op grond hlervan kunnen de mutaties 
Ingedeelt worden in drle verschillende groepen. De eerste graep bevat eiwitten zonder 
activitei! en een totaal gebrek aan Iysosomale localisatie. De tweede groep bestaat ui! 
enzymen die wei in het Iysosoom belanden maar geen activiteit hebben, terwijl de derde 
groep mild is met eiwitten die Iysosomaal zijn en enlgszins actief. Een mutatie betrof Mn 
van de vijf geconserveerde aminozuren die het actieve centrum van neuraminidase vormen 
(Tyr370Cys). De betreffende patient is homozygoot voor deze mutatie en he eft een 
normale hoeveelheld enzym dat aanwezig is in het Iysosoom, alhoewel zonder enzym 
activitelt. Ais gevolg van deze mutatie heeft deze patient de ernstige vorm van het type II 
sialidosis. We kunnen voor aile patienten betrauwbare genotype-phenotype correlaties 
aantonen. Mutaties behorende tot de eerste graep worden aangetroffen in type II sialldosis 
palienten, terwijl mutatles uit de derde groep aanleiding geven tot het veel mildere type I 
ziektebeeld. Het ziektebeeld wordt bepaald door de aanwezigheid van een zeer geringe 
hoeveelheld neuraminidase activitelt in de Iysosomen van de pati6nten. Echter, het is 
bekend dat ook andere genetische en niet-genetische factoren de ziekte kunnen 
beinvloeden. 
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De in dit proefschrift beschreven studies geven een nieuw Inzlcht in de 
... elgetlschapperiViiiflys6somaar heuramlhidase, . iliclusiefdeintetacties met PPCA en[l' 
galactosidase en de betrokkenheld In de LSZn sialidosls en GS. De genotype-phenotype 
correlatles van slalidosls patienten zal een beter beg rip geven van het ziektebeeld van deze 
patienten. De verworven kennis over neuraminidase en de betrokkenheid in slalldosis kan 
tevens van groot belang zijn in de toekomstige ontwikkeling van theraplMn voor deze 
patienten. 
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Abbreviations 
AMP adenosine 5'-monophosphate 
ATP adenosine 5'-triphosphate 
Blp immunoglobulin binding protein 
(c)DNA (complementary) deoxyribonucleic acid 
CMP cytidine 5'-monophosphate 
CPW wheat carboxypeptidase W 
Cpy yeast carboxypetidase Y 
C-termlnal carboxy-terminal 
dBEST database expressed sequence tags 
ER endoplasmic reticulum 
FVIII factor FVIII 
GalNAc N-acelyl-galactosamlne 
GALNS N-acetyl-galactosamine-6-sulfate sulfatase 
GlcNAc N-acelyl-glucosamine 
GS galactosialldosis 
kb kilo base 
kDa kilo Dallon 
LSD lysosomal storage disease 
Man mannose 
ManNAc N-acetylmannosamine 
MLiV mucolipldosis IV 
(m)RNA (messenger) ribonucleic acid 
MU methylumbelliferyl 
Neu5Ac N-acetylneuraminic acid 
N-linked asparagine-linked 
N-terminal amino-terminal 
PPCA protective protein/cathepsin A 
vWF Von Wille brand factor 
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